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Abstract
American Heart Association officials and other expert cardiologists recommend omega-3
(n-3) dietary supplementation for the secondary prevention of cardiovascular disease, a
prevalent health problem in the United States. Physicians’ lack of understanding of
possible n-3 preventive health benefits results in underprescribing n-3 dietary
supplements and lower n-3 dietary supplement product sales. N-3 dietary supplement
marketers do not understand physician n-3 prescribing decision criteria enough to
optimize high-impact communication to physicians to increase n-3 dietary supplement
product use. The purpose of this phenomenological research study was to improve n-3
marketers’ understanding of how physicians reach decisions to prescribe or recommend
products including n-3 dietary supplements. Argyris’ ladder of inference theory provided
the study framework to facilitate understanding physicians’ decision criteria. Rich data
collected and analyzed from 20 primary care physician interviews in Kentucky, Indiana,
and Tennessee revealed physicians use similar decision criteria for drugs and n-3s. Three
essential influencers of physician decisions included clinical evidence, personal
experience, and cost. Other influencers were opinions of peers, pharmaceutical
representatives, samples, direct-to-consumer advertising, and knowledge of dietary
supplements. Study outcomes may inform pharmaceutical marketers regarding
presentation of clinical evidence, cost emphasis, and pharmaceutical representative skills
and may facilitate competitive advantage for n-3 marketers. The social benefit of this
study is improved physician understanding of n-3s may result in more accurate and
appropriate prescribing to augment positive health outcomes.
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Section1: Foundation of the Study
The American Heart Association recommends omega-3 (n-3) dietary
supplementation for the secondary prevention of cardiovascular disease (Lee, O’Keefe,
Lavie, Marchiolo, & Harris, 2008) but physicians’ lack of understanding of possible n-3
preventive health benefits results in the underprescribing of n-3 dietary supplements and
lower n-3 dietary supplement product sales (Dickinson, Shao, Boyon, & Franco, 2011).
N-3 dietary supplement marketers do not understand physician n-3 prescribing decision
criteria. The purpose of this study was to explore the ladder of inference physicians
cognitively ascend when deciding if they will recommend or prescribe omega-3 fatty acid
(n-3) dietary supplements to their patients. The ladder of inference is a decision criteria
model theory (Argyris, 1976) consisting of sequential, logical steps individuals take to
reach logical conclusions. By analyzing each decision logic step among study subjects
(physicians), I discovered and gained a better understanding of physician decision
processes and concluded critical communication links useful for n-3 marketers to help
solve marketers’ business problem of low physician cognizance of n-3 health benefits and
their commitment to n-3 utilization. Adams, Kohlmeier, and Zeisel, (2010) supported the
lack of sufficient physician education regarding n-3s. The business problem included the
difficulty in communicating the complex mechanisms of n-3s to physicians and
subsequently from physicians to their patients.
In this study, I explained the study topic, applied business research to a business
problem, specified the research study plan including its design and methods, and
described the potential benefits the research study would generate for business and
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society. In this research study, I followed the Onwuegbuzie et al.’s (2012) exemplar for
teaching and learning qualitative research. According to Onwuegbuzie et al., the
qualitative research process involves 13 distinct and dynamic components: (a)
determining the study goal, (b) formulating research objectives, (c) determining rationale,
(d) determining purpose of research, (e) defining the research question, (f) selecting the
sample design and size, (g) selecting research design, (h) collecting data, (i) analyzing
data, (j) validating data, (k) interpreting data, (l) writing the final report, and (m)
reformulating the research question as appropriate. I addressed and satisfied these 13
qualitative componentsin the following six subsections: (a) background, (b) problem
statement, (c) purpose statement, (e) data research methods and reliability, (f) data
analysis and validity, and (g) application to business practice and implications for social
change.
Background
Although cardiologists and knowledgeable primary care physicians can
understand n-3 health benefits, the business problem for n-3 marketers is a deficiency in
understanding why many primary care physicians do not regularly recommend n-3
dietary supplements to their patients (Dickinson, Boyon, & Shao, 2009; Dickinson, Shao,
Boyon, & Franco, 2011). In one survey of 109 U.S. medical schools, 79% of instructors
reported deficient dietary supplement education; only 30% of medical schools had a
separate dietary supplement course (Adams, Kohlmeier, & Zeisel, 2010).
Regarding the background of n-3 safety and efficacy, many but not all clinical
study investigators support n-3 dietary supplements for reducing cardiovascular disease
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epidemiology. For example, Siddiqui, Harvey, Ruzmetov, Miller, and Zaloga (2009)
reported n-3 dietary supplements counter health consequences of red meat consumption
containing arachidonic acid (AA), an omega-6 (n-6) fatty acid that exacerbates systemic
inflammation and clogs arteries in humans (atherosclerosis is the number one cause of
death in the United States; Venes, 2009). Investigators such as Cottin, Sanders, and Hall
(2011) and Lee, O’Keefe, Lavie, Marchiolo, and Harris (2008) explained n-3s,
specifically docosahexanoic acid (DHA) and eicosapentanoic acid (EPA), compete with
arachidonic acid and other n-6s for phospholipid membrane positions in human cells.
These investigators concluded ample EPA and DHA consumption mitigate n-6 health
consequences. Other supporting evidence includes the Food and Drug Administration
(FDA) approval of Lovaza, a prescription n-3 supplement containing 465 mg EPA and
375 mg DHA for hypertriglyceridemia (Serebruany et al., 2011).
Other clinical trial results support the positive preventive impact of consuming
sufficient amounts of quality n-3s. For example, medical investigators reported the n-3
long-chain (LC) polyunsaturated fatty acids (PUFA): EPA and DHA, abundant in marine
fish, act to lower lipid blood levels to reduce cardiac events and decrease the progression
of atherosclerosis (Kopecky, Rossmeisl, Flachs, & Kuda, 2009, p. 361). Kopecky et al.
(2009) linked adipose tissue to the beneficial effects of n-3s on health, explaining a
reduction in the inflammation of adipose tissue and improved glucose and lipid
metabolism. Kopecky et al. further concluded the dietary intake of fish oil or concentrates
containing both EPA and DHA improves lipid metabolism and insulin excretion and
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regulation, ancillary benefits not addressed in this study. They concluded that in human
subjects, n-3s achieve steady-state serum levels within 1 month.
In another example, Mayo Clinic Proceedings cardiologists reported results from
thousands of published clinical trials over three decades indicated cardiovascular
protective effects (Lee et al., 2008) reported clinical trial evidence (n = 32,000) of
cardiovascular events reduction in 19–45% of patients ingesting n-3s versus placebo. Lee
et al. cited the results of three specific large trials (n = 32,000) demonstrating the positive
benefits associated with n-3s, either from oily fish or fish oil gel caps (Lee et al., 2008).
Simopoulos (2011) noted how human beings evolved on a diet with a ratio of n-6s to n-3s
of approximately 1:1 whereas in modern times, Westerners consume diets with ratios of
10:1 to 25:1, (n-6s to n-3s). Simopoulos also noted how industrialized societies increase
energy intake while decreasing energy expenditure and consume a diet rich in saturated
fat, n-6s, trans-fatty acids, and decreased n-3s. Mirmiran et al. (2012) cited a substantial
body of evidence to support a balanced dietary ratio of n-6:n-3 for the prevention of
cardiovascular disease and lower incidence of metabolic syndrome.
The American Heart Association recommends a diet of fatty fish at least twice per
week (London et al., 2011). London et al. (2011) noted patients with coronary heart
disease should consume more than 1 gram daily of combined EPA and DHA. In addition,
London et al. also opined indisputable evidence exists n-3s have a positive impact on
cardiac electric activity. The American Heart Association (AHA) has endorsed n-3s for
secondary prevention of cardiovascular disease and the AHA, American College of
Cardiology, and the European Society of Cardiology found the n-3 evidence strong
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enough to issue public recommendations for increased n-3 dietary intake (Lee et al.
2008).
Some investigators reported conflicting results and offer opposing viewpoints of
n-3 safety and efficacy. Regarding n-3 safety, De Caterina (2011) noted the AHA advised
caution with respect to fish contaminants. Brasky et al. (2013) linked high n-3 blood
levels to increased prostate cancer. Other investigators attributed prostate carcinogenesis
and other cancers to environmental toxins potentially in fish oil and unpurified fish oil
supplements including pesticides, trace minerals, or methylmercury (Ginsberg & Toal,
2009; Mullins & Loeb, 2012).
Other investigators expressed skepticism regarding n-3 efficacy. For example,
Chen et al. (2011) determined no significant differences in lowered epidemiology of
sudden cardiac death, cardiac death, and all-cause mortality. Whelan, Gouffon, and Zhao
(2012) determined one substance converted by the body to EPA (SDA) was not effective
in lowering triglycerides, HDL, or LDL levels. Borghi and Pareo (2012) raised
skepticism regarding the efficacy of n-3s in reducing ventricular arrhythmias. Vlablik,
Prusikova, Snejdrlova, and Zlatohlavek (2009) raised the possibility n-3 dietary
supplementation may raise undesirable low-density lipoprotein (LDL) cholesterol levels
when used in high doses for patients with hypertriglyceridemia.
In a large study (n = 12,356), Bosch et al. (2012) evaluated high-risk patients
including those with impaired fasting glucose, impaired glucose tolerance, or diabetes
and concluded n-3s had no effect on reducing cardiovascular events in this high-risk
group. Kromhout, Giltay, and Geleijnse (2010) determined low dose n-3 dietary
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supplementation (226 mg EPA and 150 mg DHA) did not reduce fatal or nonfatal
cardiovascular events. In a quantitative method analysis of 20 studies, Rizos, Ntzani,
Bika, Kostapanos, and Elisaf (2012) determined no statistically significant correlation
between n-3 supplementation and lower risk of all-cause mortality, cardiac death, sudden
death, MI, or stroke. It is important for n-3 marketers to understand objectively although
substantial clinical evidence exists to support n-3 efficacy and safety, a number of
investigators offer credible and contradictory evidence.
Perhaps because of this contradictory evidence or perhaps because physicians do
not have sufficient knowledge, survey results indicated primary care physicians do not
routinely recommend n-3 dietary supplements to patients (Dickinson, et al., 2011). Two
studies reported most physicians acknowledged they did not have sufficient education
regarding dietary supplements but expressed a desire to acquire more knowledge
(Dickinson, et al., 2009). These findings provided the foundation for the problem
statement in this study.
Problem Statement
Marketers of n-3s understand important cardiovascular disease statistics in the
United States: More than 120,000 Americans under the age of 65 die prematurely from
heart disease each year (Centers for Disease Control [CDC], 2011) and U.S. health care
costs rose from $714 billion in 1990 to $2.3 trillion in 2008 (CDC, 2011). Health care
cost increases may result from a deficiency in cardiovascular disease preventive
medicine. Physicians understand cardiovascular consequences of high cholesterol and
triglyceride blood levels. Although not all clinical investigators support the safety and
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efficacy of n-3s, results from more than 100 clinical studies demonstrated reduced
cholesterol and triglycerides after concentrated n-3 dietary supplementation (London et
al., 2011).
The general business problem for pharmaceutical marketers is physicians’ lack of
understanding of possible n-3 preventive health benefits (Dickinson et al., 2009;
Dickinson et al., 2011) resulting in the under-prescribing of n-3 dietary supplements and
lower n-3 dietary supplement product sales. The specific business problem is n-3
marketers do not understand physician n-3 prescribing decision criteria so n-3 marketers
can optimize high-impact communication to physicians to increase n-3 prescribing and n3 dietary supplement product use.
Purpose Statement
The purpose of this phenomenological research study was to improve n-3
marketers’ understanding of how physicians reach decisions to prescribe or recommend
products including omega-3 (n-3) dietary supplements and which product characteristics
may be the most important to physicians. I explored physicians’ n-3 dietary supplement
knowledge, and decision criteria (ladder of inference; Argyris, 1976). Understanding
these complexities may help n-3 marketers to develop learning tools (predictors) to
influence physician decisions (criteria) to recommend patient consumption of quality n3s.
Appropriate for a qualitative phenomenological study design, I interviewed 20
primary care physicians located in Kentucky, Indiana, and Tennessee. Interviewing
physicians was justified because of their opinion-leader statuses and influence over

8
patient health (Ashar & Rowland-Seymour, 2008). The marketing context study objective
answered the primary research question to determine the n-3 ladder of inference
physicians ascend. The business implication may facilitate n-3 marketers’ understanding
of physician customers’ thinking and needs. An improved understanding by n-3
marketers may culminate in more effective n-3 marketing, clearer communication, and
increased preventive medicine behaviors by physicians. Increased n-3 use among the
general population may result in improved health, reduced cardiac disease, and reduced
U.S. healthcare spending.
Nature of the Study
I used the qualitative method to gather data and analyze the data to find useful
information and understand thought processes and decision criteria among physician
subjects. Bertolotti and Tagliaventi (2007) employed qualitative methods to identify
complex views, opinions, and perceptions of participants. According to Bertolotti and
Tagliaventi, the purpose of a qualitative study is to identify themes and constructs among
the words used by participants in response to open-ended questions. In this study, without
prompting, all physician subjects used words to indicate they did have some knowledge
of n-3 benefits preventing cardiovascular disease. Even so, I used words such as “Please
tell me your opinion regarding…” to encourage open expression and opposing
viewpoints.
According to Csordas, Dole, Tran, Strickland, and Storck (2010), interviewers
should choose words based upon careful assessment of the pretext, subtext, and context
interview factors. Pretext involves any previous conversations between interviewer and
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study subject, and the possible influence of those conversations. Subtext refers to the
influence of subjects’ hidden agendas and relevant to this study, meant allowing subjects
to voice their hidden agendas to support or reject n-3 safety and efficacy in the prevention
of cardiovascular disease.
Regarding the context of the setting, I insisted upon a quiet, private interview
room free of interruptions to protect the interview setting. Additional steps included
carefully planning interview questions, electronically recording and transcribing data
verbatim, and using detailed, descriptive text. I documented my personal bias in favor of
n-3 efficacy and safety but described steps I took to prevent bias during interviews. I was
careful not to contradict any physician subjects who questioned n-3 safety and efficacy.
Regarding data analysis, Bertolotti and Tagliaventi (2007) emphasized the
importance of data analysis objectification, a critical element to support study validity. In
this study I used inter-coder agreement, triangulation, peer review, and member checking
to ensure study validity. The complexity of collected data did not necessitate coding
software such as HyperRESEARCH (Textor & Hedrick, 2012) to facilitate coding
efficiency and objectivity. Approved by an Institutional Review Board (IRB approval 
05-29-13-0265406), one other coder and I worked independently but collaboratively to
drive convergent and divergent themes from data collected from physician subjects
(inter-coder agreement). The other coder signed a Confidentiality Agreement to protect
subjects’ anonymity and privacy.
I selected physician participants based upon their willingness to participate
(access) and their open perspectives regarding diverse opinions. By description, these
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criteria necessitated the inclusion of some physicians who already prescribed or
recommended n-3s. Geographical scope, a willingness to set aside sufficient time without
interruptions, and a private setting defined acceptable participant access criteria.
For data collection, I conducted personal interviews using a semistructured format
to facilitate free expression by participants and allow clarifying questions. The data I
collected was qualitative. Neuman (2011) observed a quantitative research method is
appropriate for seeking numeric responses to narrow question responses. However, the
rightness of understanding how physicians make decisions was achieved perhaps to a
greater degree without quantitative measurement.
Before data collection, I validated the research interview instrument through one
pilot test interview and used interviewing-the-investigator technique (Chenail, 2011) to
determine realistic responses as well as improve interviewing skills. These preparatory
steps were taken to enhance the trustworthiness of collected data and therefore improve
the reliability and validity of coding, theme development, analysis, and study outcomes.
After data collection and theme development, I sent identified themes and transcript
excerpts to participants for the purposes of member-checking and triangulation. I
protected the confidentiality of all participants and identified only the initial of the
subject reviewing the document. The intent of this step was to enrich study validity,
conformability, and outcomes significance. Approximately one-half of study subjects
responded and all who responded affirmed document accuracy without revisions.
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Research Question
Using the primary study question, I invited situational examination (contextual
application) and expanded knowledge (Ellis & Levy, 2009). The answer shaped the
strategy for n-3 marketers regarding how physicians make medical decisions using
observable, selected data, and how they add personal meanings, assumptions, and
conclusions to the data resulting in behavioral action. My primary research question was:
For the purpose of marketing strategy, what is the ladder of inference physicians use to
recommend n-3 dietary supplements?
The specific interview questions were:
1. Considering the previously explained ladder of inference and reflexive loop
(Ayers, 2002), what processes do you go through to determine what products
you will prescribe or what dietary supplements you will recommend?
2. What credible clinical evidence have you seen regarding fish oil dietary
supplements?
3. What made the evidence credible or incredulous?
4. What are the risks of taking fish oil dietary supplements?
5. What are the risks regarding specific patient groups or disease states?
6. What are the important differences between quality fish oil dietary supplements
and low quality fish oil dietary supplements?
7. What are right daily amounts of DHA and EPA?

12
8. If clinical evidence is credible and convincing regarding fish oil efficacy for
health prevention for disease amelioration, what education and
communication methods to physicians are best?
9. Similarly, what education and communication methods to patients are best?
10. Within the context of the ladder, please explain your present professional
opinion regarding the health value of fish oil dietary supplements, specifically
fish oil containing n-3s, for patients with no contraindications.
11. What are your prescribing or recommending practices regarding n-3 fatty acid
dietary supplements and the priority of n-3 dietary supplements as compared
with other dietary supplements (e.g., multivitamins, chondroitin, niacin)?
12. How influential are your peers’ prescribing practices to your decisions?
13. When you speak with your peers, what percentage of them would you say are
committed to frequently recommending omega-3s?
14. If all your patients took a high quality omega-3 every day, what would be the
impact on your whole practice?
15. If all your patients took a high quality omega-3 every day, what would be the
positive impact on U.S. healthcare costs?
Conceptual Framework
Physicians, in general, lack sufficient knowledge of dietary supplements, and in
particular n-3s (Ashar, Rice, & Sisson, 2008), to discuss with confidence these substances
with patients (Kemper, Amata-Kynvi, Dvorkin, Whelan, Woolf, Samuels, & Hibberd,
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2003). I found no reference more recent than 2003, which supports a gap in the literature
and the need for this study.
Ladder of inference theory (Argyris, 1976) provided a conceptual framework for
deciphering and prioritizing the complex and competing factors influencing physicians’
knowledge and willingness to recommend n-3s. Ladder of inference theory includes six
ladder rungs as requisite steps leading from data to enacted behavior. These progressive,
logical ladders are as follows: (a) observable data and experiences, (b) selected data from
observable data, (c) assumptions based upon meanings added to data based upon cultural
and personal experiences, (d) conclusions drawn from assumptions, (e) adopted beliefs
about the world, and (f) actions taken based upon beliefs (Argyris, 1976). Using the
ladder of inference model to guide interview questions added structure and meaning to
physician subject responses. This structure also facilitated data coding, interpretation, and
analysis. The ladder of inference theory facilitated physicians’ self-understandings,
helped identify needs for education and marketing purposes, and fostered efficiency when
attempting to drive theme clarity and outcomes from the group upon member-checking
follow-up.
Definition of Terms
Allopathic: A system of treating disease by inducing a pathological reaction
antagonistic to the treated disease (Venes, 2009).
Atherosclerosis: Arterial disorder characterized by restricted blood flow from
cholesterol-lipid-calcium deposits in the walls of arteries. Over time, arteries may
become completely blocked. If a plaque ruptures within a blood vessel, the blood vessel
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can close, and organs or tissues may infarct. Risk factors for atherosclerosis are tobacco
abuse, diabetes mellitus, elevated blood lipid concentrations, hypertension, family
history, male gender, menopause in women, microalbuminemia, chronic kidney disease,
increased age, sedentary lifestyle, and obesity (Venes, 2009).
Atherogenesis: The formation of plaques beneath the membrane of artery linings
(Venes, 2009).
Auto-ethnography: As the researcher, my experience automatically derives from a
cultural connection or identification with the subject (Sergi & Hallin, 2011)
Complementary and alternative medicine (CAM): CAMs are alternative therapies
to conventional treatments. Conventional treatments demonstrate efficacy and safety to
achieve FDA approval. Complementary medicine indicates a therapy may be added to a
conventional treatment. Alternative medicine implies a therapy other than a conventional
treatment. The Cochrane Collaboration provides a classification of CAM treatments
(Wieland, Manheimer, & Berman, 2011).
Chemotaxis: Cellular movement toward or away from chemical stimuli. The term
chemotaxis primarily refers to phagocytic white blood cells (Venes, 2009).
Docosahexanoic acid (DHA): Long chain polyunsaturated n-3 (Venes, 2009).
Docosapentanoic acid (DPA): Long chain polyunsaturated n-3 fatty acid
metabolized by the body into eicosapentanoic acid (EPA) (Whelan, 2009).
Eicosapentanoic acid: Long chain polyunsaturated n-3 fatty acid.
Essential fatty acid (EFA): A polyunsaturated fatty acid necessary in the diet for
proper growth, maintenance, and bodily function. Diets deficient in EFAs may contribute
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to changes in cell structure and enzyme function, resulting in decreased growth and other
disorders. Symptoms include nail problems, brittle hair, dandruff, allergic conditions,
dermatitis, and eczema in infants (Venes, 2009).
Homeopathic, homeopathy: Based upon the proposal that very dilute doses of
extracts, medicines, or other substances producing symptoms of disease in healthy people
will cure those diseases in affected patients (i.e., “like cures like”). Homeopathy differs
from allopathy because homeopathy emphasizes the body healing itself (Venes, 2009).
Hypertriglyceridemia: A condition marked by too many triglycerides in the blood
(Venes, 2009).
Ladder of inference: A mental model containing decision rungs, all of which are
confirmable by others, except the bottom rung of observable data and experiences.
Subsequent ascending rungs include I Select Data (from what a researcher can observe), I
Add Meanings (cultural and personal), I Make Assumptions (based on the meanings the
researcher adds), I Draw Conclusions, I Adopt Beliefs (about the world), and I Take
Actions (based on the researcher’s beliefs). An individual can unconsciously ascend the
ladder quickly, perhaps too quickly, taking actions based upon established beliefs,
triggered by observed data. This process is a reflexive loop (Ayers, 2002).
Momentary salience: the temporal influences of personal mood and environment
affecting a decision (Weiss, Weiss, & Edwards, 2010)
Omega-3 fatty acids (n-3s): Essential fatty acids with double bonds at the third
carbon away from the omega (methyl) end of the molecule (Venes, 2009).
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Physician: An individual who successfully completed the prescribed curriculum
of studies in a medical school officially recognized by the country of the medical school
location, and who has acquired the requisite qualifications for licensure in the practice of
medicine (Venes, 2009).
Preventive medicine: The branch of medicine to prevent disease and methods to
increase power of patient and community to resist disease and prolong life (Venes, 2009).
Qi gong (qigong): The Chinese approach to healing based upon the harnessing of
inner energy sources. Therapists employ movement, breathing exercises, meditation, and
relaxation (Venes, 2009). In the medical field sometimes referred to as qi (Wieland et al.,
2011).
Reflexive loop: Human reactive behavior where an individual interprets observed
data selectively, biased by personal beliefs and experiences (Ayres, 2002).
Rigor: The process of identifying gaps between what was actually done versus a
prescribed or standard method using a measurement approach throughout the analysis
to assure accuracy and reduce the risk of shallow analysis (Zelik, Patterson, & Woods,
2010).
Stearidonic acid (SDA): An n-3 fatty acid with similar biological properties to
EPA found in plant sources such as soybean oil, hemp seed oil, and black currants
(Whelan, 2009).
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Assumptions, Limitations, and Delimitations
Assumptions
Assumptions are statements about factors not observable or testable (Neuman,
2011). My first assumption was that physician subjects want to recommend what is in the
best interest of their patients. The second assumption was most physicians do not
recommend n-3s and this study confirmed this assumption also supported by the
literature. The third assumption was the integrity of the physician subjects and the
substance of physician conversations supported this assumption. My fourth assumption
was that the conducting of interviews in private settings to limit uncontrollable variables
(e.g., interruptions) would enhance uniformity, prevent material bias, and ensure
confidentiality (Alcadipani & Hodgson, 2009).
Limitations
Two limitations of this study included purposeful sampling of primary care
physicians in a limited geography (Kentucky, Indiana, Tennessee). I did not select
physician subjects from other specialties because of a lack of relevancy and focus upon
cardiovascular preventive medicine. Physicians in a wider geography, for example, on the
west coast or east coast of the United States may have different viewpoints of n-3s.
A third limitation was the sample size (n = 20), although I did not gather
significant new information after the 15th interview and therefore, believe I reached the
point of saturation in less than 20 interviews. Saturation is a guiding principle of sample
size determination in qualitative studies (Carlsen & Glenton, 2011). Mason (2010)
asserted the concept of saturation is elastic and true saturation is contingent upon a
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number of variables such as the aims of the study, homogeneity of participants, and skill
of the interviewer. The focused aims of this study, similar specialties among physician
subjects in a limited geography, and richness of data gathered during interviews support
the possibility of achieved sample saturation for this defined population.
Kerr (2010) that explained investigators cannot predict saturation before the study
but for practical purposes, investigators need to plan number of subjects. From a
literature review, Kerr determined investigators who sought to establish sample size
guidelines for qualitative methods of inquiry advocated samples sizes of six to 20
subjects. Similar to Mason (2010), Kerr stated that saturation depended upon
heterogeneity of subjects and study objectives. These guidelines support the purposeful
sample size for this focused physician decision-criteria marketing study.
Delimitations
Delimitations included the conscious inclusion and exclusion criteria specified in
this study and Informed Consent. I based purposeful selection upon interest in the study
subject, an open perspective regarding diverse opinions, and access. Geographical scope
and a willingness to set aside sufficient time without interruptions in a private setting
defined acceptable participant access criteria. Considering these delimitations, I could not
determine if interviews would have elicited different data if the physician participants did
not have an interest in the topic, practiced in states other than Kentucky, Indiana, and
Tennessee, or who did not agree to participate in this study.
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Significance of the Study
Reduction of Gaps
Marketers of n-3s may benefit from the research findings of this study to improve
understanding of how physicians think regarding prescribing or recommending decisions.
The ladder of inference posits individuals do not test self-generating beliefs to validate
truth (Argyris, 1976). For example, individuals believe own beliefs are the truth, and the
truths they believe are the obvious truths. Individuals also believe they base beliefs and
conclusions upon real data (Argyris, 1976). The next ladder is the data individuals select
to believe to formulate truth is, in fact, real data (Argyris, 1976). In this study, I examined
the steps in the ladder of inference relevant to prescribing or recommending decisions;
these important study outcomes may reveal strategic business opportunities for marketers
of n-3 dietary supplements.
One unintended, but relevant, theme that emerged from this study was the
physician participants’ unanimous and unsolicited opinions regarding the inadequacy of
dietary supplement training in medical schools. This theme reinforces the findings of
Adams, Kohlmeier, and Zeisel (2010). Based upon ProQuest multiple database searches,
few studies have been published regarding this subject.
Implications for Social Change
Validating prospective business (marketing) and societal benefits were central
intentions of this study. In a university IRB-approved pilot interview with a physician, J.
Lach (personal communication, November 17, 2011), Lach confirmed the prevalence of
cardiovascular disease in his practice and in the general U.S. population. Lach expounded
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upon the possible social benefits of a preventive cardiovascular disease product like
Lovaza. The data from the pilot interview, therefore, confirmed the prospective social
change benefits of this study. Contemplating the effects of physicians’ more frequent
prescribing and recommending n-3s (behavioral change), physicians who participated in
this study confirmed the possibility of substantial societal benefits resulting from reduced
cardiovascular disease, providing the positive outcomes of some n-3 studies were true
and the negative outcomes of other n-3 studies were not true.
Study Prospects for Improving Society
Change occurs when a research study affects society. In this case, the marketing
of n-3 supplements, medicine, and science intersect each other with possibly different
values (Matheson, 2008). Matheson expounded how business profits motivate
pharmaceutical marketers, good health motivates physicians, and the truth motivates
researchers. So determining this study’s prospects for improving society requires
objectivity with respect to n-3 safety and efficacy as well as a fair appraisal of the impact
of effective marketing on society. The outcomes from this study may drive improved
communication and symmetry between physicians and patients regarding accountability
for preventive health. Physicians may more effectively collaborate with their patients to
accomplish requisite n-3 dietary changes. All of this may be positive for society,
providing n-3s deliver the preventive cardiovascular disease benefits claimed in many but
not all clinical studies.
The societal implications for this study follow a sequential chain. First, marketers’
improved understanding of physician inference ladders may enable more effective
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communication between n-3 marketers and physicians regarding the possible preventive
cardiovascular disease value of n-3 dietary supplementation. Second, physicians’
assumptions and conclusions based upon credible, observable data may lead to a more
educated cognitive framework regarding n-3s. Third, physicians’ experiences may
reinforce behavioral change. The change in physician subjects’ attitudes and behaviors
may expand preventive medicine practice.
When published, study results may expand societal benefits in a wider, national
geography. Additionally, study findings may influence the population of primary care
and specialist physicians to recommend n-3s to their patients as preventive medicine.
America’s cardiovascular disease epidemiology may decrease along with the concomitant
health interventional treatment costs.
A Review of the Professional and Academic Literature
This section includes six related literature review areas. First, I identify and
describe CAM as the nondrug classification system including n-3s. Next, a portion of the
literature review supports the efficacy, safety of the correct n-3s, and n-3 daily dosages as
dietary supplements although another portion of the literature review raises questions
regarding the safety and efficacy of n-3s. In the subsequent three sections, I cite literature
to support the knowledge deficiency and need for physician education as well as a
framework for understanding physicians’ recommending and prescribing decisions. In the
final section, I highlight the importance of the role of the patient and the importance of
the physician’s achievement of patient conviction and compliance. The literature review
encompasses multiple databases and search engines, including ProQuest Central,
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ABI/Inform Complete, Academic Search Complete/Premier, Science Direct, Business
Source Complete, Google Scholar, and PubMed. Additionally, corporate and trade
sources provided leads to scholarly journals. I used search words such as “omega-3,”
“cardiovascular disease,” “eicosopentanoic acid,” “docosahexanoic acid,” “fish oil,” “fish
oil contaminants,” “dietary supplements,” “physician education of dietary supplements,”
“omega-3 clinical evidence,” “omega-3 safety,” and “omega-3 efficacy.”
Complementary and Alternative Medicine
The Cochrane Collaboration has become an important source of information
collection and organization of 396 reviews regarding CAM therapies (Wieland et al.,
2011). The Cochrane Collaboration has defined CAM operationally, and Wieland et al.
(2011) articulated how the standardized definition has provided an objective,
reproducible, and systematic method for defining, revising, and classifying multiple
CAM therapies. Wieland et al. described how some medical school officials have
integrated CAM therapies into medical school curricula, in addition to randomized
controlled trials (RCTs) and systematic reviews. Despite increased mainstream openness
to CAM therapies, practitioners, researchers, and consumers concede certain therapies
remain outside the mainstream medical model such as CAM therapies. For example,
according to Wieland et al., medical professionals agreed acupuncture is a CAM
classification but disagreed about other CAM classifications, such as vitamin
supplements. To reduce ambiguity, enhance understanding of the field, guide research,
and augment the safe use of CAM therapies, Wieland et al. described how a theoretical
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definition of CAM evolved into a more important and pragmatic standardized operational
CAM definition.
In this classification process, Wieland et al. (2011) first considered theories of
disease and whether or not the historic notion of the subject therapy was considered CAM
or conventional. Second, the researchers excluded CAM classifications from entities
currently accepted by the medical community, including insurance payers and the FDA.
Third, the researchers considered who administered the therapies; they were more likely
to classify therapies as CAM if the patient self-administered the therapy or if non-medical
practitioners administered the therapy. Interestingly, Wieland et al. did not include
efficacy evidence because they noted the presence of too many therapies not currently
accepted as efficacious (e.g., chemotherapy), or noted the lack of convincing evidence of
efficacy.
Wieland et al. (2011) considered information obtained from the US National
Library of Medicine's PubMed database, including the Medical Subject Headings
definition of complementary therapies and the complementary medicine-subset search
strategy. From the review and decision process described above, Wieland et al. identified
51 groups of CAM therapies used for treating or preventing disease. Wieland et al. gave
preference to CAM therapies in their operational definitions to therapies previously
subjected to RCTs. Wieland et al. noted they would expand their operational CAM
definitions over time as additional clinical research is completed.
The Cochrane CAM field listed more than 200 CAM therapies. Regarding n-3s,
the physician researchers included fish oil (n-3s) as one classification, but also included
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DHA and EPA as separate classifications. Perhaps the reason for overlap is Wieland et al.
(2011) described RCT evidence as an important criterion for inclusion. See Appendix A
for the CAM therapy list.
To assess physician acceptance of CAM, Johnson, Priestley, Porter, and Petrillo
(2010) conducted an online survey to members of a professional health educator listserv
(n = 501). The researchers’ purpose of their study was to examine health educators’
attitudes regarding CAM while examining the educators’ use of CAM therapies,
presumably to confirm expressed attitudes by the educators. The study results indicated
educators have positive attitudes toward CAM in general.
Ninety percent of respondents used at least one CAM therapy in the previous 12
months (Johnson, Priestley, Porter, & Petrillo, 2010). On a 5-point scale, a score of 1
indicated the respondents strongly agreed, whereas a score of 5 meant the respondents
strongly disagreed. The response scores of men and women respondents to the statement
“CAM should be included in professional health education preparation curriculum” were
2.2 and 1.87, respectively. To the statement “CAM is a threat to public health,” the male
respondent mean score was 3.93 and the female mean score was 4.23. The researchers
noted a physician interest in CAM and CAM use by physicians was increasing in the
United States.
Omega-3 Cardiovascular Efficacy and Safety
In this section, I provide evidence to support, as well as refute, the efficacy and
safety of n-3s. Harvard University and University of Western Australia authors
Mozaffarian and Wu (2012) posited clinical evidence indicates EPA and DHA possess
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collective and complementary cardiovascular benefits for humans. Some studies noted by
Mozaffarian and Wu suggested favorable cardiac diastolic filling (facilitated cardiac
blood flow), arterial compliance (arterial wall flexibility), and reduced metrics of
inflammation and oxidative stress. Combined EPA + DHA or docosapentanoic (DPA)
acid + DHA levels were associated with a lower risk of fatal cardiac events. The authors
noted based upon the current evidence, increasing consumption of either DHA or EPA
would offer cardiovascular advantages versus little or no consumption.
Reviewing clinical trials including more than 30,000 subjects with cardiovascular
or hyperlipidemia history—the Diet and Reinfarcation Trial (DART), Japan EPA Liquid
Intervention Study (JELIS), and Gruppo study Italiano per lo Studio della Sopravivenza
nell’Infarto Miocardico (GISSI), Vrablik et al. (2009) opined a number of conclusions.
First, Vlabik et al. determined uncontrolled diets as independent variables in clinical trials
could influence study outcomes, especially in long-term follow up. The investigators
opined evidence supported a recommended daily EPA and DHA dietary supplement
intake of 500 mg to 1,000 mg.
Vrablik et al. (2009) also opined EPA and DHA could reduce triglyceride levels
by 25%-35% and in cases of severe hypertriglyceridemia, by 45%. Vrabik et al. also
observed evidence where only DHA increased the levels of good cholesterol HDL. The
researchers suggested both EPA and DHA reduce atherosclerosis development, reduce
blood pressure slightly (5.8 mmHg for systolic and 3.3 mmHg for diastolic), and at
higher doses (>2g/day), reduce systemic inflammation and inhibit platelet aggregation.
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In another literature review, De Caterina (2011) recapped the history of n-3s, from
obscurity to substantial researcher interest. In the 1960s, Danish investigators reported
the Greenland Inuit population showed a low incidence of heart disease. In the first
epidemiologic observations of Inuits in Greenland (who regularly consumed a diet
consisting of fish, seal, and whale), scientists suspected a nutritional factor was
associated with cardiovascular protection. These observations were later confirmed in
studies of Northern Canada and Alaska natives who consumed traditional diets as well as
high fish-consuming Japanese, Western, and Chinese (De Caterina, 2011) and rural
inhabitants Nenet Autonomous Okrug in Russia (Petrenya et al., 2012).
In 25 studies involving 280,000 participants, De Caterina (2011) reported an
inverse association between fish consumption and morbidity or mortality from coronary
heart disease. De Caterina determined blood levels of n-3 fatty acids correlated inversely
with death from cardiovascular causes and total mortality. De Caterina also cited clinical
trials with other cardiovascular outcomes including lowered triglycerides, reduced risk of
sudden cardiac death, decreased systemic inflammation, slowed buildup of
atherosclerotic plaque, and reduced risk of thrombosis and stroke. De Caterina stated the
AHA recommended adults eat fatty fish at least twice a week as well as vegetables
containing n-3 fatty acids (ALA). De Caterina noted the AHA also recommended
coronary heart disease patients consume approximately one gram of EPA and DHA
(combined) per day, from oily fish or fish-oil capsules (with physician consultation and
advice). The AHA recommended higher daily doses of EPA and DHA (2 - 4 grams) as
useful in patients with severe hypertriglyceridemia (> 500 mg of triglycerides per
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deciliter) to reduce serum triglyceride levels by 20% to 40%. In this paradox, Catarina
explained how one type of desirable fatty substance lowers another undesirable fat in the
human body.
In a blood sample experiment, Holub, Wlodek, Rowe, and Piekarski (2009)
reported correlative results from living human subjects (n = 2,053). The researchers
compared fatty acid ratios between anti-inflammatory, healthy n-3 (EPA and DHA) with
the pro-inflammatory n-6 arachidonic acid using the following ratios: n-6/n-3, AA/EPA,
AA/DHA, and AA/EPA + DHA. Although correlational analyses indicated inverse
relationships between the concentration of n-3s in the serum and each of the four ratios in
phospholipids, the researchers concluded the strongest statistically significant inverse
relationship was evident between serum n-3s and the n-6/n-3 ratio. These research results
support a diet high in n-3s will reduce the level of n-6s in serum phospholipids and
support the theory of preferential cell wall acceptance of n-3s over n-6s, thus reducing
deleterious health effects of phospholipids too high in n-6 concentrations. In a controlled
quantitative experiment consisting of 107 hyperlipidemia patients, Krysiak, Gduladymek, and Okopien (2011) also found a diet high in n-3s (EPA 465 mg and DHA 375
mg twice daily) significantly lowered plasma triglycerides (p < 0.05).
In another study, Saravanan, Davidson, Schmidt, and Calder (2010) presented
evidence of n-3 efficacy in reducing triglycerides and reducing the incidences of heart
failure, atherosclerosis, stroke, and systemic inflammation. Regarding inflammation,
Saravanan et al. discussed anti-inflammatory mechanisms including n-3 modulating
effects on neutrophils, macrophages, T-cells, and dendritic cells. In the presence of
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certain pro-inflammatory stimuli (e.g., n-6s) these cells release chemical mediators to
increase the inflammatory response. Systemic inflammation of blood vessel walls can
lead to cardiovascular disease.
Saravanan et al. (2010) reviewed clinical trials to assess daily EPA/DHA dosage
regimens, ranging between 1 gram to 4 grams per day, depending upon triglyceride level
acuity and patients’ regular dietary consumption of n-3 fatty fish. The authors determined
a one-gram daily dosage of EPA and DHA dietary supplements equals an intake of 55
grams of tuna, trout, salmon, or sardines, and 652 grams of cod. To determine adequate
intake, Saravanan et al. used the n-3 index. The n-3 index is a relatively new approach to
determine the appropriate quantity of n-3s in the body by measuring the amount of EPA
and DHA in red blood cells. Saravanan et al. reported an n-3 index of 8% or higher as the
guideline for the highest cardiovascular protection whereas an n-3 index of 4% or lower
as the least cardiovascular protection.
In another study, Soltan and Gibson (2008) provided information regarding
recommended daily intake recommendations for n-3 ingestion and concentrations of n-3s
by fish type. The researchers recommended 500 mg/day of DHA/EPA n-3s in healthy
adults, 1g/day for patients with coronary heart disease, and 2–4g/day for patients with
hypertriglyceridemia. In general, researchers determined that fatty fish provided potent
sources of n-3s thereby reducing consumption requirements to achieve daily desired n-3
intake. Unfortunately, several species of popular dietary fish provide poor quantities of n3s. Poor sources include Atlantic cod, whiting, barramundi, and southern Bluefin tuna.
Farmed tuna contained considerably more desirable n-3 fat than wild tuna.
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Soltan and Gibson (2008) determined the most potent sources of fish species for
n-3s were swordfish and Atlantic salmon. Consumption of only 40g (1.4 ounces) of these
species provides 1 gram of n-3s. Conversely, an individual would have to consume
approximately 400g (14 ounces) of barramundi or southern Bluefin tuna to ingest 1g of n3s. The researchers noted the impracticality of ingesting enough popular dietary fish
portions to achieve sufficient n-3 levels and emphasized the need for n-3 dietary
supplements. Soltan and Gibson also elucidated how some fish contained much
arachidonic acid, an undesirable n-6 fatty acid. Fish species with high n-6 content include
northern whiting, shrimp, and barramundi. Popular dietary fish with low n-6 content
include salmon, red snapper, and southern Bluefin tuna.
Deckelbaum and Torrejon (2012) reported n-3s promote health and prevent
disease in a number of human body systems, but the mechanisms of EPA and DHA may
be the most remarkable in cardiovascular disease. Cardiovascular benefits result from
progressive chain mechanisms improving chemotaxis and other anti-inflammatory
responses, reducing oxidative damage and systemic inflammation, reducing
atherogenesis, reducing vascular resistance, and lowering blood pressure. However,
Deckelbaum and Torrejon noted the inadequacy of cold water fish and other dietary
sources to achieve n-3 daily intake recommendations.
As one partial solution, Deckelbaum and Torrejon (2012) recommended genetic
modification of soybeans to produce high volumes of stearidonic acid (SDA). In human
metabolism, the body synthesizes SDA into EPA. In another study including SDA,
Whelan (2009) advocated the therapeutic and health-promoting effects of n-3s from fatty
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fish sources and SDA because an n-3 precursor found in many vegetable oils, Į-linolenic
(ALA), may not provide the same health benefits because of its partial conversion to n-6
and n-9 fatty acids.
Whelan (2009) noted another benefit of investigated fatty acid, SDA, as an
alternative source of n-3 because of concerns for fish oil purity. According to Whelan,
researchers have determined SDA may have similar biological properties to EPA. SDA
sources include soybean oil, black current, and hemp seed oil. In a scientific comparison,
Whelan concluded SDA shares many of the same biological effects as EPA, and
therefore, may become an important food additive and contribute a significant supply of
n-3 dietary supplementation for the Western world.
Based on a meta-analysis of 25 RCTs, Whelan et al. (2012) concluded EPA and
DHA dietary intakes, on average, reduced triglyceride levels 27 mmol/L. In their
literature review, they found EPA and DHA dietary intake had the most pronounced
effects on circulating triglyceride levels at daily doses > 2g/day, but with smaller effects
on HDL and LDL cholesterol levels. Dosages ranged from 0.8g to 5.4g/day. Whelan et
al. highlighted most studies employed dosages in the 2–4g/day, with the most pronounced
effects on triglycerides at doses greater than or equal to 3g/day.
Marik and Varon (2009) reviewed 11 randomized, placebo-controlled studies,
including 39,044 patients with histories of recent myocardial infarction, heart failure,
implanted cardioverter defibrillator, hypercholesterolemia, and peripheral vascular
disease. Average doses of n-3 EPA and DHA ranged from 0.6–3.0g/day. Patient followup period ranged from 1.0–3.4 years. Marik and Varon concluded specific EPA/DHA n-3
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dietary supplementation reduced the risk of cardiovascular deaths (p = 0.002), sudden
cardiac death (p = 0.04), all-cause mortality (p = 0.02), and nonfatal cardiovascular
events (p = 0.02). Although multiple regression analyses did not demonstrate a doseresponse relationship, patients in this study ingested higher average doses than
recommended by the 2008 expert panel (Harris et al. 2009). The authors recommended n3 dietary supplements as a practice of secondary cardiovascular event prevention.
N-3 fatty acids may reduce blood pressure and pulse rate according to the results
of a meta-analysis by Hoy and Keating (2009). A mean systolic/diastolic BP reduction of
2.3/1.5 mm/Hg occurred with a mean n-3 dosage of 4100 mg/day. In subgroups, Hoy and
Keating reported more meaningful blood pressure reduction in older subjects (age >45
years) versus younger subjects. Additionally, Hoy and Keating determined hypertensive
subjects experienced more blood pressure reduction than did normotensive patients. Hoy
and Keating also determined n-3s reduced pulse rate. Mean heart rate was significantly (p
= 0.002 vs. placebo) reduced by 1.6 beats/minute in subjects who consumed a median n-3
dosage of 3500 mg/day. In subgroup analysis, Hoy and Keating discovered a significant
(p < 0.001) reduction of 2.5 beats/minute in subjects with mean heart rates of 69
beats/minute at baseline, but no significant change in subjects with mean heart rates of
<69 beats/minute at baseline.
Regarding recommended n-3 dosages, Hoy and Keating (2009) opined n-3
dosages for the secondary prevention in patients with a history of myocardial infarction is
1000 mg/day. In patients with hypertriglyceridaemia, Hoy and Keating recommended a
dosage regimen of 2,000 mg/day – 4,000 mg/day depending upon patient response. The
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researchers noted patients might choose to take n-3 supplements with food to avoid
gastrointestinal disturbances. This analysis demonstrated sufficient n-3 dosages may
provide clinically significant reductions in serum triglyceride levels, blood pressure
reduction in patients with untreated high blood pressure, and heart rate reduction,
irrespective of sex or age.
Somewhat confirmatory, Cabo, Alonso, and Mata (2012) reported some studies
indicated n-3 consumption reduces systolic blood pressure. However, Cabo et al. noted
study results were not consistent. Cabo et al. recommended n-3 supplementation as
beneficial for mildly hypertensive patients, preferring dietary changes before starting
drug therapy.
As a corollary to cardiovascular disease, Grenon, Hughes-Fulford, Rapp, and
Conte (2011) cited population studies indicating peripheral artery disease (PAD) affects
more than 12% of people over 65 and 20% over 75. Grenon et al. explained PAD
treatments cost more annually than coronary artery disease or cerebrovascular disease.
PAD also includes development of thromboses resulting in possible emboli.
Explaining the root causes of PAD, Grenon et al. (2011) confirmed U.S. daily
dietary intake of 1.6g of ALA, but noted ALA’s inferior desirable biological activity to
EPA and DHA. Grenon et al. also compared the average dietary intake of ALA (1.6g) to
the average dietary intake of 14.8g/day of n-6 linoleic acid. They listed sources of n-6
fatty acids as corn oil, soybean oil, safflower oil, and sunflower oil. Sources of n-6
arachidonic acid include poultry and meats. Conversely, sources of ALA include flaxseed
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oil, canola oil, and soybean oil but soybean oil contains more LA than ALA. Grenon et
al. listed only oily fish and fish oil capsules as viable sources of EPA and DHA.
Grenon et al. (2011) explained the differences in end-mediators resulting from
consuming n-3s versus n-6s in the diet. Consuming n-6 produces end-mediators to
promote systemic inflammation, including lipoxins, thromboxanes, prostacyclins, and
leukotrienes. Conversely, n-3s produce resolvins and protectins, substances active to turn
off inflammation. Tartibian, Maleki, and Abbasi (2010) explained how n-3s also alter
cyclo-oxygenase and lipoxygenase pathways to reduce inflammation. Somewhat
evidentiary, the Tartibian et al. study demonstrated how n-3 consumption during intense
wrestling training improved pulmonary function of wrestler athletes. Grenon et al. also
reported one fish-oil-enriched meal improved flow-mediated brachial artery vasodilation
(FAD). Improved FAD for PAD patients may lower systemic inflammation and reduce
progressive atherosclerosis, improving circulation and abating the risk of PAD.
The circulatory effects resulting from ALA dietary consumption evolve from
complex chemical mediator synthesis mechanisms. Discussing dietary plant oils as
sources of ALA and n-3s,Vrablik, Prusikova, Snejdrlova, and Zlatohlavek (2009)
explained of the essential n-3s, ALA, which is present in plant oils such as walnuts,
soybeans, and flaxseeds, only 5% of ALA is converted into EPA and DHA in the body.
Most of the ALA converts to n-6 arachidonic acid, thereby adding to the excessive and
potentially harmful levels of arachidonic acid already prevalent in the American diet.
This conversion process adds understanding of another way (in addition to red meat
consumption) n-6s accumulate in the body.
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As possible contradictory evidence to the dietary effects of ALA, Kris-Etherton,
Hu, Ros, and Sabaté (2008) advocated the possible health value of ALA in nuts. KrisEtherton et al. also discussed how after ingestion, the body converts some ALA to EPA.
Pooling results from four U.S. epidemiological clinical studies, Kris-Etherton et al.
evaluated cardiovascular health effects from the consumption of different tree nuts and
peanuts, dietary sources of ALA and other cardio-protective nutrients. The study
compilation indicated individuals who consumed nuts five or more times per week
reduced risk of fatal coronary heart disease by 39% and nonfatal myocardial infarction by
32%. Additionally, men who consumed nuts two times per week had a 47% reduction in
sudden cardiac death. Subjects who consumed peanuts twice per week had a lower
incidence of coronary heart disease by 34%.
Kris-Etherton et al. (2008) described the ingredients and mechanisms by which
nuts exert these health benefits. The nut mechanisms reduce oxidation, reduce systemic
inflammation, and reduce vascular reactivity. Nut ingredients that reduce oxidation
include tocopherols, phenoloic antioxidants, melatonin from walnuts, mononsaturated
fats, and PUFAs. Nut ingredients that reduce inflammation (as measured by a reduction
in circulating C-reactive protein [CRP] levels) include ALA, metabolized in the body to
PUFA n-3s. Nut ingredients responsible for increased vascular reactivity (vasodilation,
reduced cellular adhesion to blood vessel walls, reduced atherosclerosis) include larginine, ALA (to n-3), and other antioxidant nutrients.
Kris-Etherton et al. (2008) noted the predominant study of walnuts as potent
sources of these desirable active ingredients. Kris-Etherton et al. cited the American
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College of Cardiology prediction by 2050 the American incidence of cardiovascular
disease will double. They advocated an overall diet high in fruits, vegetables, nuts, whole
grains, legumes, low-fat dairy products, and lean protein.
In another study, Tovar et al. (2012) advocated the modulating effects of a healthy
diet including n-3s in individuals with cardio-metabolic diseases (CMD) and metabolic
syndrome (MetS). Administering a healthy diet with daily intakes of multiple function
foods including n-3s (subject daily dosages were 2.4g for women and 3.0g for men),
Tovar et al. demonstrated statistically significant CMD and MetS risk-reduction health
benefits. In a crossover design study with treatment and washout periods each lasting 4
weeks, subjects (n = 44) between the ages 50 to 73 were randomly assigned to either a
control diet (CD) or active diet (AD). Subjects maintained their habitual diets during the
CD arm. The AD included a specified menu including (a) items rich in antioxidants; (b)
n-3s; (c) probiotics (Lactobacillus strain) and prebiotics, including intact barley kernels,
whole kernel rye flower, and isolated barley fiber; (d) low glycemic foods, such as high
fiber bread, whey protein, and vinegar; and (e) soybean products and margarine enriched
in stanol esters and dry almonds.
Tovar et al. (2012) determined statistically significant CMD and MetS riskreducing effects from the AD arm but not the CD arm. The AD arm benefits included: (a)
8% reduction in systolic BP, (b) reduced high sensitivity C-reactive protein (hs-CRP)
scores by 29%, indicating reduced vascular inflammation, (c) lower Framingham Study
algorithm cardiovascular risk scores by 30%, and (d) lower Reynolds cardiovascular risk
scores by 35%. AD arm benefits also included: (a) reduction in triglycerides by 19%, (b)
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reduction in LDL by 34%, (c) reduction in HDL by 10%, (d) reduction in the LDL/HDL
ratio by 27%, and (e) reduction in the ApoB/ApoA-1 ratio by 10%. The ApoB/ApoA-1
ratio measures apolipoproteins, which when combined with LDL/HDL cholesterol ratios
indicate risk of MetS.
Tovar et al. (2012) noted the satiating effects of the AD, which allowed ingestion
of some animal meat and how the AD was more effective than the Mediterranean diet,
the Nordic diet, and the vegetarian diet in its reduction of systemic inflammation and
cardiovascular risk. Although not an intended study outcome, the researchers posited the
weight loss drop in the AD group probably resulted from satiety associated with the diet
higher in protein content. Tovar et al. stated the drop in systolic BP probably resulted
from the high dietary supply of long-chain n-3s. Although the researchers in this study
did not focus singularly upon n-3 efficacy, the Tovar et al. provided some evidence of the
possible contributory and potentiating effects of n-3s upon good cardiovascular health
when combined with other healthy dietary initiatives (see Appendix B).
In another study of n-3s with other dietary supplements, (Radler, et al., 2011)
demonstrated health benefits of n-3 ingestion combined with polyphenols and L-carnitine
in MetS subjects (n = 22). After 12 weeks of therapy, subjects experienced a free fatty
acid serum reduction of - 29% and serum triglyceride reduction of - 24% (each p < 0.05).
Although the findings were statistically significant, one limitation of this trial was the
combination therapy.
From a global perspective, clinical research outcomes have enhanced international
interest in n-3s (Ginsberg & Toal, 2009). Ginsberg and Toal reported consumer concerns
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regarding negative methyl-mercury purity messages and therefore developed a
risk/benefit summary for consumption by fish species. Farmed salmon, herring, and trout
species had the highest benefit/risk ratio. Other species had a small net benefit or net risk
rating (e.g., flounder, canned light or white tuna, halibut) but swordfish and shark rated
high risk/low benefit. A logical conclusion is concentrated EPA/DHA purified fish oil
supplements may provide n-3 health benefits while obviating methyl-mercury
consumption risks associated with commercial fish food species. According to De
Caterina (2011), the AHA advised caution with respect to fish contaminants but
acknowledges some species are low in methyl-mercury, noting fish oil supplements are
free of methyl-mercury.
The following studies also provide some evidence to question the safety and
efficacy of n-3s. In a meta-analysis of clinical trials including 33,429 subjects with
cardiovascular disease, Chen et al. (2011) determined no significant differences in
lowered epidemiology of sudden cardiac death, cardiac death, and all-cause mortality.
One limitation of the Chen et al. analysis was trial heterogeneity including n-3 dosage,
baseline disease severity, and follow-up duration. One important feature to this study is
46% of subjects were receiving concomitant statin therapy to lower cholesterol and
triglycerides.
Regarding SDA as a source of n-3s, Whelan, Gouffon, and Zhao (2012)
questioned the suitability of genetically altered SDA as a replacement for DHA/EPA
from fish sources. Whelan et al. (2012) noted the challenge of a sustainable fatty fish
supply to provide the world population ample n-3 dietary supplementation. Whelan et al.
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noted previous researchers who advocated genetically altered soybean oil modified to
produce SDA concentrations of at least 30%, as a suitable replacement for EPA from fish
sources at a ratio of 3.7 grams of SDA to one gram of EPA. In a retrospective review of
three human clinical trials comparing SDA with EPA for clinical effects in lower
triglycerides as well as LDL and HDL cholesterol levels, Whelan et al. determined SDA
was not effective in lowering triglycerides, HDL, or LDL levels.
In a presentation of evidence after evaluating several epidemiological studies
spanning 15 years, Borghi and Pareo (2012) raised skepticism regarding the efficacy of n3s in reducing ventricular arrhythmias. The investigators acknowledged the role of n-3s
in moderating atrial fibrillation. Borghi and Pareo opined n-3s may not reduce the
incidence of cardiac mortality and sudden death in ventricular arrhythmic patients.
Raising skepticism of n-e efficacy in a specific patient group, Bosch et al. (2012)
studied 12,536 patients who were at high risk for cardiovascular events. Study subjects
received at least 900 mg ethyl ester n-3s or placebo daily and the investigators followed
this group for a median period of 6.2 years. This group of high-risk patients included
those with glucose metabolism impairment: impaired fasting glucose, impaired glucose
tolerance, or diabetes. Bosch et al. concluded n-3s had no effect on cardiovascular
outcomes in this group of high-risk patients.
In a literature review of n-3 clinical trials, Vlablik, Prusikova, Snejdrlova, and
Zlatohlavek (2009) raised the possibility n-3 dietary supplementation may raise
undesirable low-density lipoprotein (LDL) cholesterol levels when used in high doses for
patients with hypertriglyceridemia. Vlabik et al. explained EPA is the specific n-3
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correlated with higher LDL blood levels. Vlabik et al. noted the effects of EPA on LDL
levels may be mitigated by DHA because investigators have demonstrated DHA
increases desirable high-density lipoproteins (HDL). Vlabik et al. explained DHA
changes the sub-fraction distribution of LDL particles so the particles are less sticky and
therefore less likely to contribute to atherosclerosis. Therefore, for patients taking high
doses the inclusion of sufficient DHA in n-3 formulas with EPA may prevent a rise in
LDL or at least prevent deleterious health effects associated with higher LDL.
In a multicenter, double-blind, randomized, placebo-control trial of 4,837 patients
with previous myocardial infarction incidents, Kromhout, Giltay, and Geleijnse (2010)
determined low dose n-3 dietary supplemenation (226 mg EPA and 150 mg DHA) did
not reduce fatal or nonfatal cardiovascular events. Subjects consumed margarines with
EPA/DHA, ALA, or placebo identical appearances and investigators monitored cardiac
events for up to 40 months. A total of 13.9% of all patients experienced major
cardiovascular events and the rate of events in the EPA/DHA group was 46 per 1,000
compared to the rate of cardiovascular events for placebo or ALA of 45.7 per 1,000.
In a study of 834 men with prostate cancer, Brasky et al. (2013) linked high n-3
blood levels to increased prostate cancer (i.e., 44% increase in low-grade prostate cancer
risk and 71% increase in high-grade prostate cancer risk). Brasky et al. also correlated
higher blood levels of linoleic acid (n-6s) to a lower incidence of prostate cancer. The
authors opined n-3 fatty acids are involved in prostate carcinogenesis. Other investigators
attribute prostate carcinogenesis to environmental toxins including pesticides and trace
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minerals (Mullins & Loeb, 2012). Unpurified fish oils may contain one or more of these
toxins including methylmercury (Ginsberg & Toal, 2009).
In an objective to assess the role of n-3s on major cardiovascular outcomes,
Rizos, Ntzani, Bika, Kostapanos, and Elisaf (2012) reviewed 20 studies including 68,680
patients reporting 7,044 deaths, 3,993 cardiac deaths, 1,150 sudden deaths, 1,837
myocardial infarctions (MI), and 1,490 strokes. Rizos determined no statistically
significant correlation between n-3 supplementation and lower risk of all-cause mortality,
cardiac death, sudden death, MI, or stroke. The investigators concluded the published
randomized evidence does not support universally statistically significant reductions in
cardiovascular outcomes in different patient populations. The studies in this section may
inform n-3 marketers of important, contradictory n-3 viewpoints and evidence.
Applicable Decision Criteria and Theory
In the following sections, I describe several decision variables applicable to
physician prescribing decisions. The multiattribute utility (MAU) decision model is
appropriate to facilitate understanding complex, prescribing decisions. The MAU model
constructs utilities and consequences of individual decisions. Weiss et al. (2010)
proposed a modified MAU decision model including the variable momentary salience to
explain violations of individual policies. Weiss et al. simplified the MAU decision
hierarchy for pragmatic purposes to differentiate between every day, little decisions, and
infrequent, big decisions.
Momentary salience is primarily an emotional influencer including the influences
of personal mood and environment. The modified MAU decision model is important in
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the context of this ladder of inference study, because physicians evaluate complex
utilities and consequences expected from prescribing decisions but at the same, can be
influenced by momentary salience factors. This modified MAU theory provides a
corollary framework to ladder of inference theory to facilitate the organization and
understanding of physicians’ logic, beliefs, and desires triggering their n-3
recommending/prescribing behavior.
In business marketing settings, rather than the psychological construct MAU,
marketing vernacular uses customer needs. Customer needs apply to both physicians and
patients, because patients are the end-consumers; although the focus of this study is upon
physician–customer needs. Modified MAU and ladder of inference theories, used
together when analyzing and interpreting study data may augment trustworthiness to
study outcomes. Using both theories simultaneously may facilitate the translation of
empirical, psychological study findings to pragmatic, business purposes of fulfilling
customer needs.
Customer Needs and Ladder of Inference
A justificatory starting point for inference ladder application and understanding
defines basic customer needs. Montoya, Netzer, and Jedidi (2010) revealed physicians
respond to competent pharmaceutical detailing of efficacy and safety features as well as
receiving drug samples the physicians can trial with patients. Physician detailing and
drug sampling support physician needs, evidentiary by the 2005 United States
pharmaceutical industry marketing spending the majority of approximately $18 billion on
physician detailing and drug sampling (Montoya et al., 2010). In a longitudinal analysis
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(24 months) following a firm’s launch of a post-menopausal drug, Montoya et al.
evaluated the effectiveness of sampling and detailing on driving prescriptions and
discovered company waste through excessive sampling, excessive detailing, and incorrect
physician targeting. Montoya et al. concluded both detailing and sampling have longterm influence on physicians’ prescriptions; detailing is particularly effective as an
acquisition tool whereas sampling is mostly effective as a retention tool.
In addition, Montoya et al. (2010) determined sampling had a stronger short-term
effect than detailing, but detailing had a stronger long-term effect. The researchers also
demonstrated how ignoring physician buying behavior dynamics and not evaluating
marketing activity effectiveness could lead to suboptimal resource allocation. Detailing
and sampling activities fulfill customer needs as Montoya et al. demonstrated by
physician prescribing behavior frequency (i.e., inactive, infrequent, and frequent
prescribing). These physician-customer satisfaction elements apply to physician ladder of
inference analysis. Information from pharmaceutical detailing is intriguing, because
physician acceptance of information perceived as complete and accurate is a similar
construct to ladder of inference data observation and selection. Subject relevant, n-3
dietary supplement cardiovascular efficacy, safety, and differential quality attributes may
influence physicians to recommend n-3s.
Montoya et al. (2010) did not differentiate between relational and transactional
decision influencers from detailing. These influencers may be obvious or hidden. To
identify hidden influencers, Gofman, Moskowitz, and Mets (2010) presented rule
developing experimentation (RDE), an adapted conjoint analysis model. RDE is a
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systematic approach to random experimentation of product feature or promotional
messages mixes. Using RDE, researchers determine customer needs and preferences by
eliciting customer responses to prototypes. Researchers develop silos of varied and
important product or message elements and present combinations likely to appeal to
customers. The underlying RDE conceptual framework applied to this doctoral study to
develop deep inquiry interview questions and drive clear understanding of customer
needs using follow-up e-mails for member checking of transcript content and theme
development among the 20-subject physicians.
Similar to the hidden customer needs discoverable through RDE (Gofman et al.,
2010), Bassi (2007) used latent class (LC) analysis to determine which physicians were
most receptive to pharmaceutical representative sales calls. Bassi used LC analysis to
measure the latent importance of seven criteria to 487 Italian practitioners. The seven
criteria included: (a) attention of industry keeping physicians up-to-date, (b) frequency
and dependability of pharmaceutical representative visits, (c) helpfulness to physicians
with diagnostic and therapeutic problems, (d) respect for physician's experience and their
suggestions, (e) knowledge and professionalism of pharmaceutical representatives, (f)
industry current events and activities information, and (g) quality of global promotions
and information provisions. Using LC factor analysis, Bassi identified, post hoc, which
segments of practitioners were most receptive to sales efforts of pharmaceutical
representatives.
In a study that the authors designed to evaluate physicians’ prescribing decision
criteria, researchers Huisman-Baron, van der Veen, Jansen, van Roon, and Brouwers
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(2011) posited elderly patients are at increased risk for adverse drug reactions because of
physiological changes (e.g., reduced renal or liver function), multiple morbidities, and
polypharmacy. The researchers listed the following as primary drug criteria that
physicians typically use in drug selection: effectiveness, safety, clinical experience, and
convenience. Huisman-Baron et al.’s primary study purpose was to determine the criteria
set for optimal drug selection in frail, elderly patients. From a list of 31 questionnaire
criteria presented to a panel of 32 physicians who treat geriatric patients as well as 26
pharmacists (n = 58), the group consented upon 23 criteria divided among four
categories: effectiveness, safety, experience, and convenience. A criterion of particular
relevance to this doctoral study, which included 23 criteria, was the number of doses
needed to treat, which Huisman-Baron et al. stated was especially important with
preventive medicine, dosage frequency, and cardiovascular adverse events. Through
study outcomes, investigators confirmed and explicated prescribing decision criteria and
added important considerations for elderly patient formularies.
In a relevant quantitative study (n = 135), Tichelaar et al. (2010) purposed to
correlate which factors determined drug choices by medical faculty (generalists and
specialists) and final-year medical students, and specifically the impact of the teachers’
favored drugs upon the students’ choices. As a basis for the study, the researchers noted
practicing physicians reach their prescribing decisions heuristically, and therefore, may
not be aware of their own drug choice logic or value judgments. Tichelaar et al. noted
unlike diagnostic reasoning, which is well documented in the literature, little is known
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about therapeutic reasoning (i.e., the decision process physicians use to make treatment
choices).
Tichelaar et al. (2010) presented the respondents with six case studies and asked
them to rank 14 factors influencing their prescribing decisions. In general, the medical
students prescribed similar drugs to general practitioners and ranked examples from
teachers as higher influencers. Clinical specialists prescribed a broader range and more
potent drug products than generalists or medical students. Generalists and specialists
placed more emphasis upon the following practice-related and drug-related factors: own
clinical experience, patient convenience, and compliance of the patient (practice related),
drug effectiveness, scientific literature, and information from the pharmaceutical industry
(drug related). Other decision influencers included easy administration of the drug, side
effects, drug costs, therapeutic spectrum, standard treatment guidelines, patient casestudies presented by professors, opinions of colleagues, education, and postgraduate
education. Tichelaar et al. concluded medical curricula should include more therapeutic
reasoning and medical school professors should present medical students with more
clinical problems to add meaning and understanding to the prescribing logic of students.
In a 7-point, Likert scale mail survey to 201 general practitioners and 513 medical
students (n = 714), Godin, Beaulieu, Touchette, Lambert, and Dodin (2007) determined
to identify those factors leading to physicians’ recommending CAM treatments to their
patients. Godin et al. measured eight variables as behavioral determinants. Intention was
defined by subcomponents: (a) attitude (advantages and disadvantages of CAM
treatments), (b) behavioral beliefs, (c) subjective norm, (d) normative beliefs, (e)
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perception of control (including knowledge of CAM treatment and reimbursement for
treatment), and (f) control beliefs. Attitude referred to a person’s overall evaluation of
behavior, also measured indirectly by behavioral beliefs. Subjective norm measured the
social pressure from others to perform, whereas normative beliefs measured approval
perceptions from others resulting from one’s behavior. Perception of control was the
control extent one perceives to have over self-behavior, and control beliefs pertained to
the perceived difficulty or barriers to performing the behavior.
Seventh, variable moral norm measured the intensity of an individual’s personal
feelings of obligation toward performing the behavior. Eighth and last, descriptive norm
measured the individual’s perception of the prevalence of behavior among peers. Based
on the results of the multivariate analysis of variance (MANOVA) analyses performed in
the study, the requisite to CAM prescribing, investigators prioritized the perceptions of
the physician and medical students as follows: (a) low risk to health, (b) CAM treatment
effectiveness, and (c) absence of conventional treatment alternative. Subjects with
positive intentions to recommend CAM treatments also indicated the importance of
involving the patient and associations with open-mindedness, contributions to improved
health, and a strong therapeutic alliance.
In a relevant retrospective study to determine whether pharmaceutical advertising
exerted undue influence on physician prescribing behavior, Joyce, Carrera, Goldman, and
Sood (2011) compared narrow versus broad prescribing of drug products in 10
therapeutic classes. The researchers also compared brand and generic prescribing
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tendencies among physicians. They measured patient-level outcomes, including
medication adherence, therapeutic switching, and out-of-pocket drug costs.
As a measurement instrument, the researchers used the medical possession ratio
for medication adherence, defined as the number of days of medication held by the
patients over the 6-month period following the physician’s initial prescription. Joyce et
al. (2011) concluded physicians prescribed broadly in 10 therapeutic categories, choosing
generics and brands. In eight out of 10 therapeutic classes, physicians prescribed at least
three different drugs. Joyce et al. also noted the physicians regarded pharmaceutical
representative detailing as an important source of information. The pharmaceutical
representatives’ drug sampling also provided greater flexibility for low-income patients
as well as clinical experience for physicians.
With respect to drug cost as a physician need, in a study to determine the
influence of managed care about physician prescribing habits, Rice (2009) measured the
breadth of physician prescribing of 13 drugs during 1997–2000. Also measured was
whether physicians in HMOs tended to prescribe the same drug for the same medical
condition. Rice determined physicians in HMOs are less diverse in their prescribing
choices than choices by other physicians. Rice also determined HMO physicians were
more price-sensitive and therefore, more likely to use generic substitutes. Rice concluded
HMOs have a modest influence on physicians’ prescribing of generic drugs.
Rising healthcare costs drove investigative interest to determine attitudes and
factors influencing physicians’ prescribing in Greece and Cyprus (Theodorou et al.,
2009). In both countries, physicians regarded the National Medicines Organization,
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similar to the FDA in the United States, as the most important source of information
regarding adverse drug reactions and scientific journals the most important source
regarding new drugs. Physicians ranked efficacy as the number one criterion for drug
selection justified by publications in medical journals. Regarding adverse drug reactions
and new drug information, physicians ranked pharmaceutical representatives as the third
most important source of information. Even though Theodorou et al. (2009) reported
physician attitudes toward drug therapy, these findings may also define the influences
placed upon physicians in their decision-making processes for CAM and n-3 therapies.
Computer-assisted prescribing is another potential influencer of physician
prescribing and fulfills a need for information organization and instantaneous access to
information. Noting the high volume of prescriptions written and resultant inevitability of
some poor outcomes, in a review of two research articles covering 29 trials, Maxwell
(2010) presented modest evidence for computer-assisted prescribing. Maxwell noted
benefits of computer-assistance to aid physicians with treatment standards, drug
interactions, side effects, dosages, lifestyle change recommendations, and even restrictive
formularies. In one trial of dyslipidemia patients, the collaborative system improved
cholesterol levels slightly over a 1-year period, but the regimen did not include n-3
dietary supplements. The findings in this section provide important background for
planning discovery of n-3 recommendation criteria by physicians. Study outcomes may
also influence n-3 marketing plans.
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Dietary Supplement Physician Education
In a survey, investigators explored physicians’ beliefs, attitudes, intentions,
knowledge, and behaviors regarding CAM. Milden and Stokols (2004) presented results
from 196 board-certified physicians of varying specialties who practiced medicine in
California. The findings revealed only 20% of surveyed physicians received some sort of
CAM training in medical school. Sixty-one percent of physicians did not regard personal
CAM efficacy and safety knowledge as adequate, and 81% of surveyed physicians stated
they wanted more CAM education. Milden et al. asserted physicians are crucial in
influencing patients' use and beliefs about CAM. These findings raise important issues
with respect to physicians’ medical education and patient care.
Kemper et al. (2003) assessed knowledge in herbs and dietary supplements
(H/DS) in a survey (n = 537) of 111 medical doctors, advanced practice nurses,
pharmacists, and dieticians. The e-mailed survey was distributed to in-training (16%) and
practicing clinicians (84%) at Harvard Medical School, Children’s Hospital, Dana Farber
Cancer Institute, Boston Combined Pediatric Residency Program, Massachusetts College
of Pharmacy and Health Sciences, Brigham and Women’s Hospital, Massachusetts
General Hospital, and the Veterans Administration. An important subject inclusion
criterion was previous H/DS training. Of the specialists, registered dieticians scored the
most correct (60%) on the 10-question survey.
Two important findings of the Kemper et al. (2003) survey were physicians’
average score was 9.2 (out of 20) on the H/DS knowledge test and physicians scored 3.0
out of 10 on H/DS confidence questions (i.e., confident to discuss H/DS with patients).
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The researchers noted the risks of H/DS and the importance for clinicians to discuss
H/DS with patients as routine healthcare practice. Kemper et al. expressed the concern
consumers/patients would turn to unqualified store clerks, websites, or popular magazines
or books for clinical advice if healthcare professionals were silent.
Physician-authors Ashar and Rowland-Seymour (2008) provided evidence of
prevalent consumer use of dietary supplements (20% of the population) to maintain or
promote health, spending more than $23 billion annually. Notwithstanding this abundant
use, the authors posited that patients and physicians are often unaware of limited
government dietary supplement regulation as well as potential risks. Ashar and RowlandSeymour observed the lack of physician knowledge about dietary supplements potentially
strains the doctor–patient relationship. They presented a 6-step approach for physicians to
use for competent patient advising. The six steps include (a) inquiring about supplement
use, (b) evaluation of the supplement, (c) discussion of DS regulatory issues, (d)
discussion of available safety and efficacy data, (e) comparison of the risks and benefits
of optional conventional therapies, and (f) monitoring for adverse events and therapeutic
responses. Ashar and Rowland-Seymour recommended physicians should enhance their
own DS knowledge, a theme consistent with this research project.
In a quantitative study consisting of data from 165 completed physician surveys,
Silverstein and Spiegel (2001) posed three primary research questions. The researchers
first determined most physicians asked their patients about the use of CAM treatments.
Second, physicians did not routinely check references to determine safe usage. Third,
Silverstein and Spiegel reported surveyed physicians had insufficient knowledge of CAM
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treatments, correctly answering an average of 1.39 out of 10 CAM safety questions.
Despite these results, the researchers opined the medical community is increasing its
awareness of CAM treatments—benefits and risks.
In a multicenter, online educational intervention program to 335 physicians in 15
internal medicine residency programs, Ashar et al. (2008) conducted an objective
assessment of physician DS knowledge. In a pretest, the researchers measured baseline
knowledge of commonly used dietary supplements. Despite medical school education
and training curricula, baseline knowledge of dietary supplements was low (pretest score
ȝ = 59.7%). Ashar et al. reported low scores in response to questions regarding safety and
drug-supplement interactions. Regarding efficacy, only 36% knew fish oil lowered
triglyceride blood levels. They concluded the residents' knowledge of dietary
supplements was poor, but an online didactic education module could improve
physicians’ knowledge and potentially enhance patient–physician communication
regarding DS usage.
Legare et al. (2011) noted the role of continuing professional development (CPD)
is the primary process physician generalists and specialists use to stay current and
improve knowledge and skills requisite for patient care optimization. They developed a
global instrument to assess the value of CPD activities on clinical practice. Legare et al.
verified the acceptability and value of CPD instruments, what features needed revision,
and what CPD instrument content needed deletion or addition. Immediately following
completion of CPD and 2 weeks later, session participants completed the assessment tool
to rate aspects of the CPD program. Two overriding principles promulgated by promoters
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of the knowledge to action process (KTA) for healthcare professionals guided
determination of program success: the knowledge creation cycle and the action cycle.
In another study assessing doctor–patient communication of DS, Young, Faurot,
and Gaylord (2009) explored the use of DS among hospital patients, and noted DS usage
is common in the United States. Young et al. raised the possibility of DS usage concern
among hospital patients, and therefore, determined to assess the degree of patient–
physician communication regarding patients’ DS usage. The cross-sectional,
observational study of 60 hospitalized patients at the University of North Carolina
Medical Center revealed although nearly 80% of patients used some form of DS,
physicians documented inquiring about patients’ usage only 20% of the time.
Twenty-five percent of patients used multivitamins (the DS most used), and 4%
of patients used some kind of fish oil. Young et al. (2009) concluded the use of DS in
hospitalized patients is common, but patient–physician communication regarding DS
usage is limited. Noteworthy observations from this study are the small percentage of
physicians who seriously considered DS usage among hospital patients as well as the
small percentage of patients who took fish oil (unspecified with respect to the fish oil’s
DHA and EPA potency).
Underscoring the importance of physician–patient communication, in an
interesting Swiss study of 6,133 patients who completed a written survey, researchers
Busato and Künzi (2010) determined higher general patient satisfaction, higher
expectations of healing, and better physician–patient communication among CAM
patients than conventional primary care patients. They concluded better outcomes among
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CAM therapy patients. Busato and Künzi asserted effective communication between
physician and CAM patients played an important role in patients’ expectations of positive
outcomes. This research supports the importance of physician–patient communication
perhaps relevant to positive long-term outcomes from n-3 dietary supplementation
compliance.
Results from another study support how physicians can provide important role
models for their patients. Weiner, Swain, Wolf, and Gottlieb (2001) provided an eightpage survey of all 614 internal medicine specialists of the Wisconsin Research Network
with an MD or DO degree. The researchers collected survey data from categories of
stress associated with medical practice, including self-awareness, sharing of feelings and
responsibilities, self-care, developing a personal philosophy, and setting limits. Weiner et
al. grouped data into wellness promotion categories, including relationships, religion,
self-care, and approaches to life. Regarding relationships, physicians advocated such
wellness-promotion practices as being involved in and spending time with family,
friends, colleagues, or the community. The religion or spirituality theme included prayer,
Bible reading, attending church services, and involvement in church activities.
Self-care activities included reading, good nutrition, avoiding drugs or alcohol,
getting treatment for depression, professional counseling, leaving unhealthy relationships,
taking vacations, aerobic exercise, hobbies, and meditation. Work activities promoting
wellness included medical practice specialty choice, limiting practice size, and deriving
meaning from one's vocation. The final wellness category was approaches to life and
comprised philosophical outlooks, including positivism, success orientation, maintaining

54
balance in life, and specific strategies for accomplishing these approaches. Interestingly,
according to Weiner et al. (2001), physicians demonstrated increased psychological
wellbeing (SPWB) scores when using any of the five wellness-promotion practices when
compared with nonusers.
The approach to life practice was associated with statistically significantly higher
SPWB scores (P<0.01) than the use of any other category of wellness-promotion practice.
Weiner et al. (2001) stated the use of wellness-promotion practices by physicians was
more consistent with patients' definition of health than with physicians' typical absenceof-disease model. They exhorted physicians to incorporate a broader model of health
behavior practices into their own lives to interact more functionally with their patients.
Weiner et al. reasoned healthy role models make better healers, because they tend to give
advice and interact with patients with more impact and identification.
Also with respect to physician modeling, in a study sponsored by dietary
supplement companies, the Council for Responsible Nutrition conducted market research
to determine how many physicians took dietary supplements personally and whether or
not those physicians recommended the same supplements to their patients (Dickinson et
al., 2011). The researchers conducted a survey among 900 physicians and determined
72% of physicians took a multivitamin, but that only 27% took a supplement for heart
health including n-3s, vitamins B6, B12, or E. Although one study outcome was 79% of
physicians recommended dietary supplements to their patients, Dickinson et al. (2011)
did not explain which supplements the 79% recommended, to what kind of patient, or
why.
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Other studies demonstrated most physicians do not believe they are themselves
adequately educated regarding dietary supplements (Adams, Kohlmeier, & Zeisel, 2010;
Dickinson et al., 2009) and some may be reticent to recommend dietary supplements to
their patients. In this qualitative research study, I gathered information to facilitate
understanding why physicians do or do not recommend dietary supplements, what
information physicians need, and how physicians make rational decisions to recommend
supplements. An educated audience may regard this qualitative study on its own more
than a scientific survey because of more value-based, scientific logic (i.e., the medical
reasoning or ladders of inference used by medical practitioners). Conclusions from this
qualitative study may spawn follow-up, confirmatory quantitative studies.
Factors Affecting Patient Compliance
N-3 marketers should not underestimate the importance of patience compliance as
a major physician decision criterion. Patient compliance demographics may also
influence n-3 marketers regarding targeted market segments. Olafiranye, Jean-Louis,
Zizi, Nunes, and Vincent (2011), affiliated with the State University of New York,
Brooklyn Research Foundation on Minority Health, Kingsbrook Jewish Medical Center,
and Sophie Davis School of Biomedical Education, concluded a substantive body of
evidence suggests patient anxiety independently predicts adverse cardiovascular events.
These events include coronary heart disease, stroke, sudden cardiac death, fatal
ventricular arrhythmias, and congestive heart failure. Olafiranye et al. cited studies
suggesting individuals with anxiety disorders demonstrate unhealthy lifestyles including
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unhealthy diets. Individuals with anxiety disorders may be less likely to comply with
physician recommendations to change unhealthy diets or take dietary supplements.
Perhaps more troubling, Olafiranye et al. (2011) noted individuals with recent
coronary hospital experiences were not inclined to make dietary changes, thereby
increasing future cardiac risks. The implication here is physicians’ recommendations may
not make a difference in health outcomes. N-3 marketers should regard patients in this
category as less likely to comply with physician recommendations.
Motivation and understanding also affect patients’ engagement in taking
responsibility for positive, healthy behaviors. Epstein, Aaron, Baicker, Hacker, and Pauly
(2009) discussed the changing landscape of healthcare including the difficulty in
understanding the implications of healthcare reform, skyrocketing costs, a physician
shortage, patients’ habits, engagements, and responsibilities for their own health. Rao et
al. (2010) stressed the importance of patients understanding accountability for their own
health and underscored the importance of physician-patient communication. Physicians
may have work harder to convince unmotivated patients, an important factor for n-3
marketers to consider regarding physician prescribing decisions.
Marketers of n-3s should also consider patient literacy and numeracy as
compliance variables possibly affecting physician decisions. Martin et al. (2010) assessed
the 10-year risk of coronary heart disease correlated with four literacy skills of 409
subjects. Martin et al. assessed reading, numeracy, oral language, and aural language
skills. They found a statistically significant (p = .001) inverse relationship between
numeracy/aural skills and coronary artery disease among women but not men. However,

57
study sample bias may have contributed to this gender inequity. Martin et al. noted only
12% of the population has proficient health literacy and rates of cardiovascular death are
substantially higher (19.3%) among individuals with inadequate literacy versus
individuals with adequate health literacy (7.9%).
Brooks and Pui (2010) suggested numeracy scores were better predictors of
patients’ abilities to understand health information sometimes vital for life or death
decisions. The researchers studied the relationship in numeracy test scores and general
mental ability (GMA) test scores because medical practitioners rely upon GMA scores as
predictors of patients’ understanding of health-related information. Brooks and Pui
provided the rational basis and administered the Wonderlic Personnel Test, the Numeracy
Scale, the Rational-Experiential Inventory Test, and the Mini-International Personality
Item Pool to 200 undergraduates.
Regarding other compliance factors possibly effecting physicians’ decisions,
Brooks and Pui (2010) found the strongest positive correlations between numeracy and
GMA, and between numeracy and rational cognitive style. Numeracy positively
correlated with rational decision making, whereas GMA did not. Interestingly, Brooks
and Pui reported negative correlations between numeracy and two personality traits:
extraversion and neuroticism. They posited introverted, emotionally stable individuals
might make better health-related decisions. Brooks and Pui also correlated numeracy and
GMA and recommended practitioners consider patients’ numeracy scores.
Underscoring the importance of correlating patient conviction to compliance,
Nelson, Reyna, Fagerlin, Lipkus, and Peters (2008) presented background evidence low
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numeracy inhibits patient decisions regarding preventive medicine choices, reduces
medication compliance, impairs risk communication, and affects medical outcomes.
Additionally, Nelson et al. reported patients with low numeracy scores are less likely to
engage in preventive medicine behaviors and inferior disease management. Finally, they
reported low-numerate individuals tend to base medical decisions on short-term benefits
and costs rather than long-term outcomes. The implications of this article for marketers of
n-3 products are patient consumers with higher literacy scores may be more likely to
welcome preventive medicine concepts and comply with preventive regimens. In
addition, market segments consisting of patients with higher education levels may be
more profitable for n-3 marketers. The implication for physicians’ decision criteria is
patients with deficient numeracy and literacy skills may require additional effort and
monitoring to secure DS regimen compliance.
Patient interest in CAM therapies is another compliance factor. In one study to
determine how patient interest in self-care with CAM influenced them to take CAM
therapies, researchers Bradley et al. (2011) telephone surveyed 321 patients with Type 2
diabetes. They determined patient interest in trying CAM therapies did not correlate with
patient insurance coverage, demographics, clinical status, health history, or self-care
behaviors. Bradley et al. also determined patients were more likely to try CAM therapy if
they were not satisfied with their current medical treatments for controlling blood sugar.
Additionally, Bradley et al. (2011) determined patients were more likely to try
new CAM therapies if they previously used CAM. Bradley et al. determined public
interest in CAM therapies has increased in recent years. The implication of the Bradley et
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al. study for patient compliance with n-3 dietary supplements is physicians may find
more success recommending n-3s to patients positively inclined to CAM therapy or
dissatisfied with conventional medicine overall.
In a similar study, Gaul, Schmidt, Czaja, Eismann, and Zierz (2011) explored
patient attitudes toward CAM with two questionnaire surveys completed by 432 primary
headache patients and 194 low back pain patients in Austria and Germany. Gaul et al.
discovered no correlation between patient demographics and CAM use. They determined
patients were more likely to use CAM therapies if they had previous CAM experience.
Additionally, lack of effectiveness of conventional treatment was another statistically
significant CAM use motivation.
Interestingly, Gaul et al. (2011) noted patient concerns about drugs were four
times higher among patients inclined toward CAM therapy. In contrast to the Bradley et
al. (2011) study where the condition was diabetes with less symptomatic manifestations,
the Gaul et al. study consisted of highly symptomatic pain patients. Consistent findings
regarding previous CAM use and lack of conventional therapy efficacy drove CAM
interest and usage among patients. These factors are important relevant to n-3 treatment
compliance.
Another potential factor relates to the study of symptoms. In a Canadian-based
study of population patterns in patients who use CAM therapies, researchers Metcalfe,
Williams, McChesney, Patten, and Jetté (2010) concluded Canadians appear to use CAM
therapies in conjunction with conventional therapies. From a cross-sectional survey
completed by 400,055 Canadians, the researchers determined CAM use was higher for
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asthma (15.1%) and migraine headaches (19.0%) than diabetes (8.0%). Metcalfe et al.
also reported literature review findings of CAM therapy use varying between 6% and
84%. From a literature review, the researchers also reported higher CAM use among
individuals with higher income or education levels, women, certain ethnic groups, and
those with chronic conditions.
These study results support the hypothesis asymptomatic patients may be less
compliant overall, or less compliant with CAM therapies. If generalizable, the relevant
decision criterion for physicians relates to compliance. For n-3 marketers, the best
candidates for n-3 therapies may be patients with higher income or education levels,
women, and those who suffer from chronic, symptomatic cardiac conditions.
Drug and CAM Marketers’ Methods to Physicians
To facilitate application and integration of these constructs, provided in this
section is an historic and present-day backdrop of marketing methods used by
pharmaceutical and CAM marketers. Controversy has surrounded the issue of direct-toconsumer (DTC) drug advertising, especially prescription drugs. Although most n-3
brands are nonprescription, the concerns raised by physicians regarding prescription drug
advertising to patients apply to over-the-counter supplements as well.
Historical marketing. In a precedential case of pharmaceutical promotion
deception, Landefield and Steinman (2009) discussed misinformation and manipulative
practices of Parke-Davis. In 1996, a young, newly employed biologist discovered and
reported illegal off-label promotion of Neurontin by Parke-Davis management and sales
personnel. Ultimately, the company pleaded guilty and agreed to a $430 million
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settlement in 2004 to resolve the criminal charges and civil liabilities. The
whistleblowing action highlighted subtle, clandestine approaches to promote off-label
use, including dinner programs, continuing medical education courses, consultant
arrangements, and personal conversations between sales representatives and physicians.
Landefield and Steinman concluded the methods and programs used by Parke-Davis were
legal, but noted the prospects for abuse.
To determine DTC benefits and risks, Frosch, Grande, Tarn, and Kravitz (2010)
examined proponent and opponent studies from peer-reviewed literature and determined
some ads contained accurate and balanced information although some ads were deficient
or misleading. Ads frequently did not disclose alternative treatments, risks, or costs, and
prompted patients, many with insufficient education or understanding, to request
physicians to prescribe an advertised drug. Physicians may not have seen the
advertisements for drugs patients requested or were not fully educated regarding new
drugs at the time of patients’ requests. These situations predispose conflict and Frosch et
al. reported results from national surveys where 39% of physicians and 30% of patients
regarded DTC as interfering with the physician-patient relationship. Frosch et al.
enlightened the potential magnitude of this problem because drug advertisers spent $4.9
billion on DTC in 2007. The authors cited additional survey evidence 89% of physicians
claiming DTC increased prescriptions for advertised drugs, some of which are
unnecessary.
Frosch et al. (2010) also disputed DTC proponents’ claims DTC improves patient
adherence (compliance), concluding on balance, overall evidence slightly supported
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patient adherence. Perhaps more pertinent, no evidence existed to support DTC results in
favorable health outcomes. Considering these factors, Frosch et al. constructed measures
to improved outcomes with balanced evidence and regulatory policy. They proposed
content guidelines for drug ads including questions regarding candidacy, drug benefits,
and drug risks. Frosch et al. provided a detailed questionnaire advertisers should answer
with communication understandable by eighth-grade level education listeners.
Nurse practitioners and advanced practice nurses (APNs) can also prescribe and
recommend medications and supplements to patients so their opinions regarding DTC
pharmaceutical advertising are relevant. In an online survey, 961 Texas APNs responded
to two research questions about the impact of DTC prescription drug advertising on
patient behavior and quality of care (Mackert, Eastin, & Ball, 2010). Researchers
Mackert et al. (2010) reported 49% of APNs believed DTC did not help nor harm the
physician–patient relationship. Of the remaining 51%, 31% believed DTC hurt, and 20%
believed DTC helped.
Importantly, 69.6% of APNs believed DTCs led patients to request specific drug
brands and 57.8% said patients requested switching to the advertised brand. APNs
(63.8%) reported DTC drove patient involvement in his or her healthcare, but 57.7%
stated the patients demanded inappropriate therapies. APNs (63.5%) acknowledged DTC
informed patients to ask intelligent questions but 66.1% of APNs stated DTC caused
patient misperceptions and questions (46.2%) about health care advice. Marketers of n-3s
may find DTC advertising methods beneficial but should follow the Frosch et al. (2010)
guidelines to avoid DTC pitfalls.
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Present-day marketing. Approaching DTC prescription pharmaceutical
advertising from a constructive educational viewpoint, physician researchers Kaphingst
and DeJong (2004) proposed seven recommendations to improve the educational value of
DTC advertising. The researchers posed the central question regarding whether average
consumers could understand the brief risk messages, often unconsciously diluted by
neutral or positive images. Kaphingst and DeJong’s recommendations focused upon
improving communication and reducing biased, prospectively harmful promotional
messages. Specific recommendations included: (a) balance risk and benefit information,
(b) use consumer-friendly language, (c) provide additional sources of information, (d)
provide text materials geared to the eighth-grade reader, (e) explain more educational
information about symptoms and disease, (f) conduct follow-up research to determine
consumer ad comprehension, and (g) require prior approval of ads. These points add
insight for n-3 marketers.
Using DTC in another channel, marketers of n-3 dietary supplement may employ
DTC advertising using the Internet as a promotional strategy. Khosla and Khosla (2011)
noted how marketers have replaced traditional forms of drug-product advertising with
Internet advertising. They identified OTC medical products as Internet candidates
because consumers can purchase these products without a prescription. Khosla and
Khosla advocated marketers should employ Internet marketing to educate consumers and
advise them when to see their doctors. They noted the importance of balanced, truthful
ads informing consumers of potential product risks as well as benefits.
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Resulting from a comprehensive review of published and archived literature,
physician researchers Greene and Herzberg (2010) evaluated the practices of drug
marketers during the 20th century and the effects of these practices upon public health.
They reviewed ghostwriting of popular articles, DT drug advertising, public relations
events, continuing medical education content, and implicit consumer advertising
methods. Greene and Herzberg listed broad social networks used in drug promotion,
including artists, journalists, gossip columnists, physicians, filmmakers, medical
educators, researchers, science writers, and medical educators.
Greene and Herzberg (2010) explained the difficulty in the century-long
consistent flow of complex information to consumers through multiple media and big
spending. Although they advocated more regulatory scrutiny, Greene and Herzberg cited
the reality of disproportionate drug advertising spending, more than twice the budget of
the entire FDA, dwarfing the budget of the FDA office responsible for consumer
advertising oversight. Greene et al. advocated ethical transparency among drug marketers
and increased regulation of informal and non-advertising forms of drug promotion.
In an article regarding Pfizer’s market segmentation methods, Kiron, Shockley,
Kruschwitz, Finch, and Haydock (2012) discussed Pfizer’s use of analytics and tablet
personal computers (PCs) to retrieve field-marketing data daily. A team of 40-50 analysts
used this daily information to determine if field representatives were detailing the right
physicians, if they were presenting the company’s message tailored for the specific
physician market segment, and if the presentations resulted in prescriptions. In an
interview with a Pfizer executive, Kiron et al. provided an example regarding the
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promotional message designed for physicians who treat elderly patients in Florida.
Because drug-to-drug interactions are a primary concern among physicians in this market
segment, the pharmaceutical representative must deliver the company’s promotional
message as directed. Immediately after sales calls to physicians, Pfizer representatives
must enter conversation details and transmit this information to company analysts the
same day. From other data sources (e.g., IMS), Kiron et al. reported analysts can track
promotional effectiveness by measuring post-sales-call physician prescribing then using
the database information to refine physician customer segments based upon customer
preferences and responses to promotional messages.
Relevant to this study, n-3 marketers may use similar practices to Pfizer to define
physician customers most favorably inclined to recommend dietary supplements. These
physicians may be price conscious, appreciate differentiating efficacy and safety features
of cardiovascular preventive health supplements, treat patients with cardiovascular
disease, or those physicians who already recommend preventive supplements more
frequently than average. N-3 marketers could use databases to develop a holistic
marketing approach with historical product-type utilization behavior, reactions to product
profile, competitive product use, attitudes toward preventive treatment protocols, and
personality traits.
Marketers of n-3s should consider cultural influences when defining customer
segments. In an interesting study of cultural influences on a healthy diet, Sun, Horn, and
Merritt (2009) analyzed previously surveyed subjects from 25 nations (n = 21,974). The
Sun et al. cited evidence of social influencers of dietary behaviors, including family
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members, peer groups, health professionals, and mass media; other factors also
influenced healthy diet choices, such as living alone, food preference, understanding the
diet–health link, high-income residence, and concern for personal appearance. After
explicating how elemental personality traits combine with cultural environment to form
compound traits (e.g., competitiveness, playfulness, self-reliance, or task orientation), the
researchers articulated four emerging cultural dimensions: (a) individualism/collectivism,
(b) power distance, (c) masculinity/femininity, and (d) uncertainty avoidance.
Collectivist cultures value group membership. Power-distance cultures advocate
social inequality. Cultures favoring masculinity roles include assertiveness, competition,
and toughness, whereas femininity roles are oriented toward family, children, tenderness,
and home. Uncertainty-avoidance cultures value stability, low stress, and predictability
versus change and new experiences.
Sun et al. (2009) determined how public self-consciousness mediated the four
cultural dimensions. Public self-consciousness includes physical attributes and concern
with impressing others. The researchers determined cultures valuing collectivism (e.g.,
Japan or Saudi Arabia) are higher in public self-consciousness and concern for goals of
group members than cultures who advocate individualism (e.g., Americans). Sun et al.
tested the validity of their 4-point Likert scale surveys and determined Cronbach alpha
values of 0.81 and 0.76. Their primary conclusion was public self-consciousness
positively and statistically significantly correlated with a healthy diet intention (p = 0.00).
Secondarily, Sun et al. concluded a negative relationship between individualism and
public self-consciousness (p = 0.00), power distance and public self-consciousness (p =
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0.00), masculinity and public self-consciousness (p = 0.00), and a negative relationship
between uncertainty avoidance and public self-consciousness. The researchers noted
cultural differences drove 12% of the variance in public self-consciousness and 26% of
the variance in a healthy diet intention. Sun et al. also noted power distance was the
highest predictor of public self-consciousness. Marketers of n-3s may use these cultural
findings to develop market segments.
Weighing cultural influencers against personality trait influencers may facilitate
n-3 marketers to define n-3 segments with effective marketing plans. Laura (2011)
compared Hofstede’s cultural framework to the five-factor model (FFM) to investigate
thoughts, feelings, behavior patterns, and preferences among individuals. Hofstede’s five
cultural differentiating criteria included: (a) uncertainty-avoidance index, (b)
individualism index, (c) power-distance index, (d), masculinity index, and (e) long-term
orientation index. FFM differentiates among five personality traits: (a) extraversion, (b)
agreeableness, (c) conscientiousness, (d) neuroticism, and (e) openness to experience
(Laura, 2011). In some circumstances, culture may exert more behavioral influence than
personality trait. The relevance of these models here relates to distinct cultural
influencers as well as personality tendencies. Marketers should consider cultural and
personality trait influencers when defining targeted market segments.
Method and Design
Golafshani (2003) prescribed specific methods for qualitative researchers to
establish reliability and validity. Conversely, Holt (1991) rejected the application of
objective methods and offered an antithetical, alternative interpretive approach instead of
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traditional approaches by others. Golafshani proposed researchers should use methods to
substantiate the reliability and validity of qualitative research and researchers should
replace traditional reliability and validity vernacular by quality, rigor, credibility,
transferability, and trustworthiness. Golafshani acknowledged the researcher should
protect the constructivist and naturalistic tenets of qualitative research.
Even so, Golafshani (2003) insisted triangulation and other methods could
enhance the rigor of the research without compromising its inherent value. An objectivist
approach to qualitative research was possible without altering the reality description
expressed by the respondent and interpreted by the researcher. Researchers should
employ triangulation for both data collection and analysis and should strive to make their
research findings generalizable. A true test of validity is replication by wider groups in
similar, if not identical circumstances.
Holt (1991) refuted mainstream qualitative study validity and reliability
techniques on the basis such techniques “contradict the nature of the interpretive task, and
pose insurmountable problems in application” (p. 59). Holt argued a subject or
researcher’s individual, contextual interpretation of any event is not verifiable as accurate
or truthful. Another individual might relate the same experience differently because of a
separate, unique frame of reference and context. Individuals construct whole
interpretations from parts, and in addition to contextual interpretation, an individual
interpretation of parts emanates from that individual’s use of rhetorical words, traditions,
political views, and history (i.e., events change as time passes). Holt argued reviewers
should employ an interpretive technique and judge interpretations by the insight provided
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and the power to convince (Thompson’s gestalt experience, as cited in Holt, 1991). Holt
posited if enough peer experts agreed, the consensus would define the predominant
interpretation.
Holt (1991) and Golafshani (2003) both emphasized the importance of preserving
the naturalistic benefits of qualitative research. Both drove convincing arguments the
reliability and validity criteria used for quantitative research are not applicable for
qualitative research, although Golafshani embraced the concepts, but used different
labels. Both authors cited other reputable sources who advocated reliability and validity
testing for qualitative research.
For example, Holt (1991) discussed traditional methods of testing naturalistic
inquiry including credibility, transferability, dependability of measure, and
conformability. Holt added a fifth criterion, integrity, citing Belk, Sherry, and Wallendorf
(1988). Holt explicated the 10 recommended techniques of Belk et al.: (a) prolonged
engagement and persistent observations, (b) use of triangulation with different
researchers for data collection and interpretation, (c) frequent on-site team interaction, (d)
negative case analysis, (e) peer debriefing, (f) member checking, (g) limiting exceptions,
(h) purposeful sampling, (i) reflexive journals, and (j) independent audits. Golafshani
(2003) cited additional authors who advocated validity techniques by different names that
enveloped reliability at the same time. Neuman (2011) advocated applying similar criteria
to those recommended by Belk et al.
Other authors advocated similar methods to add validity to naturalistic and
qualitative research, some with more detail. Bernard and Ryan (2003) outlined eight
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observational techniques and four manipulative techniques for unbiased theme
development. Shepherd and Rentz (1990) provided steps “to minimize the subjectivity of
coders” (p. 62). Scott-Jackson, Druck, Mortimer, and Viney (2011) discussed
interviewing techniques to guard against bias and reactivity, threats to validity. Brent and
Slusarz (2003) recommended computer assistance “to assess and improve the reliability
of coding by the researcher” (p. 299). Last, Zelik, Patterson, and Woods (2010) proposed
a model with eight specific components to establish rigor and prevent shallow analysis in
qualitative research. Zelik et al. observed just because researchers employ the word rigor
as a justificatory warrant for their studies, does not necessarily provide assurance.
The preponderance of evidence and opinions of experts drive the need for
doctoral students to employ robust methods in qualitative research to establish and
maintain research project validity. At the same time, researchers should appreciate and
maintain the naturalistic benefits intended by qualitative methodology. The five criteria,
10 methods, and the rigor scale are useful elements to ensure trustworthiness and
credibility in qualitative research studies.
Shepherd and Rentz (1990) presented the critical incident technique. With respect
to content analysis, they presented specific techniques regarding coding schemes and
code processing. Shepherd and Rentz emphasized the coding scheme should reflect the
purpose of the research and the scheme should emerge gradually as the researcher
becomes familiar with all the accumulated data. They also discussed minimized coder
subjectivity by using a small unit of analysis (e.g., simple word or smallest phrase),
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employing mutually exclusive response categories (e.g., black or white, not both) and
maintaining the independence of the codes so the codes are not linked.
Shepherd and Rentz (1990) presented a compelling argument the word rigor is
often platitudinous rhetoric as applied to qualitative data. They provided eight examples
of shallow analysis and presented an alternative chart with eight attributes as criteria to
determine low, moderate, and high rigor. The eight attributes included hypothesis
exploration, information search, information validation, stance analysis, sensitivity
analysis, information synthesis, specialist collaboration, and explanation critique.
Shepherd and Rentz indicated researchers can use the eight attributes as measures to
prevent shallow analysis but 10 or more contextual factors influence the judging of rigor
sufficiency.
Bernard and Ryan (2003) asserted theme development is a mysterious process and
researchers typically lack instruction and skills for discovery and consistency. They
identified four important tasks in theme development: (a) discovering the themes and the
subthemes, (b) limiting themes for practicality, (c) building theme hierarchies, and (d)
linking themes to theories or models. Bernard and Ryan noted themes must be visible in
data, may be symbolic, culturally dependent (contextual), and derived from codes. They
outlined 12 techniques, eight observational and four manipulative, to facilitate competent
theme processing.
Themes emerge from coding. Brent and Slusarz (2003) advocated the use of
qualitative analysis programs to facilitate coding of typically voluminous transcribed
data. Researchers benefit from coding software applications because the software can
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enhance reliability, limit missed codes, and reduce researcher time and workload. Brent
and Slusarz analyzed the coding process and disclosed computational strategies as casebased reasoning, natural-language generation, semantic networks, and production rules.
Brent and Slusarz stated programs learn and become more valuable to the researcher as
the program amasses transcribed information garnered from observations or interviews.
Qu and Dumay (2011) differentiated interviewing perspectives, and therefore,
data interpretation and thematic development, based upon the interviewer’s worldview.
They defined the neo-positivist, romanticist, and localist perspectives. With some overlap
among categories, Qu and Dumay argued neo-positivists use structured interview
technique and study facts, romanticists use unstructured interviews and focus upon
meaning, and localists use semistructured interviews to focus upon context and the
interviewee’s account of events. Interviewer worldview and technique therefore
influences data interpretation and thematic development.
Considering different worldviews and interview approaches used by qualitative
researchers, Qu and Dumay (2011) reported how quantitative researchers regard
qualitative interviews as unreliable and subject to bias. Qu and Dumay emphasized how
careful interview preparation, use of competent interviewing skills (e.g., questioning,
listening, dyadic conversational skills, etc.), and protecting against asymmetrical control
can produce a rich data set. Qu and Dumay stated no one interview approach is right, no
single format is appropriate for each interview, and the same questions will not always
work. The unique compositional experience of each interview can affect data collection:
the personality of the interviewer, the perspective of the interviewee, and the interview
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setting (Qu & Dumay, 2011). The collection of data, its coding, thematic development,
analysis, and interpretation, together present a complex task to optimize desired
meaningful study outcomes. Those desired outcomes include a clear understanding from
study subjects to formulate effective communication for educating physicians and
influencing n-3 prescribing behavior.
Regarding educating physicians, Legare et al. (2011) noted the role of continuing
professional development (CPD) as a primary process physician generalists and specialist
use to stay current and improve knowledge and skills requisite for patient care
optimization. Legare et al. developed a global instrument to assess the value of CPD
activities on clinical practice. Legare et al. verified the acceptability and value of CPD
instruments, what features needed revision, and what CPD instrument content needed
deletion or addition. Both immediately following completion of CPD and two weeks
later, session participants completed the assessment tool to rate aspects of the CPD
program. Two overriding principles promulgated by promoters of the KTA process for
healthcare professionals guided program success determination: the knowledge creation
cycle and the action cycle.
Adding credibility to the action cycle concept in KTA, Rodriguez, Marquett,
Hinton, McBride, and Gallagher-Thompson (2010) studied action plans as a follow-up
tool to assess changes in clinical practices after training. One study objective included the
assessment to change barriers. Three months after clinical training, 73% of respondents
acknowledged action plans stimulated specific behavioral changes in clinical practice.
These results highlighted the importance for including action plans in the methods and
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design of the present doctoral study. In the present study, therefore, I included a specific
follow-up question to determine if respondents increased their recommending of n-3s as a
study outcome to drive real, effective, behavioral, and clinical practice change.
Psychological cognition mechanisms precede behavioral change and Cova,
Dupoux, and Jacob (2010) explained pure scientific models consisting of desire and
intentions as psychological states cannot explain human behaviors. Cova et al. (2010)
reasoned behavioral models are also deficient because these models do not include a
moral causal variable and therefore cannot correctly predict human intuitions or actions.
Depending upon context, cognition, and the decision-maker’s moral compass, an
individual may decide consciously to take action (or refrain from taking an action), which
baffles the logic of observers. This explains how individuals can initiate behaviors others
regard as illogical, but to the individual, the behavior is irrefutably and morally right.
Important for n-3 marketers, supported by data collected from interviews in this study,
physicians consider moral rightness when making decisions.
Transition and Summary
Section 1 was an introduction to possible n-3 health benefits, the business
problem of marketing n-3s, the research questions, and qualitative study design and
methods I used to drive study outcomes and answers to research questions. The outcomes
of this study may fill gaps in understanding physician prescribing decision processes. If
120,000 Americans die each year prematurely from cardiovascular disease (CDC, 2011)
and if the daily ingestion of the proper ratios of n-3 can reduce cardiovascular disease by
19% to 45%, the prospective societal benefits of this doctoral study are substantial.
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Study outcomes may facilitate n-3 marketers’ sustainability and profitability
because an improved understanding of physician prescribing decisions may improve
effective communication with physicians resulting in physician prescribing behavior
change. Increasing preventative medicine behavior among physicians in this capacity will
enhance public awareness and society’s cardiovascular health. These study outcomes are
consistent with the Walden University DBA Doctoral Study rubric. Section 2 includes
more study method detail regarding the role of the researcher, data collection, and data
analysis.
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Section 2: The Project
Purpose Statement
In this qualitative, phenomenological research study, the purpose was to improve
n-3 marketers’ understanding of how physicians reach decisions to prescribe or
recommend products, including omega-3 (n-3) dietary supplements and which product
characteristics may be the most important to physicians. I explored physicians’n-3 dietary
supplement knowledge and decision criteria (ladder of inference; Argyris, 1976) and
found physicians’ inference ladders for prescription drugs are similar to physicians’
inference ladders for n-3s. The education of physicians and the ladders of inference
physicians cognitively ascend determined their n-3 prescribing/recommending choices.
By understanding these complexities, n-3 marketers will be able to develop effective
learning instruments and promotional tools (predictors) to influence physicians to
recommend patients comply with a daily dosage regimen of quality n-3s containing
adequate DHA and EPA concentrations (criteria).
In Kentucky, Indiana, and Tennessee, I interviewed 20 primary care physicians.
According to Ashar and Rowland-Seymour (2008) physicians are opinion leaders
because of their primary influences over patient health thereby justifying the selection of
physicians as participants in this study. The study objective was to answer the primary
research question regarding what ladder of inference physicians use to recommend
dietary supplements, especially n-3s. Another study purpose was to gather useful
physician marketing strategy information regarding n-3s and cardiovascular disease
reduction. The business implication was to facilitate n-3 marketers’ understanding of
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physician customer thinking and needs. An increase in physician education may
culminate in more preventive medicine behaviors by physicians, augmented marketing
effectiveness of n-3s, increased n-3 use among the general population resulting in
improved health, reduced cardiac disease, and reduced U.S. healthcare spending.
Role of the Researcher
The role of the researcher, in this data collection process, was to interview the
study participants. Using a digital recorder, I recorded the interviews and a qualified
assistant transcribed the interviews verbatim. I enlisted coding services from a second
coder to code the transcripts and develop themes to increase internal validity (Bertolotti
& Tagliaventi, 2007). Transcriber and coder assistants signed Confidentiality Agreements
and an IRB approved their participation.
Chenail (2011) emphasized the important central role of the researcher who
serves as the research instrument, primary collector of data, driver of investigator-subject
contextual interactions, facilitator of communication flow, and conveyor of interview
atmosphere and communication ease. In this role, if a study subject is reticent to talk
openly, the researcher should ask open-ended questions and prevent open-ended
questions from turning into closed-ended questions. As the primary data collection
instrument, the researcher is also the primary threat to study trustworthiness and source of
bias. Interviewer/researcher bias may occur with the researcher’s abnormal psychological
state or discomfort with the study subject, lack of preparation, or inappropriateness of
interviews.
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The process of qualitative research requires a fully immersed investigator. Sergi
and Hallin (2011) noted the application of ontology to qualitative approaches, where the
researcher’s experience is deeply emotional and personal, necessary to reveal the richness
of the situation. Sergi and Hallin posited although some may describe qualitative research
as a linear, step-by-step procedure, the qualitative approach is inherently a lived
researcher’s whole-self experience whereby the researcher feels the emotions and
perspectives of the study subjects. Through this lived experience including its affective
facets, the researcher gains a richer image of the subject matter and goes closer to the
real-life experience.
Sergi and Hallin (2011) emphasized that the researcher’s experience is an
inevitable part of the research study and is therefore a thick performance. This framing is
fundamental to understand and address bias. This understanding also accentuates change
and practice as fluid elements in qualitative research: change because study subjects
continually evolve and practice because, by definition, practice involves the researcher’s
thinking, skills, and rationality, but also the researcher’s emotion, body, power, intuition,
and a contextual interpretation. Sergi and Hallin differentiated their emphasis of the
researcher’s performance from autoethnography. Autoethnography assumes the
researcher’s experience automatically derives from a cultural connection with the subject.
Rather, acknowledging the importance of the researcher’s role with personal emotions
expands transparency and understanding of reflexivity, imagination, and ethics.
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Participants
I obtained access to research participants through published physician list records.
The purposeful sample consisted of physician subjects interested in the study subject,
acknowledged an open perspective regarding diverse opinions specified in the signed
Informed Consent document, and who were accessible. I selected participants in three
targeted states with whom I did not develop personal relationships previously.
I protected participants through informed consent (see Appendix C) and protocol
implementation approved by an institutional review board (IRB). Before commencing
any data collection, subjects understood, signed, and returned Informed Consent
documents to the interviewer. This group of medical professionals understood principles
of ethical research.
Research Method and Design
In the sections below, I describe the research method and design as follows: (a)
description of research method and design, (b) justification of method and design, and (c)
relevancy to the business problem statement. The method and design were appropriate
with respect to the problem statement. This subsection is an expansion of Nature of the
Study in Section 1.
Method
This qualitative method was appropriate for this marketing topic. Smith, Bekkar,
and Cheater (2011) discussed the difficulties of choosing qualitative research methods in
topics involving health care because most researchers use quantitative methodology.
Smith et al. advocated researchers should employ qualitative methods to explore
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complexities affecting health, including economic, social, environmental, and political
factors. Bekkar et al. also advocated qualitative methods as adjunctive to quantitative
methods. They reasoned qualitative methods can expand the investigator understanding.
After discussing the problems of fit with ethnographic, phenomenological, and
grounded theory designs, Smith et al. (2011) recommended a generic approach to
researcher using qualitative methods in health care. Smith et al. reasoned investigators
who maintained an open, holistic perspective rather than pursue evidence to support a
predetermined theory would enhance credibility among readers in the medical
community. Although I intended n-3 marketers as the primary audience of this marketing
study, some in the medical community may find the outcomes of this study relevant and
useful (e.g., physician impressions of their own knowledge of dietary supplements).
Research Design and Method Justification
In this study, I followed important guidelines that were recommended by
Malterud (2001), who observed some members in the health care community are
skeptical regarding qualitative research, citing the perceptions of subjectivity and absence
of facts with qualitative research methods. Malterud posited qualitative research findings
could be important in health care and outlined important processes for qualitative
researchers to enhance acceptance by members of the health care community. Malterud
noted the difference in procedure for data interpretation but underscored similar research
principles, including relevance, validity, and reflexivity as overall standards for
qualitative inquiry. Malterud also warned of the challenges presented with reflexivity,
transferability, and interpretation assumptions, criteria emphasized by members of the
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health care community. Malterud that noted researchers must be prepared to answer
questions regarding their findings and interpretations, internal and external validity,
context and bias (explaining the value of contextual interpretation), and data analysis
processes.
Regarding interpretation and analysis, Malterud (2001) advocated a thorough
analysis, including a discussion of valid, alternative interpretations. Proper data analysis
includes decontextualization and recontextualization. Decontextualization extracts
portions of data for scrutiny and compares these units within the holistic context of the
rest of the data. Recontextualization confirms the consistency of patterns within the study
context (Malterud, 2001).
The researcher-emphasized knowledge does not emerge from data only, and
researchers must include empirical substance and theoretical bases to form valid
conclusions. Malterud (2001) emphasized researchers who fail to acknowledge theory
and claim an inductive approach reduce credibility because theory influences all
researchers. Last, to enhance qualitative study trustworthiness, Malterud advocated a
transparent path description from data collection to findings in the research report to
facilitate readers’ understanding of research procedures.
Accentuating the lower opinion of some health care community members
regarding qualitative research, researcher Beck (2009) emphasized evidence-based
practice, including critical appraisal of evidence. Beck ranked highest the quantitative
systematic reviews of RCTs. Beck posited critics rate qualitative studies lower than
quantitative studies because researchers do not base evidence upon statistics. Researchers
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who employ quantitative methods use data collection instruments validated to strict
standards whereas qualitative method researchers use perceived subjective instruments.
Beck advocated qualitative studies as useful to enhance understanding of patients’ lived
experiences and described five trustworthiness criteria to use when evaluating qualitative
studies. Consistent with Beck’s thinking, the outcomes from this phenomenological
research study can enhance n-3 marketers’ understanding of physician prescribing and
recommending decisions.
Al-Hamdan and Anthony (2010) provided a useful contrast between positivism
and post-positivism research approaches. Positivism is the foundation for quantitative
methods, whereas post-positivism is the foundation for qualitative methods. Al-Hamdan
and Anthony described positivists as committed to transferring the precepts of naturalism
and natural sciences to the social study objectives as a conceptual unification of methods.
Positivists approach social science data as undeniable facts and attempt to apply scientific
laws to establish truth. Al-Hamdan and Anthony positioned positivists as those who study
the social world with a hypothetic-deductive method to find objective data through
natural-world observations. Critics of the positivist approach state the approach does not
allow the researcher to examine human behavior in depth.
Conversely, Al-Hamdan, and Anthony (2010) described postpositivist researchers
as interpretive sociologists focused upon studying the individual who are active and
mindful of contextual surroundings, able to make independent choices. Although
postpositivists consider observed and real lived experiences of subjects, they do
acknowledge the existence of the metaphysical as beyond individuals’ physical senses.
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Postpositivists engage in rich, holistic analysis not in positivist research approaches. AlHamdan and Anthony identified reality influencers such as culture, gender, and beliefs.
Al-Hamdan and Anthony (2010) cited postpositivist research critics who
described qualitative researchers as those who present interesting stories with isolated,
potentially biased findings not advancing the discipline, because they do not spur further
reproductive research to establish external validity. In this study, the qualitative design
and interview methodology were relevant to finding important information to solve the
stated business problem. Learning how physicians make prescribing decisions constituted
more than presenting interesting stories. Employing the methodological techniques
described above facilitated the objectivity and unbiased findings of the study. Openended exploratory interview questions with follow-up clarifying questions yielded
information specific enough and relevant enough to enable significant meaning to study
outcomes regarding the articulated business problem.
Population and Sampling
The study population included physicians who practice primary care and
cardiovascular medicine worldwide. The purposeful sample in this study included
primary care physicians in a limited geography (Kentucky, Indiana, Tennessee). The
sample size was sufficient (n = 20) because I did not gather significant new information
after the 15th interview, evidential I reached saturation in less than 20 interviews.
Saturation is a guiding principle of sample size determination in qualitative studies
(Carlsen & Glenton, 2011). Mason (2010) argued saturation is elastic and true saturation
is contingent upon a number of variables including the aims of the study, homogeneity of
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participants, and skill of the interviewer. Consistent with Mason’s factors affecting
saturation, the focused aims of this study, similar specialties among physician subjects in
a limited geography, and richness of data gathered during interviews support the
possibility of achieved sample saturation for this defined population.
Kerr (2010) stated investigators cannot predict saturation but for practical
purposes, investigators need to plan number of subjects. From past studies, Kerr
determined investigators who sought to establish sample size guidelines for qualitative
methods of inquiry advocated samples sizes of six to 20 subjects. Similar to Mason
(2010), Kerr stated saturation depended upon heterogeneity of subjects and study
objectives. These guidelines supported the purposeful sample size for this focused
physician decision-criteria marketing study. Further justifying the sample size and intent
of this study, Bloomberg and Volpe (2012) advocated studying a small number of
subjects for phenomenological study investigators to conduct deep inquiry and collect
thick, rich data thus reducing the need for a larger sample.
Data Collection
Instruments
With respect to data collection, I followed the advice of scholarly investigators.
Rubin and Rubin (2012) advocated responsive interviewing to uncover and examine
complex, hidden phenomena. Responsive interviewing emphasizes the mutual
involvement of both the interviewee and the interviewer essential to derive meaning. To
derive reliable and valid meaning, the interviewer must build a reciprocal relationship
with the interviewee and demonstrate respect to create a conversational partnership.
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Similarly, Denzin and Lincoln (2008) underscored the importance of an intimate
relationship and resultant participatory engagement between the interviewer and
interviewee.
The interviewer must remain cognizant of emotional effects of the interview on
both parties and prevent biases by acknowledging potential areas of vulnerability and
data contamination. By using main questions, probes, and follow-up questions, the
interviewer can drive in-depth interviews to facilitate understanding of the obvious and
unobvious aspects of complex human behavior and collect rich, thick, data. The
interviewer should employ main questions to structure the interview, probes to elicit
more specifics and maintain conversation flow, and follow-up questions to explore
comments and ideas emerging during partnership conversations (Denzin & Lincoln,
2008).
In a relevant study in which investigators used subjects’ words to develop themes
related to CAM therapies, Ritenbaugh et al. (2011) developed outcome instruments
derived from patients’ words instead of preexisting theory. The researchers produced a
final questionnaire consisting of 18 items. These items included assessments of positive
and negative self-perceptions in the following outcome domains associated with CAM
therapy compliance: physical, social, psychological-cognitive, psychological-affective,
spiritual, and whole person. In this study of physician decision criteria, physicians used
words indicative of similar domains. Therefore, the Ritenbaugh et al. study outcomes
provided a useful framework for understanding physician subject responses.
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To test the quality of the interview protocol and as a safeguard against researcher
bias, Chenail (2011) proposed a pilot study to test planned interview questions and
procedures as well as interviewing-the-investigator technique. I used both tests in before
conducting this study. Chenail specified the qualifying criteria for interviewing the
investigator as the investigator must be part of the study subject population or have a
strong understanding of the study subjects. A pilot study requires IRB approval with
human subjects, achieved in this study. Interviewing-the-investigator method does not
require IRB approval.
The benefits of pilot studies include finding weaknesses or possible failures and
determining if the interview questions are vague, irrelevant, unproductive, or too
complicated. Pilot studies also provide the interviewer an opportunity for practice, obtain
feedback from subjects regarding the questions, determine interview duration, and revise
or edit questions. Chenail (2011) noted data collected during the pilot study is typically
not included in the main research study. The pilot study included an in-depth interview
using planned study interview questions (see questions listed below in Data Collection
Technique section). The pilot study subject answered questions regarding the
effectiveness of planned interview questions.
Subject answers to interview questions and interview procedure informed planned
field research (Chenail, 2011). During the pilot study, I practiced interview and follow-up
question administration, test audio recording procedures and function, and received
feedback from the pilot study subject (Neuman, 2011). I also explained study
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background, consent form including risks, benefits, and privacy, study methods, and
study procedures to the participant.
To test the instrument in this doctoral study, I also used interviewing-theinvestigator technique and tape-recorded the process. Regarding practical steps for
interviewing the investigator technique, Chenail (2011) explained the investigator can
play the role of the interviewed subject only, or play both roles (interviewer and
interviewee). Chenail advised the investigator may enlist the help of a colleague or
faculty chair to accomplish this process. Chenail recommended a cyclical process to
incorporate ideas emerging during the trial interviews until no further changes evolve
during the process.
A unique benefit of interviewing-the-investigator technique is the investigator
experiences the thoughts and feelings of the interviewee (study subject). The investigator
should document any feelings or discoveries of potential biases with corrective actions
because the IRB will analyze the investigator’s pre-study steps to determine instrument
rigor. Finally, the interviewer should identify and document pretextual, subtextual, and
contextual factors to control response divergence (Csordas et al., 2010). These two
instrument tests increased my awareness of voice intonation, placement of audio
recording device, revised question sequence, and improved my skill in using impromptu
exploratory and clarifying follow-up questions.
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Data Collection Technique
Study subjects heard interview questions for the first time during live interviews. I
audio recorded each interview. In addition to audio recordings, I made written notes to
document subjects’ main responses to questions.
To determine interview format for this study, I considered Turner’s (2010)
interview design descriptions: (a) informal conversational interview, (b) general
interview guide, and (c) standardized, open-ended interview design. According to Turner,
most critics regard the informal conversational interview as unstable and unreliable. The
general interview guide approach allows an interviewer freedom to ask questions using
personal style or paraphrase. To minimize inconsistent responses from study subjects, I
did not use the general interview guide approach. According to Turner, the best format is
the standardized open-ended interview, because the interviewer asks participants identical
questions with additional probing questions for clarification. This procedure reduces
researcher bias and is the interview protocol I used for this study.
Turner (2010) provided suggestions for conducting qualitative interviews,
including preparation, participant selection, pilot testing, effective research construction,
follow-up questions, and interview implementation. Turner’s other ideas include
selecting participants who will be willing to share their story honestly, avoiding evocative
or judgmental wording in open-ended questions and not asking why questions or asking
them with care. Turner advised flexibility by the researcher if a subject does not answer a
question (i.e., come back to the question later in the interview) or if the subject answers a
question before the interviewer asked the question. The interviewer should also be
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prepared and ready to ask immediately follow-up questions, consistent with the interview
protocol planned for this study.
Demonstrating a model for interviewing physicians and other clinical staff,
Curran et al. (2012) conducted qualitative research using interview data collection
methods to test the effectiveness of an intervention for anxiety: Coordinated anxiety
learning and management (CALM) in 17 U.S. primary care clinics (n = 47). The
investigators trained the interviewers prior to study inception. The interviewers employed
a core group of nine questions included in the interview guides. Prior to the study, a
group of investigators decided upon the questions after revising the questions several
times, including question revision after interviews had begun. The interviewers asked
open-ended core questions to determine facilitators and barriers to implementing CALM.
The interviewers also used open-ended questions to find the facilitators/barriers to
sustaining CALM after study completion. Interviewers recorded the conversations,
subsequently transcribed verbatim. Curran et al. (2012) reported in two instances, the
transcriber used the interviewer’s notes because the audio tape-recorder malfunctioned,
which highlights the importance of interview note taking I used in this study.
Curran et al. (2012) designed the interview protocol to support conventional
(inductive) and directed (a priori) content analyses. In this respect, the protocol included
a mixture of overview questions (e.g., “Tell me about your role and involvement in the
CALM project”) and specific follow-up probes designed to facilitate contextual
understanding, procedures, peer influences, and attitudes. Curran et al. (2012) explained
they designed interview questions to encourage subjects’ open expressions. This

90
approach subsequently enables data analysts to focus upon describing phenomena freely
without constriction to a specific theory or behavioral model. Interview questions also
elicited data later subjected to directed content analysis whereby investigators explored
predetermined themes and concepts leading to predetermined codes. Curran et al. noted
their emphasis on inductive data collection, applicable and used in this study.
I followed the suggestions of Skirbekk and Nortvedt (2011), who demonstrated
relevant qualitative study interviewing methodology in a medical setting. The purpose of
their study was to understand medical professionals’ conflict between care and concern
for particular patients versus impartial considerations of justice, which become central to
moral deliberations. From interview results conducted with physician and nurses in
Norwegian hospitals (n = 21), Shirbekk and Nortvedt discovered the dominant value
norm: making differences for patients. Nurses, more than physicians, based their care
decisions upon patients’ subjective needs.
In vacant hospital offices assisted by audio recording technology and a notebook,
Shirbekk and Nortvedt (2011) conducted interviews. Subsequently, transcribers
converted taped interview content verbatim. In this study, too, interviewers followed a
specific interview guide. In a consistent theme, they designed the interview questions to
facilitate open discussion and reflection upon phenomena of common interest.
Shirbekk and Nortvedt (2011) described their technique as active interviewing,
with both the interviewers and interviewees epistemologically active, participating in the
process of making meanings. The trained interviewers encouraged nurses and physicians
to reflect upon their own experiences, tell their own stories, and assert their own opinions
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regarding the subject phenomena. Shirbekk and Nortvedt explained the roles of the
interviewers as more than reporting subjects’ responses. They emphasized the
interviewers’ active interview participation.
To document the process of active interviewing, Shirbekk and Nortved listed
specific questions asked during the interview process. Most questions were open-ended.
For example, interviewers asked subjects what they considered just treatment, what were
just priorities, how they set priorities, and how they dealt with patient priority conflicts.
Additionally, the researchers developed interview questions to explore how often they
discussed such priorities with colleagues, expectations from colleagues and hospital
executives, and their sense of responsibility for their patients. These questions and
interview methodology are relevant models for the present n-3 study.
Scheermesser, Bachmann, Schämann, Oesch, and Kool (2012) provided a
valuable schematic to depict the circular process and long-time requirements for
competent data collection and analysis. Scheermesser et al. described the process to
encompass six quality criteria of qualitative research. These criteria included: a)
documentation of the data collection procedure, b) validating interpretation by
argumentation, c) systematic, dyadic procedure, d) closeness to research object, e)
validation by coder and author communication, and f) triangulation of methods.
Interestingly, Scheermesser et al. portrayed a circular, dynamic process to accomplish
triangulation after collecting data from a purposive sample through interviews, in-depth
interviews, and focus groups. The authors reviewed collected data repeatedly to define
codes reliably, identify themes, and argued to increase the robustness of their discoveries.
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The Scheermesset et al. (2012) study example demonstrates how qualitative
research methodology is inductive rather than deductive because the nature of the
research seeks descriptions of people and their particular situations, meanings, and
experiences. The qualitative research process is antithetical to quantitative research in the
respects qualitative research is nonlinear and nonsequential. The findings of the
aforementioned investigators influenced my selection of the qualitative method and
guided interview-question design in this study.
The specific interview questions were:
1. Considering the previously explained ladder of inference and reflexive loop
(Ayers, 2002), what processes do you go through to determine what products
you will prescribe or what dietary supplements you will recommend?
2. What credible clinical evidence have you seen regarding fish oil dietary
supplements?
3. What made the evidence credible or incredulous?
4. What are the risks of taking fish oil dietary supplements?
5. What are the risks regarding specific patient groups or disease states?
6. What are the important differences between quality fish oil dietary supplements
and low quality fish oil dietary supplements?
7. What are right daily amounts of DHA and EPA?
8. If clinical evidence is credible and convincing regarding fish oil efficacy for
health prevention for disease amelioration, what education and communication methods
to physicians are best?
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9. Similarly, what education and communication methods to patients are best?
10. Within the context of the ladder, please explain your present professional
opinion regarding the health value of fish oil dietary supplements, specifically fish oil
containing n-3s, for patients with no contraindications.
11. What are your prescribing or recommending practices regarding n-3 fatty acid
dietary supplements and the priority of n-3 dietary supplements as compared with other
dietary supplements (e.g., multivitamins, chondroitin, niacin)?
12. How influential are your peers’ prescribing practices to your decisions?
13. When you speak with your peers, what percentage of them would you say are
committed to frequently recommending omega-3s?
14. If all your patients took a high quality omega-3 every day, what would be the
impact on your whole practice?
15. If all your patients took a high quality omega-3 every day, what would be the
positive impact on U.S. healthcare costs?
Data Organization Techniques
After data collection, I organized subject responses and audio recordings by
individual study subject files. I stored the raw and transcribed data in a locked office with
limited access controlled only by me. I plan to dispose of subject data using a shredder
after 5 years. Both during and after the study, I preserved physician subject
confidentiality.
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Data Analysis Technique
Data analysis links to the conceptual framework of the study. I analyzed data in
the context of ladder of inference theory. Data analysis facilitated physician selfunderstanding and helped identify physician and patient needs for education and
marketing purposes. I identified themes from recurring subject statements coded and
checked by another coder. Data complexity and diversity did not warrant
hyperRESEARCH software to facilitate code development.
Relevant to coding, thematic development, and data analysis, unconscious mental
processing of data—reflective processing—was a vital, necessary part of this qualitative
research because of the discovery of important but unobvious underlying psychological
constructs (Meek, 2003). I experienced this phenomenon often overlooked by other
researchers, according to Meek. The reflective process includes both intellectual and
emotional components, where often the gut feeling and intuition catalyze the researcher’s
conclusions or decision to proceed to the next step (e.g., not adding more codes but
proceeding to thematic development and analysis). Reflective process has its roots in
psychoanalysis, wherein Freud differentiated among the conscious, preconscious, and
unconscious minds (Modell, 2011).
According to the psychotherapist Meek (2003), understanding the workings of the
unconscious mind of subjects provides opportunities to deepen understanding and
discover unobvious mechanisms of motivation and reasoning. The psychotherapist
describes the workings of the unconscious mind as highly complex, forming associations
of disconnected concepts not necessarily in chronological order, and disassembling and
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assembling ideas not logically related. Meek provided instances of the unconscious mind
at work: Working on an unrelated jigsaw puzzle sometimes triggers a solution or an idea
relevant to a different dilemma or how awaking from a night’s sleep provides new
insights and revelations.
Meek (2003) outlined pragmatic steps for reflective processing for researchers to
follow. Researchers should break complex material into stages, make repeated passes at
the data to find new revelations, and translate material using own words to articulate new
ideas. When the researcher is stuck, one should understand any relationship between
personal conflict and the research topic and identify those links to facilitate
understanding. Second, Meek advised researchers to take breaks. Because the
unconscious mind requires time to finish combinatory play, the researcher should not
always regard a time of perceived unproductivity as wasted time. Meek exemplified how
fallow fields regenerate during the time microorganisms regenerate themselves, which
prepares them for the new season.
Third, Meek (2003) advised the researcher should gain differing perspectives
about the data by looking at data from a distance. Sometimes researchers become too
engrossed in data detail. Fourth, the decision to integrate versus deconstruct data is an
intuitive one. Meek posited researchers realize this point when their curiosity is satisfied.
Discoveries of the unconscious mind can be valuable, but reflective processing requires a
conscious stepped approach, and the steps are not necessarily sequential. This advice
served me well because during quiet and reflective times I sometimes found frustrating, I
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could organize subject responses cognitively into themes and developed a hierarchical
order of presentation (consistent with ladder of inference theory) for the study report.
Regarding specific coding methods, Li and Yeo (2011) provided specific coding
steps as a useful model. They initially established categorical cues grouping research
questions as broad categories and the follow-up probes as root categories. Li and Yeo
employed key word searches (e.g., quality, commitment, team, reward, etc.) to garner an
overall view of the data. Their next step was to identify clusters of information relevant to
the study purpose of inquiry.
Following the formation of information clusters, Li and Yeo (2011) engaged in a
rigorous and systematic patterning process until they observed recurring themes. They
also grouped examples provided by subjects with the recurring themes. By using
categorical cues and classification tables, Li and Yeo developed units of analysis and
thematic patterns. Evolving to analysis, they adopted an integrative purpose to reduce
responses to clear collective sets. Li and Yeo matched the collective theme sets to their
research questions and themes identified in literature. They emphasized three
comparative analysis steps to enhance the trustworthiness of the data: (a) derivation of
research questions and issues from related literature, (b) rigorous coding adherence to
established coding system, and (c) inter-coder involvement and verification to ensure
reliability. I used all three steps in my analysis.
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Reliability and Validity
Reliability
Beck (2009) proposed five trustworthiness criteria appropriate for qualitative
studies including credibility, dependability, conformability, transferability, and
authenticity. I described all these criteria in previous document sections, except
authenticity. According to Beck, authenticity is the degree the researchers fairly and
truthfully described study subjects’ experiences. I increased authenticity and credibility
by validating transcribed data with participants through e-mail follow-up as a method of
member checking.
Beck (2009) also provided a list of 57 valuable questions a medical professional
should employ to assess study trustworthiness. The questions pertain to study-report
sections, including the title, abstract, introduction, methods (sample and setting, data
collection, procedures, enhancement of rigor, etc.), results (data analysis and findings),
discussion, and global issues (presentation, researcher credibility, and summary
assessment). These questions guided my development of this doctoral research study.
Parenthetically, to enhance understanding of the medical professional’s foundational
ideology for evidence-based practice, Beck advocated (a) asking the burning question, (b)
collecting the most relevant evidence, (c) critical appraising clinical evidence, (d)
integrating evidence with personal experience, expertise, and patient preferences and
values, and (e) continuing evaluation of the medical decision and change in health status.
I followed Beck’s recommendations in this study and determined two compelling
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questions relating to the cost of drug or dietary supplement therapies and the personal
experiences of physicians.
Validity
Regarding qualitative research, Golafshani (2003) proposed researchers should
replace traditional validity vernacular by quality, rigor, credibility, transferability, and
trustworthiness. Golafshani insisted triangulation for both data collection and analysis
could enhance the rigor of the research without compromising its inherent, naturalistic
value. Golafshani also advocated qualitative researchers to make their research findings
generalizable, and a true test of validity is the reproducibility of study findings in wider
groups and similar, if not identical, circumstances.
Holt (1991) essentially refuted mainstream qualitative study validity and
reliability techniques on the basis that such techniques “contradict the nature of the
interpretive task, and pose insurmountable problems in application” (p. 59). Holt argued a
subject or researcher’s individual, contextual interpretation of any event is not verifiable
as accurate or truthful because another individual would relate the same experience
differently because of a separate, unique frame of reference and context (e.g., the
Roshomon parable). Holt argued reviewers should employ an interpretive technique and
judge interpretations by the insight provided and the power to convince (Thompson’s
gestalt experience, as cited in Holt, 1991). Holt posited if enough peer experts agreed, the
consensus would define the predominant interpretation.
Holt (1991) added integrity as a test to the traditional methods of testing
naturalistic inquiry including the following: credibility, transferability, dependability of
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measure, and conformability. Holt explicated the 10 techniques recommended by Belk et
al.: (a) prolonged engagement and persistent observations, (b) use of triangulation with
different researchers for data collection and interpretation, (c) frequent on-site team
interaction, (d) negative case analysis, (e) peer debriefing, (f) member checking, (g)
limiting exceptions, (h) purposeful sampling, (i) reflexive journals, and (j) independent
audits. Neuman (2011) advocated applying similar criteria to those recommended by
Belk et al.
Bernard and Ryan (2003) outlined eight observational techniques and four
manipulative techniques for unbiased theme development. Shepherd and Rentz (1990)
provided steps “to minimize the subjectivity of coders” (p. 62). Brent and Slusarz (2003)
recommended computer assistance “to assess and improve the reliability of coding by the
researcher” (p. 299). Last, Zelik, Patterson, and Woods (2010) proposed a rigor analysis
model with eight specific components to establish rigor and prevent shallow analysis in
qualitative research. In this study, I considered the discussion and advice of investigators
cited above. These elements might also enhance the external validity of subsequent
similar, but not necessarily identical studies.
Transition and Summary
The objectives of Section 2 were to justify and explicate design and methods of
this research study. Critical to the success of this study was the careful and excellent
execution of this plan. As a result, I can report meaningful, reliable, and valid results
important to the general and specific business problems articulated in this study. In the
following section, Section 3, I present study findings, outcomes, and conclusions.
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Section 3: Application to Professional Practice and Implications for Change
In this section, I provide a review, examples, analysis of information, and
outcomes from gathered data to research questions elicited during semistructured, faceto-face interviews with 20 physicians in Kentucky (16), Indiana (2), and Tennessee (2).
The physician subjects included 16 males, four females, 18 of whom were medical
doctors (MDs) and two of whom were doctors of osteopathy (DOs). Physician practice
experience ranged from one to 38 years.
Overview of Study
The purpose of this phenomenological research study was to improve n-3
marketers’ understanding of how physicians reach decisions to prescribe or recommend
products including omega-3 (n-3) dietary supplements and which product characteristics
may be the most important to physicians. I explored physicians’n-3 dietary supplement
knowledge and decision criteria (ladder of inference; Argyris, 1976), and found
physicians’ inference ladders for prescription drugs are similar to physicians’ inference
ladders for n-3s. Argyris’s ladder of inference model facilitates constructing a
hierarchical schema to facilitate understanding physicians’ decisions, ideal for the
physician context because higher ladder rungs are not accessible in the absence of bottom
ladder rungs. With physicians, as expected, the bottom ladder rungs are drug or dietary
supplement safety and efficacy. After establishing efficacy and safety, physicians
consider a number of other important factors (i.e., ascending ladder rungs) such as cost
and reimbursement, their own patient experiences and outcomes, peers (especially
specialists), performance and behaviors exhibited by pharmaceutical representatives,
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supply of samples, direct-to-consumer advertising, and personal experiences of patients
or themselves taking the products.
I interviewed the 20 physicians in private settings conducive to few interruptions.
After concise introductions and Informed Consent completion, I outlined the interview
plan, asked questions, and closed the interviews by thanking the physicians and asking
for their follow-up response to an e-mail containing confidential transcript and them
information. Following interview transcript review and study, I developed codes and
themes in accordance with the code and theme development methods advocated by Meek
(2003) and Li and Yeo (2011). Meek recommended reading and rereading transcripts,
and then taking time away from transcribed manuscripts to contemplate coding and
thematic development. I also enlisted the help of a second coder (IRB approved) to fulfill
the intercoding verification process advocated by Li and Yeo and further validate the
triangulation process advocated by Golafshani (2003).
Bertolotti and Tagliaventi (2007) emphasized the importance of data analysis
objectification, a critical element to support study validity. Following the
recommendations of Berolotti and Tagliaventi, I used intercoder agreement, peer review,
and member checking to triangulate and confirm data accuracy and theme development.
I e-mailed physician subjects their own confidential transcript content to ensure accuracy
of transcribed content and thematic confirmation. One-half of physician subjects
responded and of those who responded, all confirmed content accuracy without
recommending revisions. I also engaged the help of a colleague in peer review. To ensure
data accuracy, I audio-recorded the 20 interviews without electronic device glitches.
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By rereading and contemplating content, I developed groups of data using codes,
developed themes from codes, and reduced too many themes into fewer pragmatic
themes and synthesized my analysis and conclusions. I evaluated my conclusions for
prospective limitations and delimitations, identified implications for social change, made
recommendations for follow-up study, and revealed introspective growth perceptions
from the experience. This process was holistic and my research and evaluation methods
integrated the problem statement, purpose statement, research question, conceptual
framework, nature of the study, qualitative design, literature review content, validity and
reliability controls originally presented in Sections 1 and 2.
The study outcomes enabled me to answer the primary research question: For the
purpose of marketing strategy, what is the ladder of inference physicians use to
recommend n-3 dietary supplements? To answer this primary research question, I first
established context. Context included how physicians determine what drugs they will
prescribe and what supplements they recommend because these decisions follow the
same hierarchy of decision logic: patient safety, product efficacy, experience, cost, and
other influencers. Physician decision logic fits ladder of inference theory (Argyris, 1976)
with respect to specific decision influence components including the following key rungs
in the ladder of inference: data selection (determining clinical trial credibility), data
interpretation (how the data fit personal experience), practical and ethical factors to
determine if assimilated data will change behavior (the action of prescribing or
recommending products including n-3s).
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Presentation of the Findings
Through a process of repeated and prolonged data analysis, I determined eight
prevalent themes from this study. The first three themes were Theme 1: Clinical Trial
Rigor, Practice Relevancy, Degree of Influence, Theme 2: Physicians’ Experience and
the Test of Time Determine Prescribing Habits, and Theme 3: Cost is an Important
Influencer, Providing Competitive Products Have Similar Efficacy and Safety. Themes 46 included Theme 4: Peer Opinions Influence Prescribing Decisions If Peers are
Specialists, Theme 5: Competent and Incompetent Pharmaceutical Representatives Have
Antithetical Effects Influencing Physicians’ Prescribing Decisions, and Theme 6:
Samples Are a Valuable Influencer to Some Physicians.
The final two themes were Theme 7: Most Physicians Have Negative Opinions
Regarding the Influence of Direct-to-Consumer (DTC) Advertising but DTC Increases
Product Awareness, and Theme 8: Lost Influencer Opportunities: Physicians Need More
Dietary Supplement Education and Lack of Dietary Supplement Curricula in Medical
Schools. All themes are relevant to the core research question. Themes 1, 2, and 3
seemed essential as influencers and more important than Themes 4, 5, 6, 7, and 8. In the
following subsection, I explain these themes in more detail and support themes with
transcript excerpts. I also discuss the pragmatic applications of these themes to
pharmaceutical and n-3 marketers.
Theme 1: Clinical Trial Rigor, Practice Relevancy, Degree of Influence
The following excerpts support clinical trial validity and reliability criteria
physicians value to determine rigor. Important clinical trial methods include double-
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blind, randomized, placebo-controlled, and number of subjects (sample size). Other
important factors to determine rigor include investigator credentials and the reputation of
the publication journal. Physicians also evaluate the relevancy of clinical trials including
study venue, study subjects, and outcomes. In the transcript excerpts below, I protect
physician anonymity by using an initial (e.g., Dr. H) not necessarily representing any part
of the physician’s real name.
First, Dr. H commented, “Very simple, number of people in the study. If it’s 150
people doesn’t tell me anything, if it’s 5,000 people for 5 years, that’s the first thing I
look at,” while Dr. T stated that, “Well how many people are in those studies? Is it a good
one, is the finding statistically significant. I look for p values and study rigor.” Other
doctors commented:
Is it effective, how many people, what are the risks, that’s big for me because we
cause a lot of problems maybe more than we solve, and I am very in tuned to that.
Generally where I get my information, they are only putting in their stuff that is
credible, statistically significant. I use Prescriber’s Letter, I love Prescriber’s
Letter. I read The Medical Letter. I read something called Core Content Review,
which is basically Cochran-based, that is where I get all my information,
basically. (Dr. O)
If I am looking, I want to know it’s a large enough study, well done study,
placebo-controlled, double-blind, that kind of thing. I want to make sure the
conclusions drawn are what I shown in the study. You know a lot of times people
try to draw conclusions for example 2 + 2 =4 therefore 4 +2 = 6, well you didn’t
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include that as part of your study so you can’t say that, you know… a lot of the
information the drug companies put out, it’s not real hard data. In fact I’d rather
get the data from an academic environment. (Dr. R)
Well, it’s the number of patients for example if you are looking at a study with 10
people versus 10,000 people, the one with 10,000 will be more meaningful,
number one. Number two it’s gonna be how long has the product been on the
market, do we have any bad reports, any recalls, FDA have any black box
warnings. (Dr. I)
I look for the size of the study, how many subjects are involved, what kind of
study is it, is it observational, is it placebo-controlled, who did the study, whether
it is university based, Institute of Health based, or pharmaceutical based study,
um, that’s what I look for when I read articles. (Dr. N)
Dr. S stated: “OK, Is it a large enough sample? Are they measuring
something important? Is it something definitive or is it something we are hopeful
will work and we are not quite sure? Either the data is soft or we don’t know the
side effects” while Dr. G remarked, “Population size is critical. 20 patients vs.
400? Primary care docs don’t necessarily look at raw data. At least they don’t
have the time to do that and don’t have the time to do it. Look at how long drug
has been on the market and credibility of company and investigator.”
Dr. C stated: “Well basically, the ones who have a significant endpoint -whatever they are testing for…reduce triglycerides or whatever…and that it works, and
something that is safe. And always, what is cost-effective, more than anything.” Dr. K
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disclosed: “I look at how they chose the study participants and whether or not it would
apply broadly.”Dr. B added: “Oh right, well obviously the source of the information has a
lot to do with it, how big the study is also has a lot to do with it.” Another physician
added:
Double-blinded studies, multi-center, the source has a lot to do with it…What
drives me crazy with some of these studies...they come up with these crazy
scales…so the study show X was better than Y on some allergy retro scale…on
some crazy scale and you say ours was .8 and theirs was .6 and okay here’s the
difference between those two. A 30% difference on a scale does not mean a 30%
difference on what I see on my patients. And on some of these depression scales it
does not give you a point of relevance and so you say I don’t know how sick a .6
is and I don’t know how much better a .8 is, does it apply, does it make my
patients better. So I think a lot of these studies give you information you cannot
use. If you are treating shingles, I want to know how fast my patients will get
better. I am not interested I splitting minutia that doesn’t matter in real life, or
when p values are such borderline and they give you scores, those drive me crazy.
(Dr. W)
Dr. A stated: “If the drug was tried on a few or hundreds of patients. Also if drug
versus another drug with better results this is important to assess… The main thing is to
read good journals, New England Journal of Medicine, JAMA…” while Dr. L advised:
“And randomized, placebo-controlled…and you like to see more than one study.” Dr. E
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remarked: “I know what the efficacy of the drug is. I want to know what kind of patients
they are and I want to know how they compare to their peers.” Other physicians stated:
Usually I look at several things, I look at, well the younger guys are much more
analytical about studies but I am going to look at whether or not it is a blinded
study. I look at the total number of people in the trial, so often we forget about
even though a New England Journal of Medicine study, it has a total of 36
participants. I like a study that probably has more people. Is it 13 patients or
13,000? Who did it? Which centers? And then, applicability is a big thing for us,
meaning did they do the study on 5,000 people from Tazmania? Really doesn’t
have anything to do with my patient population. And so they can have great
studies with great things but really doesn’t apply to me. So I think it’s important
to look at all of it and see if it’s applicable…You can rely more on a study that
came out of New England Journal and you expect studies to be credible...doesn’t
always have to be that way but usually is. (Dr. J)
I like a multisite study, I like more investigators than one investigator’s bias. And
I like double-blinded because neither the investigator nor the patient knows what
they are getting, or what they are giving. Those are the kinds of things I look at in
clinical trials, multi-site, double-blind, big numbers. Sometimes the journals that
are peer-reviewed will only allow certain studies. You’re going to have the top ten
journals, or the top five journals and then the next 10. The studies are going to be
more sophisticated depending upon where you look. (Dr. V)
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The top five journals have their pick and they are going to make you revise and
re-submit. And I am going to go towards a more sophisticated study. With throwaway journals, I might not consider the study. And then I guess the one thing I
really look at, in our academy, is the Cochran library, where they take all of the
studies of a particular thing, and group them together. So there are positive
studies, negative studies, and neutral studies and somehow they combine the
numbers and make a recommendation based upon all the studies they could find
in the literature. (Dr. J)
Theme 2: Physicians’ Experience and the Test of Time Determine Prescribing
Habits
In a relevant quantitative study (n = 135), Tichelaar et al. (2010) noted practicing
physicians reach their prescribing decisions heuristically and may not be conscious of
their own drug choice logic or value judgments. Tichelaar et al. noted unlike diagnostic
reasoning, which is well documented in the literature, little is known about therapeutic
reasoning (i.e., the decision process physicians use to make treatment choices). The
findings in this study add understanding of the heuristic physician decision process of
data selection, interpretation, assimilation, and action.
The selection and assimilation of data by physicians is a perpetual process.
Clinical trial outcomes are important but in long-term effects on prescribing habits, only
if physicians’ personal experiences support those outcomes. All 20 physicians expressed
reservations about prescribing unfamiliar products or new products on the market and
most physicians described cautious approaches regarding new product trials. With
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positive feedback and experience, physicians gradually increased product use. Clearly,
regardless of physician decision influencers, the long-term trump criterion is their
personal and patient-specific experiences. The following evidentiary excerpts provide
more insight regarding these findings:
No, I think it has to do with experience of practicing 34 years. You get somewhat
in a routine. If you have a patient who you know a drug will work, you throw in
tolerance and cost, you develop a comfort zone and you may add a new drug from
time to time. But you kinda know with Miss Jones, these other products worked,
so will this one. But you get into a routine using drugs that work and really don’t
try many new things. (Dr. G)
If you ask me, and this is just me, we are all a little different, the single biggest
thing to impact me has got to be familiarity. I’m not one that, as soon as a product
comes out on the market I’m on it. I tend to take my time, use samples, evaluate
closely. If they need an antibiotic for a certain indication, I tend to go with the one
I know works. I know these are the downsides, these are the upsides, can’t use it
with that…familiarity is probably the biggest factor for me. And if something new
on the market comes out and does not have that downside, I will start trying it
slowly and carefully. But for me the biggest part is familiarity. (Dr. V)
The physicians expressed strong opinions regarding their direct experiences with
drugs and supplements, especially new products. Dr. I stated: “Everybody has their own
experiences and own opinions. I would get more influence by the patient themselves.
Somebody says I tried this and it helped me, I would go for it even though I haven’t had
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much experience” Dr. H added: “Now with new drugs I got burned so many times, a
new drug comes out, any kind of total new drug, I sit around and let somebody else use it
for 4-6 months.” Dr. N stated: “Yeah, have been burned before about drugs that have
come out, even for 5 or 10 years, and then we found out, so we’ve all been burned.” Dr.
M admitted: “I tend to trust old friends who are not going to mislead me.”
Adding to the importance of product experience, Dr. S stated: “With some new
products I don’t feel secure enough that it’s been out long enough and that there is
enough people that have been on it.” Dr. K revealed: “I want to be familiar with the drug
and I want to know it’s mechanism of action.” Adding a comment regarding proof of
product efficacy Dr. C advised: “Something like omega-3 I can draw blood and show
someone cholesterol levels and the test the same later, maybe 3 months or 6 months later
to see/show results. Those are the kind of results that open eyeballs.” Other important
physician comments:
I am very influenced by the big trials, like the nurses trial on breast cancer, and
the big trials on hypertension, what drug over the long haul always comes out on
top. Like you can’t beat ACE inhibitors. You cannot beat hydrochlorothiazide. It
prevents more heart failure than anything else and it has been out for 30 years. I
guess that’s the big one for me. (Dr. O)
Something that is very new, I might be a little skeptical before I use it. Um, and
the thing is, most medications are not new. If you go and look they are in Europe
10 years before they are here. In Europe they are much faster. They give the OK
to go out on the market much faster than FDA does here. So if I see a medication

111
that has been on the market for 10 years in Europe but now it is here, I will go for
it. Something very new, experimental, maybe I will wait a bit to see what’s going
down the pike. (Dr. I)
Theme 3: Cost is an Important Influencer, Providing Competitive Products
Have Similar Efficacy and Safety
One surprise in this study was the emphasis and importance of cost as an
influencer of physicians’ decisions to prescribe drugs or recommend dietary supplements.
Without exception, physicians expressed frustration with inordinate product costs and
provided compelling patient experience examples where patients did not comply with
physician directions because costs were too high, even if patients knew health
consequences would result from noncompliance. Based upon physician explanations, in
the physician ladder schema of influencers cost elevated to a primary decision influencer
as perhaps the third most important ladder rung after credible clinical data and physician
personal experience. The following transcript excerpts enhance the prominence of cost in
the overall physician decision-criteria hierarchy:
That is the top priority. You know if you have patients who are Medicare or who
cannot afford the drug you are not going to use it. So that is a major issue. And
sometimes you have to acquiesce and choose a less expensive drug even when
you prefer the brand or they won’t be able to afford it and flat out won’t take it.
(Dr. G)
[Cost] Big, big. Not for me, but for the patient. Even if the clinical trial outcome
is phenomenal, I can think of a hundred medicines, amazing, look at the reduction
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in systolic and diastolic blood pressure – the results may be amazing – but if that
medicine costs the patient a hundred dollars a month, the patient is not going to
take it. You have to be practical. (Dr. D)
I think from a patient’s standpoint, the economy of the drug plays a far bigger part
than you guys realize. I have reps in here all the time and I say really, if you
would have priced this at $40, I would have 2,000 patients on it. At $140, three.
And you can’t tell me it costs $120 to make this stuff because it has been out
forever. And they say well we evaluated it and if it saves one hospitalization a
year it saves this much and I say don’t give me that crap my patients aren’t paying
it. These new diabetic drugs are now $300/month versus the old sulfonamides for
$20 that work just as well…But I think patients are more cost conscious than
ever. When formularies were $5, $10 and $15, who cares. When $5, $50, and
$100, wait a minute what is all this formulary stuff. Well you had it all the time
they just jumped it. (Dr. W)
Physician expressed strong opinions regarding costs. Dr. M stated: “Yes, it’s a big
factor. More than it used to be because things weren’t as expensive back then. They’re all
expensive now…People are really concerned about cost…as long as quality is good then
you’re going to look at cost.” Dr. F prioritized decision criteria: “Safe, effective,
available, and cost… Cost is way up there, very important.” Dr. V added: “But we want
everything covered by our health insurance and then don’t understand why it goes up
every year…is criminal in what they charge people and keep raising prices higher and
higher.” Physicians explained why cost is so important in the following longer excerpts:
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And I’d go down to the Braves game and the box down there and when I finished
my talk, I’d say after all this stuff, be honest with me, what is the single factor that
will get you to write a drug, and every stinkin’ time it was cost… Yes sir, that’s
the single most important factor… and they came to me and I said I know what I
am supposed to say, I’m supposed to say efficacy and safety and all that, I said,
it’s cost. I’ll just tell you it’s cost. And the guy next to me, he started, and he said,
he’s right. And the guy before me said, an internist from Mississippi, said I want
to change mine, he’s right, it’s cost. Every one of them said cost…But
pharmaceutical companies don’t get that. They say well if we cut the price then
they’ll cut the price and we’ll get into a price war. But if you make a good product
at a good price, doctors will use it. They’ll lie to you and tell you it’s something
else but I’ll tell you, it’s cost. (Dr. H)
It’s pretty high for me, unfortunately, but cost is very important. Regarding brand
names they are more expensive but if there is a tried-and-proven generic, I usually
go with that one first. And if they don’t do well on the medication then I will go
to the brand name. Unless it’s something that is not good enough in my mind in
that class of generic drugs, then I will go to a brand name. (Dr. P)
All these things play a role although sometimes you still feel even though it has a
black box warning, you have used this product for so long, so good to the patients,
so you pretty much put that aside and go with your gut feeling. Um, insurance, if
it’s covered or not, it’s significant. People these days they don’t want to pay a
penny over what their insurance covers… They say “Well, I have insurance” but
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you know, it doesn’t work that way. So I should tell them now it’s gonna be $200
co-pay, going up and up and they say, forget it, I don’t want it. Doesn’t matter if
it’s a life- saving medication, doesn’t matter, they won’t go for it… I think it’s
also the fact…20 years ago, only one or two medications were expensive out of
the whole realm of drugs. Today, some medications are 400 or 500 bucks. They
are routine, so that has made people skeptical about anything not covered by
insurance. (Dr. I)
Nowadays pretty huge cause patients are pretty savvy about that. They call you
back and say, “Isn’t there a $4 choice or generic for this? This costs too much.”
So you have to factor in cost a lot because if you keep writing people $70
medications they quit seeing you. It is that world now and they won’t come
back…in my parents day their copay was $5 bucks. Now a third-tier copay is $50
or $60 dollar copay and somebody tells you there is a $4 cholesterol medication
on the list at Wal-Mart. So people are savvy enough to be looking at that and
saying isn’t there a cheaper alternative I could be taking. (Dr. T)
Around here we see a lot of people who do not have insurance or who have very
poor insurance. Ah, we see a lot of people who are cash pay, people who have a
very high deductible and it won’t pay anything until they hit say $5,000 in
medical bills. So in those cases cost is a huge factor. I can give them something
but if they won’t go fill it, it doesn’t work. Or they just get mad at you, one of the
two. But more of the time they just don’t get it. I saw a patient yesterday and she
had a really bad cut on her finger and she went to the ER and got sewn up. I gave

115
her an antibiotic. She didn’t get it filled. Now it’s a big, nasty infected wound.
This was something she needed but she couldn’t afford it. So cost is a big issue
especially, if well if you take something like an antibiotic and you are on it once
that is one issue. But if you are taking something for the rest of your life, cost is a
big, big issue. (Dr. B)
Huge! I am a generic user, a big, big, generic user. With drugs, if it hasn’t been in
our magic sample closet for at least a year, I am not going to use it. Sometimes
with cardiac drugs I will use it if I know a lot of cardiologists have used it and I
have spoken with one I know who is conservative and they say yeah I am having
a lot of good luck with this drug. Antidepressants, no way. Cholesterol medicine
there really isn’t that much that comes out. And diabetic medicine, I may be more
apt to try that. (Dr. O)
Well, when I prescribe things, I am simultaneously thinking of several different
things. Efficacy and how the drug will work, cost and their co-pay status, how it
fits, ease to take it, side effect profile, I am thinking of all these things at the same
time. (Dr. R)
It’s important to me because 50% of my patients are cash pay. They don’t have
Medicaid, Medicare, or private insurance. So it’s important because what they
have to pay is going to determine whether they are compliant whether they are
going to take it, whether they are going to take it past what I give them. I may
give them a sample. But if they can’t afford and they are not going to buy it, it’s
simple. (Dr. E)
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Um, I don’t have to know it’s going to work on that individual but I have to know
it fits the individual’s lifestyle. Is this person going to be able to afford what I
choose? Is this person one who will feel comfortable taking something that is not
a prescription? Is this an expensive prescription? A lot of it is financial state. Of
course, if I believe it can help them, and they really need the more expensive
medicine, I will encourage them to really make a sacrifice for it. If I am uncertain
about it, I am going to have a lot of trouble trying to convince them to take
something I don’t necessarily believe in. [If I prescribe something too expensive]
They don’t take anything or you get a callback in a day or so saying we can’t
afford this. Is there something else we can take? It is a terrible feeling in a day
that you gave someone something that was impossible to do, was a failure, and
you shouldn’t have done it. [Pharmaceutical companies] Yes, they really don’t
factor that in very well. And they don’t think about how much these people are
taking. And if they are Medicare, they are even more vulnerable to those
problems. If they have insurance there is a hope. If they don’t have insurance they
are dead in the water.
Medicare, maybe will cover, maybe it won’t. Insurance, maybe will cover and
maybe it won’t. Uninsured people, forget it. And then they hit the donut hole and
they come in and say, “I can’t afford this for the next 3-4 months” so then we
gotta figure out what to do to get them through the donut hole. So there we have
double work. All of sudden we had a medicine I wanted to count on for a year
and I can’t count on it for a year. We have to change the script, somebody has to
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input that data into our computer system and then the patient has to bring the
bottles in so we can confirm what they are taking and make they are right. And
this just doubles our work in a year’s time with a prescription list. (Dr. R)
Yes that is the other one I was going to get to. Interestingly they pulled quinine
off the market which is the old standby that was used for ever, and it costs
pennies, and as soon as they pulled quinine suddenly we are putting people on
anti-epileptic medicine costing three figures, hundreds of dollars to put them on
this stuff, you gotta titrate it, you gotta be careful. And all of a sudden what we
used to use and treat for pennies, now we are treating for hundreds. Well, older
people, a lot on Medicare, and that donut hole becomes huge to many people. It’s
just half a year and I already have patients hitting their donut hole. And now they
have to float the whole cost of medication because even if you have an over the
counter it’s better than Lovaza...that pushes you towards your donut hole. So by
the 6th month, you’ve spent $500 towards your donut hole whereas if you bought
the over the counter version which is about the same as your copay, you’ve spent
the same but don’t have it going towards your donut hole. That’s a critical
factor.…I’ve gotta have the price and the efficacy to match. If it’s something
that’s very expensive like a cancer drug, then it’s something you can’t do without.
When you’re talking about BP medicine, I can give you a $4 medicine that is
going to work great, why would I write a $200 medicine because a drug rep told
me to? By the same token if I am using, for instance I believe in Synthroid, versus
a generic thyroid medication because it’s so important to keep your patient
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balanced. So cost enters into it, but then there are some drugs worth it. And I
think that is probably what does it for me. I‘ve gotta look at cost and sometimes I
don’t have a choice. Well you’ve made me think about why I use the things I do. I
don’t know, ease of use, cost, what the patient will use. Because I always tell my
students, you can write any damn thing you want, but if the patient doesn’t take it,
you’ve done no good. You gotta read your patient. I have patients all the time call
back I can’t afford it I can’t afford it. You stay at this long enough and you learn
what works. I don’t want those callbacks and I want to know it’s going to work
right up front. (Dr. J)
Theme 4: Peer Opinions Influence Prescribing Decisions If Peers are
Specialists
I classify credible clinical proof, personal experience, and cost as essential
influencers. Other influencers may be important as well but may vary in their degree of
impact, depending upon physician individuality and preferences. The influences of peers,
pharmaceutical reps, DTC advertising, samples, and dietary supplement education (or
lack thereof) may all have some influence, but to varying degrees depending upon the
physician person. Not surprising, younger physicians seemed more receptive to peer
influence than did more experienced physicians. The following transcript excerpts
provide insight regarding the variability of physician peer influence:
Peer influence may be most important with new medicines. Dr. L stated: “Peer
experience is important especially with new medicines.” Dr. F was positive regarding
peer influence: “It seems to work out better when I take the influence of my peers first.
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They give me specific instruction on how they have used it. If they say it works better, it
gives me a motive to try it.” Dr. O disclosed: “Yes and you get information when you
send a consult to someone and they send you back a report. I like to read my consults all
the time.” Dr. K clarified: “More if a peer feels comfortable using a medicine as opposed
to the horror stories of medicines.”
Younger physicians may be more receptive to peer influence. For example, Dr. M
stated: “Certainly influenced me in residency when I was learning things. Don’t have that
contact now. But we share with each other so yeah, we have some contact. I still listen.”
Dr. P remarked: “Peer influence…residency yes. We get into the habit of using meds and
then it’s hard to break me of the habit. “Conversely, a physician in practice for many
years, Dr. I remarked: “Not really, everybody has their own experiences and own
opinions. I would get more influence by the patients themselves…But not what other
doctors say or think. “Physicians added other insights regarding peer influence:
If there is somebody in my immediate circle like in this group here…for example
if Dr. R has been using a medication and I see his patients get good response, if I
have not been using it, I might start picking that up. Usually I am one of the
slower first adopters of new medications and if others want to try it first that is
fine with me. I will wait and if there are no problems, I might start picking it up.
I’m a fairly slow adopter when it comes to that. (Dr. N)
I find that medicine has become the complete opposite of what we ascribe to here
. . . we try to communicate, we make calls, we send complete records, we try to
do everything we can so subspecialists know all they need to know. And for the
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most part medicine is pulling apart so we don’t have as much collaboration as we
used to. Having said that, If I talk to somebody and my pulmonologist tells me
this is the best metered-dose inhaler because of this, that, and the other, sure I will
use that information…he sees the troubled cases. Subspecialists, now when you
are talking about that kind of collaboration I love to learn from those guys. They
see the trouble cases. While we see a boatload of them, we send them the ones we
can’t fix. (Dr. V)
Probably for certain specialty drugs I am certainly more influenced or more apt to
use something if the allergist I use all the time prescribes it…I probably do get
some comfort with a med when the patient comes in and the cardiologist has them
on it and I get a little more knowledge about what it is because patients are
already on it. (Dr. T)
Yes I look at what the specialists prescribe. For example if I send patients to a
cardiologist and they always come back on a particular drug, I get familiar with
that because I know if I am going to use a different drug the consultant is
probably going to change it. So a consultant has an influence on me. (Dr. J)
[Peer influence]…me particularly, not too much. ‘Cause I don’t have a lot of
interaction with peers anymore, other than the partners in my own office. I did
more of that when I did hospital rounds. We’d sit around with specialists in the
doctors’ lounge and discuss drugs. We no longer have that opportunity. Nonhospital doctors no longer have the kinds of meetings except when a
pharmaceutical company sponsors a symposium to present their drugs. (Dr. G)
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Yes we used to have roundtable sponsored by drug companies…we used to do
it. But we haven’t done one it 10 years . . . $50 for a dinner . . . takes time. But I
think it’s a good idea, you get the doctors together, buy them dinner, pay them for
their time, and let them discuss the drug and the best way to use it. I think that is a
good idea. That was when we got the most useful information because we shared
with each other our experiences and did not rely on research conducted by the
industry. This is a good idea. It’s not that we are coming for the dinner, we are
coming for the information. But when you look at it, all the drug companies have
gone to marketing nurse practitioners, not the doctors or taking them out to
roundtable dinner. That was the best system we had. (Dr. A)
Theme 5: Competent and Incompetent Pharmaceutical Representatives Have
Antithetical Effects Influencing Physicians’ Prescribing Decisions
In a relevant retrospective study Joyce, Carrera, Goldman, and Sood (2011) noted
physicians regarded pharmaceutical representative detailing as an important source of
information. This study’s results support the findings of Joyce et al. but add
understanding regarding the type and degree of influence – positive or negative –
depending upon the skills of the pharmaceutical representative and resultant physician’s
receptivity to individual representatives. Regardless of company or product, physicians
expressed strong and consistent opinions, the most vehement of all responses to interview
questions in this study regarding the behaviors and skills of pharmaceutical
representatives. Perhaps one reason for this stems from the dynamics of interpersonal
relations and some pharmaceutical representatives’ blatant disregard for the value of
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physicians’ time, lack of discernment, poor judgments in physician offices, deficiency in
identifying customer needs or embracing a customer service orientation, poor product
knowledge, high pressure tactics, and failure to deliver concise, valuable information
physicians can use to augment quality care.
Physicians also commented consistently regarding the counter-productivity of
company managers when accompanying pharmaceutical representatives. Physicians
noted the inappropriateness, redundancy, and superfluity of representatives’ comments
when accompanied by managers, almost as if they must follow a predetermined script
written by corporate or field management authors seemingly out of touch with the realworld needs of their physician customers. The following excerpts depict physician
subjects’ passion and may enlighten understanding of these findings:
People who are so bought-in to their data they are not going to even look at the
other alternatives as viable options. That just completely turns me off. If someone
says “our medicine is good and we understand there are other good ones out there,
here is what sets us apart. These are the side effects to watch for.” But when they
start saying “you shouldn’t use this or that because you should be using mine,
then I think they drank the Kool-Aid.” (Dr. L)
Ahh, the people I abhor are the ones who are so doggone aggressive. And no
matter if they see you sweating and people screaming, they gotta tell you every
study and the outcomes and just my pet peeve. And most of the time I just let
them finish but there have been a few times when I have not. But for the most
part, the ones who come in, now if it’s the first time I want to hear what they have
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to say but the ones who come around regularly, and say the same thing, I told this
one guy you just can’t be that pushy, go push someone else.
And I want to be treated the same way I treat them. Let someone come in and tell
me about their product, leave samples, see how I am doing…that’s what I want.
Most of the reps have made that adjustment. Unless they bring their supervisors
with them and they have to make the points and I have to sit there and listen to
them. It’s a game. And they ask me what if I bring my supervisor with me and
that’s what they do. (Dr. C)
Well I am pretty opinionated on this and I don’t want to step on anybody’s toes
and the only representative I have ever met from your company is ideal. OK, I
will tell you what turns me off, don’t ask me about my kids, don’t tell me I have
cute shoes on. I despise that. Don’t try to kiss up. At all. Hate that. But give me
real information, and I don’t want studies with 365 people, give me the down and
dirty and I will listen. But if you’ve already stood there and talked to me for three
minutes, which is three minutes I am supposed to be with patients, I am not going
to be able to ask questions about what I really want to know. And I want to know
the difference between the competing drugs, say, “Well the biggest difference
between these two drugs…what my drug does versus what their drug
does”…Now this may not be possible because they may not know what the
AstraZeneca drug does or what the rep is saying. But it would be nice. The facts.
And big glossy pictures, no. Now if you’ve got one page that summarizes, OK.
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But if you have to turn 4-5 pages, no, my eyes are glassed over and I’m thinking
about my next patient. (Dr. O)
Drug reps are good resources but the information is about their product but the
information is biased and not objective… The one thing is the good reps are
concerned about patient care. The worst ones are the reps that disregard the cost
of their drug and whether or not people can afford it. (Dr. F)
The best drug rep I will tell you, he is the best rep, he knows everything about his
drug. He will bring in a clinical trial with highlights and quickly point out all the
things I need to know. He knows everything. He knows what his competitors are
doing and what the benefits of each drug are, he is so into it. But some reps I will
ask them even the basic information and they don’t know. (Dr. D)
I think pharmaceutical reps that have new drugs, that is one thing they can really
do, they can hone in and give you clinical information about the drug to help you
decide . . . I haven’t run across many who I would consider “bad reps.” You
know, most of them respect your time, are concise in their delivery of
information, and I like the reps who are knowledgeable about their products and if
you ask them a question and they don’t know the answer, they will get back to
you. (Dr. G)
The biggest thing for me is when you have a new product, I want to hear from
you. I want to hear clinical data. I want to see studies. You know after you’ve
seen them five times and you keep hearing the same stuff over and over again, at
that point, if there is an update, you want to hear something short and sweet. If it’s
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something new and I ask questions on it, I’ll expect a longer answer. If it’s a drug
that’s been out for five years, you don’t expect a lot of new information on it and
you don’t want to sit there and listen to the whole thing.
I am much more receptive and I think they do a better job when the manager is
not with them. They are trying to hit bullet points and I understand and I’ll sit
there and listen to it and I know they are doing it for their boss and I’ll sit there
and listen to it. But honestly, they are not as effective as when they are alone and
they can relate to me on a personal level and give me the information I am
looking for. The best drug reps know you and how you work and know the kinds
of things you want to hear from. You know they’ll talk to you on a personal level
and they will make their bullet points they need to make. When they hammer on
you, it gets the opposite effect of what they want because they are pushing on
you. (Dr. B)
To me, they are a good informational source, biased of course, but for me, I
temper that. And If I am speaking with someone who is unfairly biased, I can also
speak my mind as to why I don’t like the drug. Some of these reps coming
through and I tell them this is a horrible product. I have actually told some reps
they need to look for another job. I have told them this is a drug that is going
nowhere and you better go somewhere where you are going to be employed for
awhile. I would think the most important thing is to establish a relationship, has
nothing to do with their product, has to do with the relationship. Say, “I know you
are busy today.” Say, “I know you are busy today and I won’t take much of your
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time.” Then don’t take much of their time. Say, “Is there anything you are
uncertain about with this product I can help you with?” And say, “I can come
back later if you don’t have much time.” Any offer to make the doctor’s day go
better. (Dr. S)
And usually the best drug reps are the ones you become friendly with and know
them. I had one rep who I finally refused to see her…she would quote me the
same slogan every time I saw her. It became a real waste of my time to walk
down the hall. She wouldn’t say hi, I didn’t know anything about her. I didn’t
know anything about her family and she knew nothing about me. I got the same
words all the time. I think it’s important they not be pushy, that turns a lot of
doctors off. Also, don’t like when they suggest why are you using that drug over
another or gosh, why would you use that when you could use this one, that turns
me off. I do remember one girl in the sample closet saying where are all these
drugs going, we are not getting any scripts, what’s happening here? Well we
ended up kicking here out of the office; she was obnoxious. I don’t understand all
of the ins and outs of the pharmaceutical industry but these folks are professionals
and I am sure they have quotas and have to sell so much of their drugs. So they
have the tedious job of hitting their numbers and keeping the doctors happy at the
same time. The best reps are the ones you can get to know a little bit, who are
confident to me it shows they are confident in their product. That ok, I don’t have
to give you the same slogan all the time it speaks for itself. There’s a lot to be said
for that and it also shows there is real concern for you. Your busy, your running
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like crazy and when the reps walk in the patients get ticked. And they really don’t
want me in the hallway spending a lot of time with reps. You know, a few of the
better reps we invite back to the office. Back in the day which dates me how old I
am, every company had one rep. And the rep came in and talked about all his
products and he knew your family and you knew his family. But now face time
became important and you have five reps for one product and the competitor has
five reps and really, it’s, it’s a waste of our time. With so many reps coming in
any more, I don’t think you have to have 20 reps/day. We’re either going to
write the product or we are not. You just see where we are with it… The one girl,
it got so bad, I told her, every time you give me your sales spiel, I will write your
competitor’s product three times. (Dr. J)
Well the ones that turn us off are the people who walk in and say will you commit
to writing this many prescriptions in the next week? And the people that think
their drug should be the first line drug and I just look at them and say well the
generic drug out there is the first line and they look at me and say well you should
make my drug first line. I say there is a good $4 generic equivalent out there that
is a good drug. I am never going to use your drug as first line so continuing to use
that as your sales pitch is not going to make me very happy. I think it more of,
you know, the high pressure, and they say, “When I come back in here you will
have written at least three prescriptions for this right?” No. (Laughing) You know
this is a small office and it is just me and the ones who just want to come in and
just chat…But I have a question, they don’t have an answer and they need to go
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look it up. The guys that say, “I see you are busy. I will check back with you”…
they think of themselves more as a resource to me than someone that is trying to
sell something to me. And I use them as a resource occasionally. “Have you been
hearing of this side effect?” And they will tell me “yes” or “no” and what they
have been hearing from other doctors. Well then they are useful and then there are
days I am running around like a chicken without a head and its useful when the
rep walks in and says, “It looks like you are busy and I will check back with you
next week.” (Dr. T)
Don’t try to push too hard. Be subtle, give information, be educated. If the
doctor wants to know more about the drug find out about it. I am finding a lot of
drug reps do not know about their drug. I don’t care how good they are dressed
up. They need to know their drug…Drug reps have a role to play but doctors
don’t have a lot of time. I know they bring lunch and so forth but just because you
spent $10 for something to eat doesn’t buy me anything. I think if the drug
companies just spend money on drug reps to educate the doctors and not
consumer advertising this is much better and will save money, instead of drug
companies spending $500M on consumer advertising. The advertising costs much
more than the drug. And the thing is it doesn’t matter, all of these drugs are the
same. If the FDA wants to help, they should stop approving drugs that cost so
much. I can prescribe prednisone for $4 but instead patients want drugs that cost
$250 and don’t work any better. Supreme Court in India ruled on lowest cost
drug. (Dr. A)
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And it’s more the big pharma reps who recite just like they were trained. Doctor,
let me show you this brochure and they want to go through all 12 pages of studies
which is great if it’s new and a revolutionary product and if I have the time. But
they are not going to vary from their presentation because that is what their boss
told them to do and they finish with, Can I count on you for the next patient and I
think really, we don’t do this. I like the guy who comes in and says hey doc we
just finished a study on X and if you are not too busy, let me show you the
highlights. Not right now I don’t have time. Great next time or may I leave it with
you?...It’s those reps who can vary their patterns who know if I am busy and they
just need a signature and leave me alone until next time. That goes much farther
than the person who says well I will wait, you go and see another patient and then
we can talk. The ones that don’t read the physicians, you get tired of them. You
know we started in the old days when we had one Merck rep, one Lilly rep, one
Boehringer rep, and you could count on that rep to take care of all of those
products. And then they went through the phase when you’d have six Merck
Reps, 5 Pfizer reps, 6 Lilly reps and you’d have six Merck reps in one day and
you wouldn’t know which product they were carrying. Gosh guys I don’t have
time for this. It’s let me remind you about my product, here are the side effects,
what can I do to help you, I would love to leave you samples, or what data can I
get you, what can I do to help that’s what you need. What’s the cost of your drug
for my patients who don’t have insurance may be all I need to know. Yes and
sometimes I just get a package insert but I need feedback on a drug, need some

130
true education on it from the rep. And it’s almost a façade and I have to say are
you really trying to help me here or not. Because I gotta figure out how to use this
drug. Tell me how to use this product because it’s not working for me this way
and I need some true education about this product. (Dr. V)
Dr. L: “…[sometimes need them to] answer a formulary question.”
Yes. The best rep is the one who will come here and talk to me, not just about
what he sells, I want him to come and educate me. This is my product and it has
this and this and this and this. And then there are other drugs on the market,
similar to ours, but this is what ours does better. But if someone comes here and
says all these other drugs are crap, don’t even waste your time, this is the best you
can prescribe, well, I would say this is the worst rep. (Dr. I)
Best rep, friendly, easy to talk to, has a drug that is actually helpful, I do feel sorry
for reps who have drugs that are not very good – there are other drugs in the
therapeutic category that are actually better. Usually one or two points are all I
can really tolerate, one to remember but if it gets into 3 or 4 points I really don’t
have that much time, quick to the point, friendly, samples, one who have discount
cards as well. Worst, ones who take too long or those who ask for a specific
number of patients: “Maybe could you start one or two patients on this drug this
month?” You know, the hard sell, that is really a big turn off for me. Just lay out
the points, this is how many points this lowered cholesterol, this can really help
you patients, that is much better. (Dr. N)
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The only drug reps that are going to bother me are the ones who insist upon
pushing the envelope. In other words, they know what the rules are, they know
what they can do and what they can’t. You don’t have to be the brightest person
in the world to understand that. If they interrupt me when I am in between patients
and they see I am busy then I am going to be upset. So walk in the door and get it
done whether you have samples or not. I don’t particularly like it when people
hold up brochures and go through them page by page. If they have one sheet and
they want to make a point then make the point. In my opinion, what you need to
do is be aware you are providing a service, not an advertisement. If you want to
provide a service no one is going to give you a problem. If you walk in and say I
have a new drug that may be of use to you and you give us the stats and be on
your way, no one is going to have a problem with that. If you try to sell me on the
same product and say the same thing over and over again, that is going to insult
me. I got it three times ago. I like it when they come in and describe their product
and tell what patients to use it on but not ask now what or how many patients are
you going to prescribe. (Dr. E)
The best rep is knowledgeable about the disease process to begin with, and then
knowledgeable about their product, has to be knowledgeable about their
competitors. You know I lean more towards the one who has a scientific
background, who can answer my questions on a scientific basis. And then give me
the information when I want it and not try to give me all the information when I
do not have time to receive it. I have one or two reps I cringe to see, who want to

132
give me the full detail, when every room is full and they have no respect for my
time. And I am just really not going to listen to anything they say. Whether they
give the whole spiel or not. (Dr. R)
I like it when they come in and describe their product and tell what patients to use
it on but not ask now what or how many patients are you going to prescribe. Right
now if they say will you write this for the next 10 or 15 patients that will be the
last time I talk to them. (Dr. M)
I like it when it appears they have some honesty about them and they are going to
tell me what is in the clinical studies and so forth and they are not going to hide
studies from me. I mean I know they all do it to some degree but I like to feel that
if I answer a question I am going to get an honest answer. Usually I’ll ask a
question I know the answer to just to see what they say and if they are lying to me
I won’t listen to anything else they have to say. (Dr. K)
Theme 6: Samples Are a Valuable Influencer to Some Physicians
Drug sampling as an influencer was supported by Joyce, Carrera, Goldman, and
Sood (2011), who noted pharmaceutical representatives’ drug sampling provided greater
flexibility for low-income patients as well as clinical experience for physicians. The
findings of this study may complement the main tenets in the Joyce et al. (2011) study by
providing information relevant to the changing health environment physicians are
witnessing and will witness in coming years, catalyzed by new health care trends and
regulations (i.e., Obamacare). Physician comments support the patient benefits afforded
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by samples, but at the same time, acknowledge private and government payer pressures
to prescribe more generics have resulted lower sample supplies.
Transcript excerpts provide more specificity regarding samples as a decision
influencer. For example, Dr. L stated: “I prefer samples to coupons. Most of the time I
don’t think patients take the coupons.” Dr. M advised: “To give good service, bring
samples.” Other physicians explained their positions regarding samples thoroughly:
[Samples are] Big, big. You see, I’ve been a physician 30 years, and in private
practice 24-25 of those. And samples have always been huge. They can try the
product and see what the toleration is before we start spending money. It has been
an unfortunate lack in recent days. Everything seems to be generic. (Dr. R)
And I think that’s where samples help a ton. Give somebody two or three days
and let them take it. Cause we’ve all seen it. You write them a script for $100 and
they take one pill and they have a side effect and can’t do it. If I had given them
that pill and they had the side effect I would have saved them $100. Or they could
say gosh I love that stuff and can take it forever…A lot of times it depends how
long they are going to be on it. An antibiotic, don’t give me two when I have to
write a prescription for five more, that doesn’t do any of us any good. So at least
give me a whole pack so I can give it to one patient today and then if it works I
can write scripts for other patients because I got good feedback. Now with a
longer term product give them a week’s worth of samples and usually they will
fall in love with it. If it’s something like a statin drug where they are going to be it
forever, that’s where the coupon comes in handy because they are going to be on
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it for a long time. And you don’t need three of these, you need two months’
worth. So it varies. With acute type stuff it’s different. And that’s where the
samples come in to make sure they are not going to turn green on the stuff after
spending $50 for pills. Oh sure, the other problem with coupons…I think patients
sometimes get pushed back from the pharmacists. I don’t know how coupons
work on that end but I get the impression from other physicians pharmacists get
tired and don’t want to fool with them. In some cases they turn the coupon into
pharmacists and then pharmacists have to get the coupon to you and in some cases
they say the pharmacist would not honor that. That’s the only problem when the
patient must present the coupon to the pharmacist. (Dr. W)
Practically speaking, there’s not a lot of difference between those medications but
what is the patient going to get? The one that is on my shelf. Because I can give it
to them, they can try it, and they can see how they do. So that is the one thing that
is out there that I think is the elephant in the room out there that pharmaceutical
companies and drug reps do not see. The government says ahh you are making
people spend more money. No I am not, I am helping people spend less money.
I tell you what, you may not want to know this but what does affect what I use is
what I have on my shelf. You know if I am looking at a diabetic medicine because
I am dealing with a lot of people who pay cash money I will look at what I have
on my shelf. (Dr. E)
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Theme 7: Most Physicians Have Negative Opinions Regarding Direct-to-Consumer
(DTC) Advertising but DTC Increases Product Awareness
The results of this study confirmed and expanded the findings of Frosch, Grande,
Tarn, and Kravitz (2010), who examined proponent and opponent studies from peerreviewed literature. Frosch et al. (2010) determined ads frequently did not disclose
alternative treatments, risks, or costs, and prompted patients, many with insufficient
education or understanding, to request physicians to prescribe an advertised drug, the
same complaints voiced by physicians in this study. Frosch et al. also determined
physicians may not have seen the advertisements for drugs patients requested or were not
fully educated regarding new drugs at the time of patients’ requests, ads increased
requests for advertised drugs, and these situations predisposed conflict with the
physician-patient relationship. This study differed from the Frosch et al. study with
respect to approximately one-third of physician subjects who offered positive or neutral
responses.
Categorically, physicians acknowledged DTC increased patient and physician
awareness. One physician observed most DTC advertisers promote expensive products
and therefore, demand for those products is tempered by patients’ unaffordability. One
physician opined DTC may increase patient visits and a few physicians stated DTC made
his job easier because patients already accepted the prescribed product. Second to the
physician emotion voiced over pharmaceutical representatives, physicians who opposed
DTC expressed strong sentiment, evidenced by the following transcript excerpts:
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I generally don’t like it [DTC] especially TV commercials, and it’s usually for
conditions that are not life threatening, they are more lifestyle based…things like
testosterone and bladder control agents things like that…Viagra…things that are
not really important to the long-term health of the patient. Things like that irritate
me. (Dr. N)
You know. I don’t think it has as big of an impact now as it did when I first
started. Because now all the stuff that is going direct to the consumer is more
expensive. Cause the patients come to me and say I saw this commercial on TV
and I should try Cymbalta and I say yeah you could try that and then they come
back and say maybe I could find something cheaper. (Dr. T)
[DTC] has had its place, at times to bring a topic to people’s awareness. And you
could use testosterone as one of those issues but it has probably been for a greater
percentage of the time, a detriment. Where people come in and they say I want
that purple pill and they don’t even have reflux, and what makes you think you
need the purple pill? (Dr. R)
That is a big turnoff. Myself, we don’t have TV, so I don’t know what’s on TV,
so I don’t see a lot of that stuff. But it’s a turnoff when a patient comes in tells me
they want it. But that doesn’t mean I won’t write it for them but it is annoying.
(Dr. O)
To tell you the truth, I don’t like it. I don’t like it because the patient doesn’t
know the whole picture. They just see what the pharmaceutical company wants to
tell them. I don’t like it but on the other hand if this patient has a problem that can
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be treated with no major side effects by taking this medication, because let’s face
it, part of the treatment is placebo. On everything, no matter what, people taking
Echinacea or something like it, it helps with the flu. Well maybe, but a big
percentage of people get better on their own, but the idea of taking something
helps them get better. So if someone wants to take something and I don’t see any
major problems with side effects or interactions then I say take it, try it, and let’s
see what happens… Like osteoporosis, I took Evista for a few days and I feel
stronger. Well you’re not going to feel anything for at least a week (laughing) but
I know the difference. It won’t help you for at least a week but the patient says
well I took Evista yesterday and I feel it in my bones, stronger. So I say if you
want to take something for osteoporosis you might as well take Evista because
you say it works. In that case I would go for it. (Dr. I)
Umm (sigh)…I think most physicians initially felt it was a bit insulting
thinking they were taking power away from us but you have to be able to deal
with it. You have to know patients are going to find out things on line. Normally
the people come in and ask, and half of them are candidates and half of them
aren’t even close. So uh, the big one now is Low-T, the low testosterone. Number
one, was that created by drug companies? Is that a real issue or one created by
drug companies? Low testosterone, there are still physicians who believe the issue
was created by drug companies to sell their drug. So I think most physicians are a
little leery of the big pharma anymore. They are more leery and they don’t believe
everything. But we have patients coming in asking but then you step back and you
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go, but you know what it generates patient visits. Maybe it isn’t all that bad,
maybe we are all in this together. But they stuff they direct market to patients I
would say about ½ really need what they come in and ask for. (Dr. J)
It changed things so dramatically in our world from the standpoint…you have to
ready to deal with it. Both the good and the bad of it. You now that they are a
little more informed. If it’s not I saw it on TV then it’s one of their friends, so we
have to deal with this stuff all the time. And everybody in our practice knows
somebody, and that person told them they oughtta talk about this…I think it
impacts us…I don’t think it sways me enough to say oh yes, you definitely need
to be on that, now, if it’s a toss-up between two or three things I will say, I don’t
have a problem with that. I won’t put somebody on it just because they say they
want to be on it…So you are trying to stay as much as you can off the radar with
the news so you know they are not reading 8 million things about it every day. If
they hear a negative story they are going to want to stop it immediately and if they
hear about side effects they will be pre-programmed to experience those side
effects. (Dr. V)
Um, it has its place. Certain things are good like getting the name out.
Unfortunately, the legality of things, they also hear the bad things 15 or 30. Take
this drug and it is great but the side effects could be death, loss of bowel control,
or something. So in some cases it makes my job actually harder. Sometimes they
come in and ask for a drug and it is absolutely the wrong one for them. There are
times it is good and you can use it for your advantage. For example, when
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Cymbalta first came out as an antidepressant well, some patients did want to take
it because they knew it was an antidepressant. Now recently they got it approved
for what is pain control. Now they know it is for pain and they will take it but you
can actually get by and use it as an antidepressant. (Dr. B)
Now I love, let me say, I love consumer advertising. I love it because it makes my
job easier. Like Abilify. People are ready to accept it. They are ready to take it.
On the other hand if it is like that bladder control medicine, that is something you
are supposed to report. People sue for taking it, they can make money on it. So
there is that part, the part that is negative, but the positive part is really helpful.
(Dr. S)
You know, if it’s a drug I am familiar with I don’t have a particular problem with
it. You know some of the pharmaceutical companies have done very well with
their consumer advertising. In the old days we didn’t have drugs advertised on TV
just in journal ads. The bigger problem I see is for drugs I don’t know OTC that
may be advertised online, supposed to cure this that or the other, you know,
herbal remedies or something they think is God’s greatest gift to medicine. I say I
don’t think it will work and try to downplay those but if they are insist, I tell them
to go ahead and try it. I suppose a lot of people make a lot of money with these
kinds of non-prescription drugs. And I don’t get a lot of patients who come in and
ask me for advertised prescription drugs. Of course drugs like Viagra, guys use
the ad as a way to introduce a problem. Overall, I don’t oppose consumer
advertising…Yes, as long as it’s close to what they are taking and not harmful. I
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learned a long time ago if a patient doesn’t feel they are getting what they need,
they will go to another doctor. Now if it’s a reasonable thing we will talk about it,
but overall, I am not opposed. (Dr. G)
I would say it affects in you in that it brings disease states to the front normally
patients would not talk about. So, for erectile dysfunction people weren’t coming
in and saying I have erectile dysfunction. With seven minutes to say what’s
important to them about their heart you don’t have a list where you get down to
say is everything working all right for you. So direct-to-consumer advertising
there made people feel comfortable enough to come to the doctor and talk about
it. (Dr. L)
I hate it…I look at the patient and wonder why they want it, if they are shortfocused. They are the consumer. Direct to consumer advertising, this should have
never happened. The reason is you bring the company between the patient and
me. I may not have a problem with the drug, but the patient asks for it, I have to
get prior authorization, and then the patient finds out how much it costs and does
not want to pay and I have to deal with it. Take testosterone, Androgel, putting
these ads all over, testing testosterone has gone up by 1,000%. My prescriptions
have gone up by 1,000 %. Whether the patients need it, probably not, many of
them are border line and want it.
Now they are talking about how many side effects they have. Nexium, 99% of
people does not need Nexium. I am told Prilosec will do the same as Nexium but
everyone wants the name Nexium…you increase costs by 1,000 % because of
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direct to consumer advertising. The government should let drug companies and
their sales people give information to the doctors and let the doctor decide and not
advertise to the consumer. (Dr. A)
Theme 8: Lost Influencer Opportunities: Physicians Need More Dietary
Supplement Education (Including N-3 Education) and Lack of Dietary Supplement
Curricula in Medical Schools
Physicians who knew the benefits of certain dietary supplements including n-3s,
those physicians were more enthusiastic about recommending these products and stated
they took a more active role advising their patients to take these products. If physicians
were unfamiliar or uncertain about the efficacy, safety, quality, or cost of certain dietary
supplements including n-3s, they expressed skepticism and would not recommend such
products to their patients. Several physicians explained deficient medical school curricula
regarding dietary supplement education.
Physician subjects, in general, desired credible, evidentiary information and
education regarding n-3 efficacy, safety, quality assurance of products, and costs. Most
physicians expressed more concern about dietary supplement quality assurance than
FDA-approved and monitored drug quality. The transcript excerpts below support these
findings and accentuate the importance of physician personal experience with dietary
supplements and specifically, n-3s:
It is hard, really hard. Patients come in and tell me they are taking supplements
but they have no idea about the quality of these supplements and neither do I…I
don’t know what they are taking they could be ordering online or getting these
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products anywhere. You just don’t know about the quality of these products. I
look at supplements and try to determine if a supplement is going to hurt them.
You know I’ve had several people come back to me and say, whether this is a
placebo effect or not, “you know I feel better when I take my supplements. I sleep
better, my energy is better, I don’t know.” But I am more confident in a
prescription medicine because I feel more confident in what they are getting…
There is a lot of evidence and I think more should be taught in medical school,
having just gotten out of medical school. I think maybe it might not get
recommended or advised. (Dr. F)
[Quality of supplements] Now that…now that…you’ve got me there. That is
something you could definitely put…that I would not be aware of. You
know…eh…this one is better than this one because we do this…I don’t know that
about this particular product…if it’s a prescription for a patient I have prescribed
then I know that but for this kind of product…if you come in and tell me hey we
don’t have mercury we go the extra mile then that’s darn right I’m going to use
your product. That highly influences me. (Dr. H)
It’s difficult. I don’t know who’s doing the studies and how can I judge one
manufacturer of omega-3 versus another manufacturer of omega-3? It’s a tough
thing and usually I am trying to determine if I have heard anything bad about this
product and you won’t hear me recommend a product unless I know the
background. (Dr. R)
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Right that’s tough, and those [dietary supplements] aren’t FDA controlled. We
don’t learn about those in medical school. And if I don’t have a personal interest
in it, I don’t even know about it so, well some of it I do know something about
and some of it comes up in Prescriber’s Letter. They will provide some
information about some of them from time to time. For example, if you have a lot
of patients on coral you should know coral can cause deterioration of coronary
arteries. And sometimes a patient will come in and say I am on ribo-something or
other and I just say, You know I don’t know anything about that. I’m not saying
you should or shouldn’t be on it but I don’t know anything about it. So, I don’t
have to know anything about that. (Dr. O)
If it’s an over-the-counter product, I am not sure. I guess the information is
available somewhere but if it is, I don’t really see it much. I am hoping what they
say is in the product is really in there and I am hoping the FDA or somebody is
looking over these products to make sure they are OK. That’s really about it. For
me it’s a pretty murky area…for some patients if I do recommend a supplement I
tell them to stick with a name brand people know. There’s lots of them out there,
calcium, vitamin D supplements, but I tend to have them stick with a name brand,
a few names that I know of…kinda stick with those. (Dr. N)
Well, a lot of times I don’t know what it is and I tell them I don’t know and can’t
give them any advice on it. Yeah, I know there is a big variance on them and I
don’t have enough information to evaluate them. Quite frankly that is something
you don’t learn in medical school. I mean that is one supplement I recommend…
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so I think the biggest problem you are going to have is getting the information out
there…like I said we don’t get a lot of this information in school so it depends
upon how interested the physician is in the subject and how much time he will
spend on it. If you have something the physician can give out to the patient and
he knows [the n-3] is a good product, then it is going to go a long ways. And if I
know it’s a good brand I will recommend the brand and this goes a long way…as
long as I know it’s affordable. (Dr. B)
Yeah I see patients who say, “I am taking this red yeast rice”. I haven’t seen that
work. (Laughing) But you have fun with that. I have not seen one patient where it
worked but they say yeah taking this red yeast rice. I am not going to tell you not
to take it but I think you might be wasting your money. I go look I up or Google
it. I have an over the counter PDR as well. What is it, what is in it and try to find a
reputable source. Try to compare something with what the patient is taking.
Attempt to tell people not to take supplements very often especially if they are
taking something with ephedrine. And if they are borderline high blood pressure
and I tell them their problem is this pill. (Dr. T)
When you go out and start buying stuff over the counter, you can’t guarantee
what patients are going to get. I was talking to a patient the other day and she said
I got a bottle of those fish oil pills and they were terrible. I smelled the product
and it was fishy nasty. I like pure products with labels that tell what you are
getting the DHA and EPA. We know one pill a day meets requirements and if I
want to treat someone for high triglycerides I put them on two a day. Well then
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the other thing is they go to Sam’s and you look at some of their omegas, and they
got 6s and 9s combined with 3s. Well that’s counterproductive because we are
trying to change the ratio between the 3s and the 6s and they’re just defeating the
purpose…You take the amount of 3’s in the puzzle and in fact you’re left with
very little 3s. In fact it might be detrimental…We want the ratio of n6 to n3 to 3:1
or 4:1, but in our diet it’s become 10:1 or 12:1. So you want to get rid of that, and
the purity. There was a study done with the athletic trainers, and I think the
[Consumer Reports] study was done in 2008. And the amount of impurities in the
product, it was about a 30% impurity rate. They found traces of arsenic, mercury,
PCBs. Our oceans are polluted. (Dr. J)
To tell you the truth those supplements are anything patients can get without
prescriptions and without asking the doctors, the majority of them they come to
me and they have already been on supplements. And they have been influenced
by friends, relatives, TV, magazines, whatever…what I recommend to people if
they don’t take anything, I recommend a well-balanced diet with a lot of fruits
and vegetables, give you the majority of vitamins, nutrients, anti-oxidants that you
need. If you want a supplement, a one-a-day multi-vitamin is adequate. If you are
a man, I recommend saw palmetto just because of the prostate protection. And
men and women, I recommend they take one baby aspirin... unless they have a
problem. And women, menopausal, should be on some type of calcium
replacement. Like Avista or injectable. For Omega-3, the jury is still out. (Dr. I)
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Well I am a big statin user. I have used n-3 along with statin, probably would use
n-3 alone. Now a lot of people talk about being on fish oil. I am not sure I always
appreciate the kind of fish oil they take, basically if the numbers are where they
need to be OK, if not we need to make adjustments. With supplements, the
evidence is not quite the same the FDA requires to approve drugs. Not the
scrutiny of production, someone could say they have an n-3 but it doesn’t have
what it says in it. So I caution patients and tell them let’s be careful take this stuff
and let’s see what it does. If it’s working, I wouldn’t pay an arm and a leg for this
stuff. So I guess my approach is cautionary. Except I do see the value of n-3s, a
multivitamin, saw palmetto for prostate…when I write a drug I know the dosage,
the quality, the side effects. When my patients take an omega-3 I don’t know the
quality and if they are going to have side effects. A big discrepancy. They
probably think they are harmless. (Dr. G)
I had a lady come in the office the other day, showed me a supplement,
and the label, because she wanted me to know how wonderful it was and I looked
at the label and there were 23 different ingredients. Twenty-three different
medications. And I said to her, “You realize there are 23 different medications in
this supplement,” and she said, “yeah.” And I said, “I don’t want you to think I
am poo-pooing it because I am not, I am telling you there is 23 different
homeopathic ingredients here that are medicines, of course they are not natural,
they didn’t fall off a tree, they went out and filled up the bottle with whatever, so
they are not natural processes, that is #1. #2, if you came in here and told me you
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had a headache and I gave you 23 prescriptions, would you come back to see
me?” “Well, no.” That is my feeling, there are some very good, n-3s probably
serve a purpose but there are people who abuse supplements because they don’t
understand what they are doing. That is my personal opinion. (Dr. E)
And with n-3s sometimes I will add to drug regimen. But it’s results and that’s for
all medicines. I don’t like a lot of supplements because I don’t know what they
are putting into them. With drugs, yes but supplements not so much so I allow
them to take cinnamon and fish oil and that’s it. Way too many brands but if they
bring me the bottle I will look at it and I will tell them I don’t know what that
ingredient is or that one and therefore you should take it…except cinnamon and
fish oil. (Dr. D)
I think there is definitely a place for them. I wish they were better studies. Not all
of them. Some of them have good studies. Generally speaking, they are not held
to the same [quality standards]…And when I am recommending a supplement
knowing there are such differences, I am not sure which brand to recommend so
that puts a lot back on my shoulders. Or if I recommend the wrong brand a) they
are not going to get what they need or b) they are going to get something
deleterious. So I feel there is a burden there and I’m not sure it should be my
burden. Or at least I am not adequately trained to know. And that’s a little bit
frustrating. I’ll tell you when I have someone who really likes to be on a lot of
different supplements and avoid any kind of pharmaceuticals, prescription
pharmaceuticals, then I try to direct them to the Internet sites where they can do
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the research. You know there are certain sites where they can evaluate the
different brands and the different compounds. So I put it back on their shoulders
as much as I can. They like to be on a lot of different things. Otherwise I just try
to stick to the few things I can trust. (Dr. K)
I hate like hell to tell them to buy fish oil because I have no idea what they are
going to end up with…I like the idea of knowing. I like the idea of knowing it’s
going to be effective, easy for the patient to get, and affordable. So effective,
affordable, and compliance. (Dr. S)
It does come up a lot. I tend to get a little more excited about it for healthy people,
for prevention. If somebody comes in and they’ve already had CABG, diabetes,
and other problems I am not sure how much this is going to help. But if someone
comes in and is healthier, maybe with a family history of heart disease but not
eating right, but is overall healthy, this I think is where omega-3s come in and can
be pretty beneficial. (Dr. N)
I tried myself to take it, a few months ago. I had such a bad odor in my mouth,
fish odor, when I would burp, so I don’t know if there is another way to take it to
eliminate this kind of side effect, so people more willing to try it…My wife went
and got some because I told her we both should try taking n-3 so I don’t know
what she bought. But man we both had the side effect and then said the hell with
it, you know burping fish everyday (laughing)…But when I tell people to put
more fish in their diet, they go to McDonalds and get big fried fish. (Dr. I)
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When I was writing Lovaza from time to time, and they say to me can’t just take
fish oil over the counter and my answer to them, remember those Total
commercials they use to have, you know you could eat those corn flakes but you
would have to eat 14 bowls to get the nutrients in one bowl of Total. So I tell
people you have to look at what is equivalent and you would have to take like 16
tablets of your fish oil to get the same fish oil that is in the 4 tablets of Lovaza so
you have to decide is it worth it to you to take 14 tablets of fish oil a day. (Dr. T)
You know it’s [n-3] been of interest for its anti-oxidant effects for a long time.
You know I can’t review all the literature and I’ll go to lectures and let’s say half
a day we are going to do cardiology type of stuff. And they present articles which
may be inconclusive regarding omega-3. But I have used Lovaza and I’ve see
triglycerides drop 50%. I’ve seen HDL raise, they’ll tell you 20% but I’ll tell you
maybe 10%. And I haven’t see it do much of anything with LDL. (Dr. T)
But you know that’s a pervasive one. Almost everybody knows about n-3s. And
n-3s have positive effects on inflammatory properties, and cholesterol, I know
something about that and I am going to recommend n-3s. But you come in and tell
me about something well gingko I know about, but some others I’ve never heard
of, no. Now n-3s, that’s easy. (Dr. O)

Applications to Professional Practice
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Physician subject comments regarding influencers of their decisions to prescribe
or recommend products have broad implications for industry and society. These
implications apply to professional practices of health care regulators, physicians, medical
school educators, and marketers of drugs and dietary supplements. For regulators, the
abundance of conversation and prioritization of cost as an influencer reinforces the
effectiveness of insurance company and government policies to drive down health care
costs. Also, physician responses supported the need for FDA regulation of DTC
advertising and manufacturing quality of drugs and dietary supplement manufacturing
quality provide valuable safeguards for society.
N-3 marketers should consider medical school students and residents may benefit
from reading the findings of this study regarding dietary supplement education. All 20
physicians interviewed expressed inadequate dietary supplement training in medical
school. By providing useful prescribing information, n-3 marketers may facilitate
physician-to-patient communication and result in safer and more effective dietary
supplement intake among members of American society.
Pharmaceutical marketers may also benefit from other findings in this study.
Credible clinical proof, personal experience, and cost are certainly essential influencers
of physician decisions to prescribe or recommend products. Other important influencers
vary in importance depending upon the physician, but include the influences of peers,
pharmaceutical reps, DTC advertising, samples, and dietary supplement education.
Regarding clinical trial proof, marketers should present relevant studies published in
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respected journals by credible investigators. Studies with optimal design should be
double-blind, randomized, and placebo-controlled with a large number of subjects.
Considering the importance of personal experience as an influencer, marketers
may increase the emphasis of personal use by physicians or third-party testimonials.
During interviews, physicians repeatedly emphasized drug and dietary supplement
marketers underestimate the importance of cost. Marketers should disclose clearly costs
of medications and supplements to physicians and should make cost disclosure a sales
and marketing message priority. Worthy of emphasis, in the physician ladder schema of
influencers cost elevated to a primary decision influencer as perhaps the third most
important ladder rung after credible clinical data and physician personal experience.
Marketers should remember to serve physicians as customers rather than
aggressively attempt to sell them products. Physician subjects provided strong negative
responses to deficient pharmaceutical representative skills and lack of tact and
consideration of physicians’ time. Pharmaceutical marketers may be better off without
pharmaceutical representatives than to deploy pharmaceutical representatives without
adequate training or with inappropriate service philosophies regarding physician needs.
Physicians essentially regarded pharmaceutical representatives with these deficiencies as
incompetent. As an extension of pharmaceutical representatives’ services, most
physicians viewed samples as useful when practical for marketers (i.e., brand name
products with no generic substitutes) and samples serve as a potent short-term brand
name reminder for physicians, consistent with the findings of Montoya et al. (2010).

152
Marketers should heed the opinions of subject physicians in this study, who
commented consistently regarding the counterproductivity of company managers when
accompanying pharmaceutical representatives. Physicians noted the redundancy and
inappropriateness of representatives’ comments when accompanied by managers.
Marketers should ensure field managers understand the needs of their customers and not
impose inappropriate or irrelevant sales points during representatives’ conversations with
physician customers.
N-3 marketers should present credible information and education regarding n-3
efficacy and safety. Because subject physicians expressed more concern about dietary
supplement quality and lack of knowledge regarding quality than FDA-approved drugs,
n-3 marketers should provide more evidence of quality assurance and purity of n-3
products. Marketers should design easy-to-understand handouts physicians can use to
describe and explain the value and differences of quality n-3 products to their patients.
Patients’ understanding of quality n-3s may be more difficult for lower educated patients
less inclined to engage in preventive medicine behaviors (Nelson, Reyna, Fagerlin,
Lipkus, & Peters, 2008). A number of physician comments support the positioning and
marketing of n-3 products.
For example, Dr. H stated: “For men and women over 40, n-3s would be
excellent.” Dr. D advised n-3 marketers: “The key may be to let the doctors know and if
we know, we will tell our patients.” Other physicians also provided important n-3
marketing considerations:
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Now as far as something like an omega-3, we already know it is a benefit. Now I
am going to be looking at is this product as good as something else. Is it cheaper?
Are there going to be side effects from it, like a fish burp…my own personal
experience is going to bias me a lot…those are the things I am going to be
throwing into my head all at one time. Let me respond back on something. You
were talking to me about quality. It is really important for me to know, to be able
to say, here is an over the counter product that is high quality. Like Lovaza, I have
no doubt this is a supreme product, goes through a lot of testing. They take out the
impurities and crap and doesn’t have fish oil burp problem the other do and so
you know you are getting a uniform product, but if I know there is an over the
counter product that is as good or can do as good a job and save the patients
$100/month I am happy and my patients are happy…I will be pretty excited about
saving patients money and I feel like I am doing the right thing for the right
reasons. (Dr. S)
I would love to see a large study that shows the clinical benefit. N-3 arm, no n-3
arm, costs a lot of money to do this, takes it out for a long period of time. And
what’s your end point, could be heart attacks, strokes, fatal heart attacks, fatal
strokes, peripheral arterial disease. (Dr. R)
I have a handout from Mayo in Cleveland and it tells them what to look for in fish
oil and I print it out and give it to them. They say the same things as you: the 3:2,
you don’t want n-6s because you have plenty in the diet already, does not go into
specific grams but gives general guidelines this is how much you need…and I am
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aware of the patients who have had heart attacks and there are many cardiologists
who have all their patients on n-3s and then there are some who say they don’t
need n-3s because their patients are on statins. And I am not sure who is right and
who is wrong depends upon the literature you read. I think the thing is if you have
a well-designed marketing piece I can give my patients because if it takes me 30
minutes to explain, forget it. Let me tell you about omega-3s and here is
something to read…the 3:2 ratio, the purity, and they can go home and digest it.
Now whether it has your branding on it or not. Some give these blatant, retarded
pieces and obviously we don’t hand them out. They go in the garbage. Well-done
handouts help us educate patients and save us time. (Dr. W)
If someone has and LDL of 130 I am probably not going to see if go any lower
than 120 but I can get a triglyceride of 250 down to somewhere in the real world,
somewhere it should be. And usually we are dealing with a patient who is taking a
statin already and I say we got your LDL down to 60 but your triglycerides are
still 410 are you eating every carbohydrate you can find? And those are the folks
where I say let’s try the omega 3’s and see what happens. (Dr. T)
You know in medicine we talk about the four A’s of success. Ability, Affability,
Affordability, and Availability. Those are the four A’s of success, there may be
fifth one is some schemas. So affability is it packaged well does it look good like
it will do the job, ability does it meet the needs of the patient, will it do what it is
supposed to do, affordability can the patient pay for it. And then availability and
that’s where you give them off the shelf at doctor’s office, online, and there is
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probably a subset of people who would like one of those the most better than any
other, some would work all 3 ways, some only at the store, some hardly ever go to
the store vs. online. (Dr. S)
You pretty much touched all bases. Everything we learn today is from our peers,
in print or the Internet, and the third one is our reps. So if you want a successful
product you have to attack those three areas: you have to have doctors talking
among themselves, print and Internet, and pharmaceutical reps. (Dr. I)
Implications for Social Change
From the outcomes of this qualitative phenomenological study, I filled a gap in
related literature by providing marketers of drugs and dietary supplements insight
regarding how physicians make prescribing decisions. A better understanding can
facilitate communication effectiveness between drug and dietary supplement marketers
and physicians. Physicians who increase their understanding of drug and dietary
supplement usage may improve prescribing efficacy and safety for patients. Physicians’
understanding of n-3 preventive cardiovascular disease benefits may result in more
frequent physician recommendations of n-3s to their patients, resulting in more n-3 intake
in the American population. Nearly all physicians that I interviewed (18 out of 20) opined
if our society consumed more purified quality n-3 supplements, our societal risk of
cardiovascular disease would decline, especially if members of our society would
improve diet and increase exercise.
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Recommendations for Further Study
Action defines the top ladder of inference rung, a change in behavior. N-3
marketers may find useful a follow-up study with the same physician subjects to
determine if the mere interview and discussion of n-3s resulted in behavioral change (i.e.,
increased contemplation and prescribing of n-3s). N-3 marketers may devote more study
to the optimal design of teaching materials for physicians and for patients. Follow up
study with medical schools regarding dietary supplement education is yet another
opportunity for further study. Considering the outcomes of this study, a follow-up
quantitative study investigators may further substantiate, confirm, and advance the
findings of this study. Last, more study could be devoted to understanding the impact of
improved dietary supplement training for pharmaceutical representatives as well as field
managers.
Reflections
From this experience, I learned more about how physicians determine which
drugs and dietary supplements they will prescribe and recommend. I was also exhilarated
by the richness of dialogue revealing the inherent goodness and dedication of physicians
as caring human beings for their patients. Although I was careful not to interject my
personal bias regarding the preventive cardiovascular health benefits of n-3s, the
discussion of clinical evidence was strong enough on its own to impassion physicians’
convictions to increase their recommendations of n-3s. From an interview-execution
standpoint, when physicians freely admitted they did not have adequate n-3 knowledge, I
realized asking a few of the detailed n-3 knowledge interview questions was
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inappropriate, would have embarrassed physician subjects, and would have negatively
affected essential rapport.
Coding and interpretation of data was more complex than I originally conceived.
As recommended by professors and cited authors in this document, long periods of
reflection aided the crystallization of eight meaningful themes. Additionally, conferring
with another coder reinforced the rightness of developed themes and added validity to
study findings. As one in the pharmaceutical industry, I may have found physician
subject responses more interesting and relevant than to readers outside the industry. Last,
my personal skills certainly improved in data collection, data analysis, and reporting of
study findings.
Summary and Study Conclusions
The purpose of this qualitative, phenomenological research study was to improve
understanding of how physicians reach decisions to prescribe or recommend products and
which influencers may be the most important to physicians. The findings revealed three
essential influencers including clinical evidence, personal experience, and cost of drug or
dietary supplement. Other influencers varied in importance depending upon physician
individuality: influence of peers, pharmaceutical representatives, supply of samples,
direct-to-consumer advertising, and knowledge of dietary supplements. I developed eight
themes related to decision influencers and provided pragmatic recommendations for
pharmaceutical marketers. The outcomes from this study may also benefit government
regulators, practicing physicians, and medical school educators. Last, the findings of this
study, supported by the opinions of 90% of physician respondents, added credence to

158
omega-3 dietary supplements as an important preventive cardiovascular disease dietary
supplement for members of Western society.
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Appendix A: Cochrane Complementary Medicine Field List of Complementary or
Alternative (CAM) Therapies
Açaí /Euterpe oleracea
Acupressure
Acupuncture
Acustimulation / acupoint stimulation
African prune / Prunus Africana / Pygeum africanum)
Aiyishu (a Chinese herbal medicine)
Alexander technique
Alpha-linolenic acid (ALA) (an omega-3 fatty acid) supplements
Amino acid supplements
Angelica
Antioxidant supplements
Arachidonic acid (AA or ARA) (an omega-6 fatty acid) supplements
Aromatherapy
Art therapy
Artichoke leaf
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Astragalus / Milkvetch (a Chinese herbal medicine)
Auricular acupuncture / ear acupuncture
Ayurveda / Ayurvedic medicine (a type of Indian (East Asian) traditional medicine)
Balneotherapy
Bee stings / bee venom
Beta-sitosterol (a component of saw palmetto)
Biofeedback
Biotin (Vitamin B7) supplements
Botanical supplements
Bovine cartilage
Breathing exercises in mind-body medicine (exclude for physical therapy, eg
treatment of cystic fibrosis)
Calcium supplements (many people would not include for prevention of
osteoarthritis)
Calendula
Calorie restriction
Carnitine supplements
Cayenne
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Chelation therapy (exclude for treatment of medically diagnosed heavy metal
poisoning (eg, mercury or lead) and for medically diagnosed excess iron (eg,
thalassemia))
Chinese herbal medicine
Chiropractic manipulation
Chitosan supplements
Chondroitin sulfate
Cold laser therapy
Color therapy /chromotherapy
Cranberry
Craniosacral massage
Dance therapy
Danshen (a Chinese herbal medicine)
Dehydroepiandrosterone (DHEA) supplements
Dengzhanhua preparations (a Chinese herbal medicine)
Devil’s claw
Devil’s nettle
Devil’s root / Siberian ginseng / acanthopanax senticosus / ci wu jia)
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Dianxianning pill (a Chinese herbal medicine)
Dietary supplements
Dihomogammalinolenic acid (DGLA) (an omega-6 fatty acid) supplements
Dimethylaminoethanol / dimethylethanolamine / Deanol (DMAE)
Docosahexaenoic acid (DHA) (an omega-3 fatty acid) supplements
Echinacea
EDTA (ethylenediaminetetraacetic acid) when used in chelation therapy as
described above(see Chelation therapy)
Eicosapentaenoic acid (EPA) (an omega-3 fatty acid) supplements
Electric stimulation therapy
Electroacupuncture
Electromagnetic stimulation therapy
Electromagnetic therapy
Electrotherapy
Elemental diet
Essiac formula
Estrogen (exclude for treatment of natural or surgical menopause) supplements
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Evening primrose oil
Eye Movement Desensitization and Reprocessing (EMDR)
Feverfew
Fish oil (omega-3 fatty acids) supplements
FlorÂEssence formula
Folic acid / folate (Vitamin B9) supplements (many people would not include for
prevention of neural tube defects)
Free and Easy Wanderer (a Chinese herbal medicine)
Gamma-linolenic acid (GLA) (an omega-6 fatty acid) supplements
Garlic
Gerovital H3 (primary ingredient is procaine hydrochloride)
Gerson therapy
Ginger
Ginkgo biloba
Ginseng
Glucosamine supplements
Glutamine supplements
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Gluten-free diet
Green tea / Camellia sinensus)
Guiling pa’an wan (a Chinese herbal medicine)
Hemp oil
Herbal medicine
High-fiber diet
Hippotherapy / equine-assisted therapy (exclude when physical therapy only)
Holistic therapy
Homeopathy
Homoharringtonine (HHT) (a plant alkaloid)
Honey
Horse chestnut
Huangqi (a Chinese herbal medicine)
Huperzine A (a Chinese herbal medicine)
Hydrazine sulfate
Hydrotherapy
Hyperbaric oxygen therapy (exclude for treatment of diving disorders or carbon
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monoxide poisoning)
Hypnosis / hypnotherapy
Imagery
Iron supplements
Jin Li Da liquor (a Chinese herbal medicine)
Kampo (a type of traditional Japanese medicine)
Kava
Ketogenic diet
Laetrile
Laser acupuncture
Laughter therapy
Lentinan (derived from Shitake)
Light therapy / phototherapy (exclude for treatment of seasonal affective disorder,
eczema, psoriasis, neonatal jaundice)
Linoleic acid (an omega-6 fatty acid) supplements
L-isoleucine (an amino acid) supplements
Liuwei dihuang pill (a Chinese herbal medicine)

185
L-leucine (an amino acid) supplements
Low fat diets
Low protein diets
Low-glycemic index diets
L-threonine (an amino acid) supplements
L-valine (an amino acid) supplements
Magnesium supplements
Magnetic therapy
Marijuana, marihuana / cannabis / cannabinoids / C. sativa / C. indica (exclude for
purely psychoactive uses)
Meditation
Mediterranean diet
Melatonin
Milk thistle
Moxibustion
Music therapy
Naturopathy
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Niacin / Nicotinamide (Vitamin B3) supplements
Omega-3 fatty acids
Osteopathic manipulation
Ozone therapy
Pantothenic acid (Vitamin B5) supplements
Passiflora
Peppermint
Phytoestrogens
Phytomedicines / Phytotherapy
Plant medicines
Play therapy
Prayer
Prebiotics
Probiotics
Procaine (only when used for aging)
Prolotherapy

187
Propolis
Protein supplements
Krestin / PSK / PSP (Coriolus Versicolor extracts)
Puerarin (a Chinese herbal medicine)
Pyridoxine / Pyridoxal / Pyridoxamine (Vitamin B6) supplements
Qi Gong
Radiesthesia
Reflexology
Reflexotherapy
Relaxation techniques
Riboflavin (Vitamin B2) supplements
Rolfing®Structural Integration
S-Adenosyl methionine (SAM-e)
Safflower Yellow injection (a Chinese herbal medicine)
Salacia oblonga
Salvia (miltiorrhiza)(injection) (a Chinese herbal medicine)
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Sanchi preparations (a Chinese herbal medicine)
Saw palmetto / serenoa repens
Selenium supplements
Shamanistic medicine (Shamanism)
Shark cartilage
Shengmai / shenmai (a Chinese herbal medicine)
Shenqi Fuzheng (a Chinese herbal medicine)
Shensu / shenfu (a Chinese herbal medicine)
Shexiang (injection) (a traditional Chinese medicine]
Shitake
Shuanghuanglian (a Chinese herbal medicine)
Sidda medicine (a type of Indian (East Asian) traditional medicine)
Soy / soybeans
Speleotherapy
Spinal manipulation
Spiritual healing
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St. John’s wort (Hypericum perforatum L)
Suxiao jiuxin wan (a Chinese herbal medicine)
Tai chi / tai ji
Testosterone
Therapeutic touch
Thiamine (Vitamin B1) supplements
Tianmadingxian capsule (a Chinese herbal medicine)
Traditional African healing
Traditional Arabic medicine
Traditional Chinese medicine
Traditional Indian medicine
Traditional Japanese medicine
Traditional Korean medicine
Traditional Tibetan medicine
Transcranial magnetic stimulation (exclude for treatment of depression)
Transcutaneous electrical stimulation
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Tui na
Ultrasound / ultrasonic therapy) (exclude diagnostic ultrasound)
Unani medicine / Yunani medicine (a type of Arabic or Indian (East Asian)
traditional medicine)
Valerian
Vegan diet
Vegetarian diet
Visualization techniques
Vitamin A supplements
Vitamin B complex supplements
Vitamin B12 supplements
Vitamin C supplements
Vitamin D supplements
Vitamin E supplements
Vitamin K supplements
Vojta method / Reflexlocomotion
White willow bark
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Xiaxingci granule (a Chinese herbal medicine)
Yoga
Zhixian I pill (a Chinese herbal medicine)
Zinc supplements
Zishen Tongli Jianonang (a Chinese herbal medicine)

Adapted from “Development and classification of an operational definition of
complementary and alternative medicine for the Cochrane collaboration,” by L.S.
Wieland, E. Manheimer, & B.M. Berman, 2011, Alternative Therapies in Health and
Medicine, 17(2), p. 55.
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Appendix B: Active Diet Ingredients
Ingredient
Soybean/soy protein
Viscous fibers
b-glucans
Guar gum
Long chain Ȧ-3 fatty acids
Almonds
Plant stanols
Cinnamon
Blueberries
Vinegar
Probiotic
Whey protein

Health Benefits
Cholesterol-lowering, anti-inflammatory
Cholesterol-lowering, prebiotic, GI-reducing

Triglyceride-lowering, anti-inflammatory
Cholesterol-lowering
Cholesterol-lowering
Antioxidant
Antioxidant, prebiotic
GI -reducing
Cholesterol-lowering, anti-inflammatory
GI-reducing

Daily Content (g) in Women, Men
21, 25
10-25*
5.8, 6.2
5.6, 6.7
2.4, 3.0
28, 28
2.0, 2.7
3.0, 3.0
74.5, 94.5
22.5, 22.5
0.1, 0.1
4.3, 4.3

Note. Adapted from “A diet based on multiple functional concepts improves
cardiometabolic risk parameters in healthy subjects,” by J. Tovar, et al., 2012, Nutrition
& Metabolism, 9(1), p. 6. © 2012 Tovar et al; licensee BioMed Central Ltd. This is an
Open Access article distributed under the terms of the Creative Commons Attribution
License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly
cited
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Appendix C: Informed Consent Form
Dear Potential Participant,
You are invited to take part in a research study entitled Physician Ladders of
Inference Regarding Omega-3 Dietary Supplements. The researcher will seek to gain an
understanding of how physicians make decisions to prescribe or recommend dietary
supplements, especially omega-3 (n-3) dietary supplements. This form is part of a
process called “informed consent” to help you understand the intent of the study before
deciding to take part. This study is being conducted by Warren P. Lesser, a doctoral
student at Walden University. You may already know Mr. Lesser is associated with a
pharmaceutical company, but this study is separate and conducted in a student role.
Protective measures have been implemented to prevent conflict of interest bias.
Absolutely no persuasive or coercive measures will be used to influence you to prescribe
or recommend any products.
Background Information:
The purpose of this study regards n-3 marketing strategy to determine decision
criteria and the ladder of inference physicians use to recommend n-3 supplements. The
business problem is the difficulty in communicating the complex mechanisms of n-3s and
their profound health benefits to physicians and subsequently from physicians to their
patients. Positive potential study outcomes regard preventive cardiovascular health
opportunities: a) N-3 marketers may understand how to improve n-3 marketing and
communication with physicians, b) increased physician education and n-3 utilization may
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lower healthcare costs, and c) patients and the general population may improve
cardiovascular health and quality of life.
Number of Subjects/Length and Description of Participation
This study will include 20 physician subjects from a geographical region
including Indiana, Kentucky, and Tennessee. Interview time lengths will be limited to 1
hour. The interview will be audiotaped to maintain the accuracy of all data collected.
Additionally, each subject will be asked to provide feedback via e-mail to confirm
interview data collected and provide additional feedback if desired. Themes may be
disclosed among group members but group member names will be kept strictly
confidential and not disclosed to other group members). You may be asked to respond to
no more than two follow-up e-mails. E-mail feedback will take no more than 10 minutes
per e-mail.
Inclusion Criteria
Physician subjects will be purposefully selected based upon interest in the study
subject, an open perspective regarding diverse opinions, and access. Geographical scope
and a willingness to set aside sufficient time without interruptions in a private setting
define acceptable participant access criteria.
Procedures:
If you agree to voluntarily participate in this study, you will be asked to:
Participate in a one-on-one interview with the researcher regarding decision
processes used to recommend dietary supplements particularly omega-3s and respond to
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no more than two follow-up emails to verify/clarify collected interview data and
identified themes.
Here are sample questions:
2a, 2b, 2c. (a) What credible clinical evidence have you seen regarding fish oil
dietary supplements? (b) What made the evidence credible or incredulous? (c) What
kind of evidence would you consider the most convincing?
3. What are the risks of taking fish oil dietary supplements? What are the risks
regarding specific patient groups or disease states?
4a, 4b. (a) What are the important differences between quality fish oil dietary
supplements and low quality fish oil dietary supplements? (b) What are right daily
amounts of DHA and EPA?
Voluntary Nature of the Study:
This study is voluntary. If you decide to join the study now, you can still change
your mind during or after the study. You may stop at any time. You may withdraw at any
time during the study. If you choose not to participate or withdraw, you will not receive
the $50 stipend and the relationship between the study subject and researcher will not be
deleteriously affected.
Risks and Benefits of Being in the Study:
Being in this type of study involves some risk of the minor discomforts that can
be encountered in daily life, such as stress or becoming upset. Being in this study would
not pose risk to your safety or wellbeing. Any risk of physical injury or harm during the
study interview is virtually nonexistent. Other risks of participation include loss of time
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and disclosure of personal prescribing preferences and decision processes to the
interviewer, transcriber, and one other coder. The interviewer, transcriber, and coder must
execute confidentiality agreements before data access. Positive potential study benefits
include: a) Gained knowledge among n-3 marketers to better communicate with
physicians, b) increased physician education and n-3 utilization, which may improve
patient health, patient quality of life, and lower U.S. healthcare costs.
Payment:
Participation in this study is voluntary but an appreciation stipend of $50 will be
paid at the conclusion of data collection. If you withdraw from this study you will not be
paid the $50 stipend.
Privacy:
Any information you provide will be kept confidential. The researcher will not
use your personal information for any purposes outside of this research project. Also, the
researcher will not include your name or anything else that could identify you in the
study reports. The privacy of all participants will be protected with all sensitive data
coded in place of source identification. All study protocol, collected data, and consent
forms will be stored in a locked container for 5 years from completion of the study.
Contacts and Questions:
You may ask any questions you have now. Or if you have questions later, you
may contact the researcher, Warren P. Lesser, via telephone or email: or
warrenlesser@yahoo.com. If you want to talk privately about your rights as a participant,
you can call Dr. Leilani Endicott. She is the Walden University representative who can
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discuss this with you. Her phone number is 1-800-925-3368, extension 3121210. Walden
University’s approval number for this study is [TBD]. The researcher will give you a
copy of this form to keep.
Statement of Consent:
I have read the above information and I feel I understand the study well enough to
make a decision about my involvement. By signing below, “I consent,” I understand I am
agreeing to the terms described above.
Printed Name of Participant
Date of consent
Participant’s Signature
Researcher’s Signature
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Curriculum Vitae
Warren P. Lesser
Experience
Campbell Soup Company, Scarsdale, NY (Sales, 1976-1978)
Boots Pharmaceuticals, Shreveport, LA (Sales and Manager of Sales Training,19781987)
MAS Home Health, Shreveport, LA (VP Marketing, 1987-1988)
SpectraCare, Inc. (Home health and I.V. infusion pharmacies, owner/founder, 1988,
harvested in 1996)
SpectraBrace, Ltd. (Orthopedic services, owner/founder, 1996, harvested in 2005)
Paradigm HealthCare Solutions, Inc., Louisville, KY (ICD-9 coding, owner/founder,
1996, harvested in 2004)
MAGNA Pharmaceuticals, Inc. (President/CEO, primary owner, 2000 – present)
Z-Xpress Car Wash, LLC, Louisville, KY (conveyor and conveyor/detailing locations,
owner/founder, 2005 - present)
Hogg’s Upstairs Taverne Gatlinburg, TN (owner/founder, 2008 - present)
Hogg’s Pub & Grub, Gatlinburg, TN (owner/founder, 2012 – present)
LandVest, LLC, renamed LV Capital, LLC, Louisville, KY (1/3 partner in patio home
development company, 1996-2008)
Education
Taylor University, Upland, IN, Bachelor of Arts, 1976
MBA course work, Indiana University at Fort Wayne, 1979-1980
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Centenary College of Louisiana, Shreveport, LA, Master of Business Administration,
1987
DBA course work, Walden University, 2010-2014

